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Periodontitis is a microbial inflammatory disease affecting the tooth supporting 
tissues1. Some recent studies showed that periodontitis is associated with adverse 
pregnancy outcome2-8. One of the pregnancy complications suggested to be related 
with periodontitis is preeclampsia. Preeclampsia is defined by hypertension and 
proteinuria in the second half of pregnancy and is characterised by systemic vascular 
dysfunction together with an enhanced inflammatory response9. Since periodontitis 
also is associated with systemic inflammation and endothelial dysfunction10, this 
prompted us to explore the possible role of periodontitis in the pathophysiology of 
preeclampsia, resulting in the clinical and experimental studies, described in this thesis. 
 In the general introduction, first, periodontal diseases, periodontal pathogens, host-
parasite interactions and the reported effects on general health are described. Next, the 
interaction between periodontal diseases and pregnancy complications are described, 
with a special focus on preeclampsia, leading to the objectives of the present thesis.
PERIODONTAL DISEASES
Periodontal diseases are plaque induced infections and pathological changes of the 
periodontium, traditionally divided into two categories: gingivitis and periodontitis1. 
Gingivitis, the mildest form of periodontal diseases, affects up to 90% of the world wide 
population and manifests clinically as edema and erythema of the marginal gingiva. 
Gingivitis does not affect the underlying tooth anchoring structures (connective 
tissue and alveolar bone) and is readily reversible by effective tooth cleaning and oral 
hygiene home care11. Inflammation that extends deeper into the supportive tissues and 
involves the periodontal ligament and alveolar bone is known as periodontitis1. This 
apical extension of the inflammatory process results in progressive destruction of tooth 
anchoring collagen fibers and supportive bone structures, clinically leading to the 
formation of deepened soft tissue pockets between the gingiva and the surface of the 
tooth1. Moreover, a chronic inflammatory process is instituted with total inflammatory 
surface areas reaching up to 40 cm2 on the tooth facing part of the gingiva12. Once 
periodontal pockets are formed and colonised with bacteria, improving oral hygiene 
alone is no longer sufficient to reverse the inflammatory process. Intensive professional 
periodontal treatment, including supra- and subgingival scaling and rootplaning (SRP) 
and surgical pocket elimination is necessary to restore periodontal health1.
MICRO-ORGANISMS INvOLvED IN PERIODONTAL DISEASES
A shift in microbial species in the dental plaque from a relatively harmless gram-positive, 
facultative anaerobic fermentative population to a predominantly gram-negative, 
anaerobic and proteolytic virulent population has been strongly associated with 
periodontal tissue breakdown13. Although more than 500 bacterial species have been 
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identified in the dental plaque14-17, only a small proportion of these micro-organisms 
are considered to play a role in the development of periodontitis. Key pathogens 
associated with periodontitis in adult subjects are the gram-negative micro-organisms 
Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), Porphyromonas 
gingivalis (P. gingivalis), Prevotella intermedia (P. intermedia), Tannerella forsythia (T. for-
sythia), Fusobacterium nucleatum (F. nucleatum) and the gram-positive Parvimonas 
micra (P. micra)18. These bacteria produce a variety of toxins19-21, such as outer membrane 
lipopolysaccharides, outer membrane lipids or lipoproteins, peptidoglycan and 
proteolytic enzymes, which may have detrimental effects on the periodontal tissues22. 
Especially P. gingivalis, a black pigmented anaerobic micro-organism, has been reported 
to possess a variety of virulence factors, including lipopolysaccharide (LPS)19;20;23. P. 
gingivalis LPS has the capacity to upregulate the host’s immune response24-26, which 
may lead to an increased production of local inflammatory mediators and effector 
molecules including cytokines27, chemokines27 and  matrix metalloproteinases28, and 
finally to periodontal breakdown28. Moreover, several serotypes of P. gingivalis with 
varying virulence properties have been described29-32. This may suggest that different 
P. gingivalis serotypes with varying inflammatory capacities exist. Alterations in cytokine 
production after stimulation with different P. gingivalis serotypes have indeed been 
reported33-36.
HOST-PARASITE INTERACTIONS
One of the first ways in which the host’s immune system recognises different micro-
organisms is through pattern recognition receptors (PRR) such as Toll-like receptors 
(TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs) and DNA receptors 
(cytosolic sensors for DNA) on innate immune cells37. TLRs are specific pattern 
recognition receptors present on a variety of cells, such as monocytes, macrophages 
and dendritic cells38, as well as on (oral) epithelial cells39, gingival fibroblasts40 and 
endothelial cells41. These TLRs detect so-called damage-associated molecular patterns 
(DAMPs) 42. A subtype of DAMPs, pathogen-associated molecular patterns (PAMPs), 
arise from pathogens and alarm an individual to invading pathogens42. Several 
surface components present on micro-organisms, like LPS, the major component of 
gram-negative bacterial cell walls, or peptidoglycan, the major component of gram-
positive bacterial cell outer membranes are PAMPs and are recognised by TLRs43;44. 
Ligation of TLRs by LPS or peptidoglycan results in activation of the intracellular 
signalling pathway and ultimately in the production of an array of cytokines45. These 
cytokines modulate inflammatory reactions. At present, 12 mammalian TLRs have been 
identified37, of which TLR4 and TLR2 have been studied most frequently46;47. TLR4 plays 
an important role as a receptor for bacterial LPS from gram-negative micro-organisms, 
















positive bacteria48;49. Activation of TLR4 leads to the production of pro-inflammatory 
cytokines, like tumour necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-6, IL-12. 
Activation of TLR2 leads to the production of prostaglandin E2 (PGE2), IL-10 and IL-
13, of which in particular IL-10 has been recognised as a potent immunosuppressive 
and anti-inflammatory molecule47;50. Thus, the micro-organisms in the dental plaque, 
that consists of an array of gram-positive and gram-negative species, may influence 
the nature of the host response to this polybacterial challenge, by activating specific 
TLRs51.
 In addition, periodontitis also has a genetic component. Various single-nucleotide 
polymorphisms (SNPs), for example in the IL-1β, IL-1RN and TLR4 genes, have been 
associated with chronic and aggressive periodontitis52. Thus, not only the mere presence 
of pathogenic micro-organisms in the biofilm, but also the genetically determined 
mode of host inflammatory responses to these pathogens determines the clinical 
manifestations of periodontitis, e.g. the severity of periodontal tissue breakdown53. It 
has indeed been shown that not all individuals are equally affected by the accumulation 
of dental plaque54. Some susceptible individuals may develop aggressive forms of 
periodontitis at a young age, while others never, or very slowly develop periodontitis55. 
The findings that increased levels of inflammatory mediators, such as TNF-α, IL-1β 
and PGE2, correlate with periodontal destruction
56-58 and the fact that these mediators 
aggravate the inflammatory response59, has led to the hypothesis that some individuals 
may be “high-responders” and respond to periodontal infection with high levels of 
inflammatory mediators which results in periodontal breakdown54. Indeed, increased 
TNF-α and PGE2 production has been observed in patients with aggressive (early-onset) 
periodontitis as compared with patients with generalised periodontitis60. A significant 
portion of the host predisposition to periodontitis may therefore relate to excessive 
innate host defenses and the subsequent activation of the inflammatory response13.
SySTEMIC EffECTS Of PERIODONTAL DISEASES
The local infection and subsequent inflammatory response of the host may not 
be limited to the periodontal tissues. With daily tooth brushing or even gentle 
mastication, periodontal micro-organisms or their bacterial products like LPS may 
enter the blood stream and disseminate into the systemic circulation61;62. This 
chronic or even permanent bacteremia or endotoxemia may activate inflammatory 
cells and endothelial cells, leading to endothelial cell activation and dysfunction as 
well as generalised inflammation63-66, with increased numbers of peripheral blood 
leukocytes 62 and increased levels of IL-6 and C-reactive protein (CRP)62;67-69. Most of 
these systemic markers of inflammation are also regarded as predictive markers for 
cardiovascular diseases (CVD) and it is believed that the systemic level of inflammation 
in periodontitis increases the risk for CVD70;71. Indeed, over the last years, meta-analyses 
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of observational studies showed that patients with periodontitis are at increased risk of 
developing cardiovascular diseases (CVD)72-75. The persistent evidence already has led 
to a consensus paper on the relationship between CVD and periodontitis, which was 
published concurrently in two leading journals in their fields, the American Journal of 
Cardiology (AJC), and the Journal of Periodontology (JOP)24. This consensus statement 
suggests that cardiologists may now examine a patient’s mouth, and periodontists 
may begin asking questions about cardiovascular health and family history of 
cardiovascular diseases. It was confirmed in a meta-analysis by D’Aiuto et al in 2013 that 
periodontal treatment reduced CVD biomarkers and improves endothelial function76. 
The importance for periodontal diagnosis and therapy in atherosclerotic individuals to 
improve their cardiovascular risk profile has been further emphasised upon by Gunupati 
et al77, who showed that periodontal treatment reduced biomarkers for atherosclerotic 
disease in periodontitis patients already suffering from CVD.
 Periodontal diseases are also implicated as a risk factor for diabetes mellitus78 and 
may be related to a number of other systemic diseases, such as chronic obstructive 
pulmonary disease (COPD), pneumonia, chronic kidney disease, rheumatoid arthritis 
(RA), cognitive impairment, obesity, metabolic syndrome and cancer79;80. It was 
shown that treatment of periodontitis in patients with diabetes mellitus leads to an 
improvement of glycaemic control81-83, and may reduce RA severity and systemic 
inflammation in RA patients84;85.
PERIODONTAL DISEASES DuRING PREGNANCy
Periodontal health during pregnancy is another topic that has engendered much 
interest over the past 50 years. For many years, it has been well established that during 
pregnancy (in 30-100% of women), a progressive increase in gingival inflammation is 
observed86-90. This phenomenon is referred to as pregnancy gingivitis and disappears 
post-partum with no permanent effects on the periodontal attachment88-90. Although 
the exact mechanisms remain to be elucidated, it is thought that elevated levels of 
circulating progesterone or oestrogen during pregnancy contribute to enhanced 
gingival vascular permeability and enhanced gingival exudates88;91-94. This may lead to 
clinical alterations of the gingiva, i.e. increased redness, oedema and a greater bleeding 
tendency, which clinically resemble inflammation95. Unfortunately, this condition not 
only leads to greater gingival probing depths96, but subsequently may transform the 
gingiva into an environment that may favour the overgrowth of specific bacteria1. 
Indeed, in a recently conducted cohort study, the presence of P. gingivalis significantly 
contributed to the worsening of gingival inflammation during the second and third 
trimester of pregnancy97.
 Pregnancy gingivitis may also be related to altered immune and inflammatory 
















inflammatory response is mildly activated100. This activation of the inflammatory 
response during normal pregnancy is characterised by increased expression of 
activation markers on monocytes and granulocytes101-103, differences in monocyte 
cytokine production104-107 and increased plasma levels of inflammatory markers, such 
as CRP108. This has led to the concept that pregnancy is a pro-inflammatory condition109 
and might partly explain the increased susceptibility to gingivitis during pregnancy.
PERIODONTAL DISEASES AS A RISk fACTOR fOR PREGNANCy COMPLICATIONS
It was first demonstrated in 1994 in an animal model that the presence of periodontal 
pathogens might have a negative effect on pregnancy outcome110. Collins et al 
demonstrated that P. gingivalis, infused in the pregnant hamster, could elicit low birth 
weight110. In humans, the first evidence of a possible association between periodontitis 
and adverse pregnancy outcomes was published in 1996 by Offenbacher et al111, 
who reported a relationship between periodontitis and preterm low birth weight. 
Since then, the relationship between periodontitis and complications of pregnancy 
has become a major topic of research in the field of dentistry. Various observational 
studies have been carried out, and many systematic reviews support the hypothesis 
that periodontitis is associated with preterm labour and other conditions complicating 
pregnancy, such as low birth weight, stillbirth, miscarriage and intrauterine growth 
retardation2-8;112. Perhaps the strongest and most convincing evidence of a relationship 
between periodontitis and preterm low birth weight until now comes from a meta-
analysis published by Vergnes et al6. The authors concluded from their data that 
pregnant women with periodontitis have a 2.8-fold increased risk on preterm birth.
 There are several pathophysiological mechanisms by which periodontitis may 
interfere with pregnancy. A route via the peripheral circulation to the placenta is 
likely to be involved, since periodontopathic bacteria have been found in human 
placental tissues113-116, in amniotic fluid117;118 or in chorionic tissues119;120. The presence of 
periodontal micro-organisms in foetal and maternal tissues has been shown to induce 
chorioamnionitis121, an intrauterine status of inflammation in tissues of either mixed 
foetal-maternal or foetal origin122. Chorioamnionitis is an independent risk factor 
for preterm birth123;124 and foetal morbidity122;125. Also, the translocation of bacterial 
products like LPS, and the action of maternally produced inflammatory mediators 
such as TNF-α and PGE2 could initiate labour
126. As PGE2 mediates cervical ripening 
and stimulates uterine contractions, it plays a role in the onset of labour127. It has been 
theorised that the increased TNF-α and PGE2 levels accompanying periodontitis may 
interfere with normal physiological mechanisms of parturition, resulting in preterm 
labour126;128.
 If periodontal infections are a cause of preterm birth, it might be expected that 
eradication of such infections would reduce the risk of preterm birth. Although the 
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results of initial studies of periodontal treatment to reduce the risk of preterm labour 
were positive8, these findings could not consistently be confirmed in later studies5;129-133. 
However, a recently published meta-analysis of RCTs found a significant reduction of 
preterm birth after periodontal treatment in a subgroup of high risk of preterm birth134.
PATHOGENESIS Of PREECLAMPSIA
Another complication of pregnancy that recently has achieved attention in dental 
research is preeclampsia. Preeclampsia is a maternal multi-organ disease, clinically 
manifest during the second half of pregnancy by hypertension (systolic blood pressure 
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) with proteinuria (≥300 mg/24 
hours or 2+ dipstick), often accompanied with varying dysfunction of major organs as 
the liver, the kidneys and the brain135. It is one of the leading causes of maternal and 
foetal morbidity and mortality in the western world, with a prevalence of approximately 
2-8%9. In the Netherlands, preeclampsia is the main cause of maternal mortality, 
showing a rising trend in the period 1993-2005136. Several factors have been implicated 
in the pathogenesis of preeclampsia, including genetic, immunologic, inflammatory, 
ethnic, socioeconomic and environmental factors, but until now the exact cause and 
pathogenesis are not fully clarified. 
 The current leading hypothesis is that the pathological processes that 
underlie  preeclampsia  occur in two stages9. Stage one starts with abnormal 
placentation and impaired vascular remodeling of the myometral spiral arteries 
that supply the placental bed137. This impaired remodeling is most likely the result 
of deficient trophoblast invasion into the myometrial arteries138. The consequence is 
insufficient placental perfusion in the second half of pregnancy, when the increasing 
demands of the growing foetus can no longer be met. Subsequently, this leads to 
placental oxidative stress and the release of various bioactive factors into the maternal 
circulation9. These bioactive factors include inflammatory cytokines such as TNF-α and 
IL-6139, as well as syncytiotrophoblast membrane microparticles (STBMs), which may 
challenge maternal inflammatory cells140. They also include antiangiogenic factors such 
as soluble endoglin (sEng), the soluble form of the vascular endothelial growth factor 
(VEGF) receptor (sFlt-1) and placental growth factor (PlGF), which may challenge the 
maternal vascular endothelium141. This may lead to stage two, endothelial dysfunction 
and an excessive inflammatory response leading to the maternal clinical features of 
the syndrome9;103;142-145. Preeclampsia, therefore, is most likely the result of a generalised 
exacerbation of the inflammatory response, including activation of inflammatory and 
endothelial cells109;138;146. 
 Besides abnormal placentation, other maternal factors predisposing to a pro-
inflammatory state, such as obesity, diabetes mellitus and chronic infection, may play a 
















PERIODONTAL DISEASES IN THE PATHOGENESIS Of PREECLAMPSIA
A possible link between periodontitis and preeclampsia was first proposed in 2003, and 
since then, a considerable amount of studies focused on this association148-168. Although 
findings were not consistent, there appeared to be a relationship between periodontitis 
and preeclampsia. One of the mechanisms involved in this putative relationship may 
be the systemic nature, i.e. the low grade inflammation in periodontitis62. It can be 
hypothesised that the chronic inflammation of periodontitis superimposes on the 
already pro-inflammatory state of normal pregnancy. The result may be an abnormally 
activated inflammatory system that ultimately leads to preeclampsia169;170. Also a 
direct bacterial infection of maternal organs by invading periodontopathic bacteria, 
might explain a possible role of periodontitis in the aetiology of preeclampsia. 
The involvement of specific periodontal micro-organisms in the pathogenesis of 
preeclampsia has been examined in some human studies153;155;171;172. In these studies, a 
higher prevalence of P. gingivalis153;171, T. forsythia153, E. corrodens153;171, P. intermedia155 or 
A. actinomycetemcomitans172 was found in subgingival plaque samples of preeclamptic 
women as compared with healthy pregnant controls. P. gingivalis, E. corrodens, T. 
forsythia, P. intermedia and A. actinomycetemcomitans all produce a variety of pro-
inflammatory factors, including LPS19;20;173;174, which may affect the immune response 
during pregnancy. Until now, however, there are no studies to substantiate a causal 
role of periodontal bacteria or bacterial products in the pathogenesis of the maternal 
syndrome of preeclampsia. Interestingly, Faas et al175 established an animal model for 
preeclampsia, in which an infusion of a low dose of LPS from the enteric bacterium 
Escherichia coli (E. coli) into pregnant rats led to activation of the inflammatory response 
and subsequently to a preeclampsia-like syndrome, characterised by hypertension and 
proteinuria. This syndrome was pregnancy specific: identically treated non-pregnant 
rats did not develop these symptoms. Therefore it might be possible that the state of 
pregnancy also influences the susceptibility for periodontopathic micro-organisms, 
like P. gingivalis or its LPS, leading to increased activation of inflammatory cells and 
pro-inflammatory cytokine production by leukocytes. This may increase the risk on 
developing endothelial activation/dysfunction and eventually result in the maternal 
syndrome of preeclampsia.
ObjECTIvES Of THIS THESIS
The focus on periodontitis as a risk-factor for preeclampsia, from a scientific point of 
view, is relatively new. Several research groups in various countries focused on this 
putative relationship and a range of epidemiological studies with varying results have 
been published. The first aim was therefore to review the current available literature 
and to provide an appraisal of the scientific evidence for an association between 
periodontitis and preeclampsia (chapter 2). 
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 Since study outcomes may depend on the adopted definition for periodontitis and 
preeclampsia, and ethnicity may play a role in the risk on developing both periodontitis 
as well as preeclampsia176;177, the second aim of this thesis was to investigate the 
periodontal condition in a homogenous Caucasian Dutch population with a recent 
history of early-onset preeclampsia (chapter 3). 
 The third aim was to explore possible causal mechanisms that could explain a role 
of periodontitis in the pathogenesis of preeclampsia. Although LPS from P. gingivalis 
has been shown to have a negative effect on the developing foetus in animal models 
in the past121;178-181, there is no information whether LPS of P. gingivalis, like E. coli LPS, 
can induce the maternal symptoms of preeclampsia. An experimental animal study 
was therefore conducted to examine whether infusion of P. gingivalis LPS in pregnant 
rats, next to affecting foetal growth, also induced the clinical features of preeclampsia 
characterised by hypertension, proteinuria and generalised systemic inflammation 
(chapter 4).
 Pregnant individuals have been shown to be more sensitive to LPS of E. coli, as 
compared with non-pregnant individuals182. It is unknown whether during pregnancy 
the sensitivity to LPS of P. gingivalis is also altered and if differences in response may 
be the consequence of differences in cytokine production. Therefore, the fourth aim 
was to evaluate cytokine production by leukocytes upon stimulation of whole blood of 
pregnant and non-pregnant women with bacteria as well as isolated LPS of P. gingivalis, 
with E. coli as reference strain (chapter 5).
 In addition, since there may be differences in pro-inflammatory properties 
between different P. gingivalis serotypes33-36, the final aim was to further investigate the 
host response to P. gingivalis and investigate whether variation in pro-inflammatory 
capacities of its LPS may determine virulence properties of encapsulated and non-
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Aim: This review evaluates the possible relationship between periodontal disease and 
preeclampsia, a major pregnancy complication. A generalized inflammatory response 
plays an important role in the pathogenesis of preeclampsia. Because periodontal 
disease is a low grade inflammatory state, periodontal disease might contribute to the 
pathogenesis of preeclampsia.
Main findings and conclusion: A literature search of PubMed, EMBASE and CINAHL 
until August 2010 revealed 12 eligible observational studies and three randomized-
controlled trials (RCTs). It appeared difficult to compare these studies, due to variations in 
definitions of periodontal disease and preeclampsia, timing of periodontal examination 
and inadequate control for confounding factors. Eight observational studies reported a 
positive association, while four studies found no association. None of the RCTs reported 
reductions in preeclamptic rate after periodontal therapy during pregnancy. Therefore, 
it is questionable whether periodontal disease plays a causal role in the pathogenesis 
of preeclampsia. The observed association in eight observational studies might be the 
result of induction of periodontal disease due to the preeclamptic state or it may be 
an epiphenomenon of an exaggerated inflammatory response to pregnancy. Larger 
RCTs with preeclampsia as the primary outcome and pathophysiological studies are 




Periodontal disease is a chronic destructive inflammatory disease affecting the tooth-
supporting tissues and is one of the most prevalent chronic infections in humans. 
The disease is caused by dental plaque, a biofilm in which gram-negative anaerobic 
microorganisms dominate. Plaque-associated periodontal diseases can be divided into 
gingivitis and periodontitis. Gingivitis refers to an inflammatory state of the gums, with 
no loss of periodontal attachment fibres or alveolar bone. In periodontitis, progressive 
destruction of collagen fibres and supportive bone structures occurs1. Periodontal 
disease is initiated by oral microorganisms, but it is believed that the severity of 
periodontal breakdown is orchestrated by the inflammatory response of the host2. 
  The inflammatory response may not be limited to the periodontal focus. It has 
been proposed that daily episodes of bacteremia or dissemination of bacterial 
endotoxins originating from the periodontal focus may induce systemic activation 
of the inflammatory response3;4. Bacteria or bacterial endotoxins in the systemic 
circulation may induce pro-inflammatory cytokine production5. These cytokines then 
further activate the inflammatory response, resulting in a chronic low-grade systemic 
up-regulation of inflammatory responses involving IL-6 and C-reactive protein (CRP)6-9. 
It also includes activation of inflammatory cells and endothelial cells and may result in 
endothelial dysfunction10-13.
  In pregnancy, the immune response plays a pivotal role in maintaining a healthy 
equilibrium between mother and foetal allograft14. During normal pregnancy, not only 
the specific immune response is shifted towards a Th2 type immune response but also 
the inflammatory response is activated15. This activation of the inflammatory response 
during pregnancy is characterized by increased expression of activation markers 
on monocytes and granulocytes16, differences in monocyte cytokine production17, 
increased circulating levels of pro-inflammatory cytokines18 and inflammatory markers, 
such as CRP19. 
  It has been suggested that exacerbation of this inflammatory response during 
pregnancy may result in pregnancy complications, e.g. preeclampsia15. Preeclampsia is 
a maternal multi-organ disease, clinically manifest in the second half of pregnancy by 
the appearance of hypertension and proteinuria20. It is a disorder unique to pregnancy, 
with a prevalence of approximately 2-3% and it is one of the leading causes of maternal 
morbidity and mortality in the western world21. The pathogenesis is not completely 
understood, but it is generally accepted that endothelial dysfunction of the maternal 
vascular system plays a key role in the clinical manifestations of the disease. Preeclampsia 
is most likely the result of a generalized inflammatory response, including activation of 
inflammatory and endothelial cells22-24. As compared with normal pregnancy, there is 
increased activation of this inflammatory response during preeclampsia16;25-28. 




































diabetes mellitus, hypertension, obesity and arterial diseases are at an increased risk of 
developing preeclampsia29-31. Because periodontal disease is also associated with low-
grade inflammation, it can be hypothesized that patients with periodontal disease have 
an increased risk of developing preeclampsia. A number of studies recently focused on 
a possible relationship between periodontal disease and preeclampsia. The aim of this 
review is to evaluate the published scientific evidence for this possible relationship.
MATERIALS AND METHODS
Search strategy
For this review, a thorough search of the literature was performed in the computerized 
databases of MEDLINE via PubMed (1969-August 2010), EMBASE (1974-August 2010) 
and CINAHL (2003-August 2010). The search strategy used was a combination of MeSH 
terms and free text words and is summarized in Table 1. 
Table 1. Search strategy
MEDLINE (via PubMed)
(“Periodontal Diseases”[MeSH] OR periodont* OR gingivitis) AND (“Pre-Eclampsia”[MeSH] OR 
preeclampsia OR eclampsia OR eclamp* OR proteinuria OR “pregnancy induced hypertension” 
OR gestosis OR EPH OR “pregnancy toxemia” OR (“hypertensive disorders of pregnancy”) OR 
“gestational pregnancy” OR “pregnancy-associated hypertension” OR “pregnancy hypertension”)
Limits activated: English, French, German, Spanish, Dutch 
Run data search: 15 August 2010
EMBASE
‘periodontal disease’/exp OR ‘periodontal disease’ OR periodont* OR ‘gingivitis’/exp OR gingivitis 
AND (‘preeclampsia’/exp OR preeclampsia OR ‘eclampsia’/exp OR eclampsia OR ‘proteinuria’/exp 
OR proteinuria OR ‘pregnancy induced hypertension’/exp OR ‘pregnancy induced hypertension’ 
OR eclamp* OR ‘gestosis’/exp OR gestosis OR eph OR ‘pregnancy toxemia’/exp OR ‘pregnancy 
toxemia’ OR ‘hypertensive disorders of pregnancy’ OR ‘gestational pregnancy’ OR ‘pregnancy-
associated hypertension’ OR ‘pregnancy hypertension’/exp OR ‘pregnancy hypertension’) AND 
([dutch]/lim OR [english]/lim OR [french]/lim OR [german]/lim OR [spanish]/lim)AND [embase]/lim
Run data search: 15 August 2010
CINAHL
S1 Search (MH “Periodontal Diseases+”)
S2 Search periodont* OR gingivitis
S3 Search (MH “Pre-Eclampsia+)
S4 Search preeclampsia OR eclampsia OR proteinuria  OR “pregnancy induced hypertension” 
OR gestosis OR EPH OR “pregnancy toxemia” OR “hypertensive disorders of pregnancy” OR 
“gestational pregnancy” OR “pregnancy-associated hypertension” OR eclamp* OR “pregnancy 
hypertension”
S5 Search (s1 OR s2) AND (s3 OR s4)
Limiters: peer reviewed; exclude MEDLINE records
Run data search: 15 August 2010
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The search was complemented by checking references mentioned in relevant review 
articles and eligible studies for additional useful publications with the following 
combinations: “periodontal diseases” and “pregnancy outcomes” or ”pregnancy 
complications” as well as “preeclampsia” and “inflammation” or ”infections”. The papers 
were first screened by title and abstract (A.K.). Full-text papers were obtained when the 
studies fulfilled the criteria of the study selection, as described below. Full-text analysis 
was performed by two reviewers (A.K., J.v.D.) independently. Case reports, letters, 
reviews, abstract-only studies and commentaries were excluded from the search.
Inclusion criteria
This systematic review included cross-sectional studies, case-control studies, prospec-
tive and retrospective cohort studies and clinical trials. No time restrictions were 
implemented with respect to the year of publication. The additional inclusion criteria 
for study selection were:
-  Publications in peer reviewed journals on studies in human subjects.
-  Papers published in English, French, German, Dutch and Spanish.
-  Comparative studies containing original data that evaluated the observational
  association between periodontal disease and preeclampsia.
-  Clinical trials comparing non-surgical periodontal treatment versus no treatment in
  pregnant women with periodontal disease regarding the rate of preeclampsia.
Quality assessment
Methodological quality was assessed using specific study-design-related checklists 
based on the quality-assessment forms designed by the Dutch Cochrane Collaboration 
(Appendix 1, Tables S1-S4). Two reviewers (A.K., J.v.D.) independently generated a 
score for the articles included. In case of disagreement, a consensus was reached by 
discussion and if necessary, a third reviewer (F.A.) was consulted. Case-control studies 
scoring five or more plusses (five out of eight items of the Cochrane checklist for 
case-control studies) were considered to be methodologically acceptable32 and were 
included in this review (Appendix 1, Table S1). For the quality assessment of cohort 
studies, the Dutch Cochrane checklist for cohort studies was used. Cohort studies 
scoring six or more plusses (six out of nine items of the Cochrane checklists for cohort 
studies) were considered methodologically acceptable (Appendix 1, Table S2). Because 
there was no adequate checklist for cross-sectional studies at the Dutch Cochrane 
Collaboration, apart from a checklist for diagnostic tests, a quality-assessment checklist 
had to be developed. This checklist was adapted from the quality checklist used for 
cohort studies and included items of checklists for cross-sectional studies (diagnostic 
tests). Cross-sectional studies scoring five or more plusses (out of eight items of this 
checklist) were included in this review (Appendix 1, Table S3). For clinical trials, studies 
Table 1. Search strategy
MEDLINE (via PubMed)
(“Periodontal Diseases”[MeSH] OR periodont* OR gingivitis) AND (“Pre-Eclampsia”[MeSH] OR 
preeclampsia OR eclampsia OR eclamp* OR proteinuria OR “pregnancy induced hypertension” 
OR gestosis OR EPH OR “pregnancy toxemia” OR (“hypertensive disorders of pregnancy”) OR 
“gestational pregnancy” OR “pregnancy-associated hypertension” OR “pregnancy hypertension”)
Limits activated: English, French, German, Spanish, Dutch 
Run data search: 15 August 2010
EMBASE
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toxemia’ OR ‘hypertensive disorders of pregnancy’ OR ‘gestational pregnancy’ OR ‘pregnancy-
associated hypertension’ OR ‘pregnancy hypertension’/exp OR ‘pregnancy hypertension’) AND 
([dutch]/lim OR [english]/lim OR [french]/lim OR [german]/lim OR [spanish]/lim)AND [embase]/lim
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S1 Search (MH “Periodontal Diseases+”)
S2 Search periodont* OR gingivitis
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S4 Search preeclampsia OR eclampsia OR proteinuria  OR “pregnancy induced hypertension” 
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scoring six or more plusses (six out of nine items of the Cochrane checklists for 
randomized-controlled trials) were considered methodologically acceptable (Appendix 
1, Table S4). Information of the quality assessment on the studies considered for 
inclusion is available in the online version of this article (Appendix 1, Tables S1-S4).
Data extraction and synthesis
For each study, the following data were independently extracted by the two observers 
and recorded in a data sheet:
-  Patient selection (patients and controls adequately defined).
-  Sample size.
-  Selection bias.
-  Exposure (periodontal disease).
-  Outcome (preeclampsia).
-  Blinding of investigators (to pregnancy-outcome).
-  Adjustment for well-known confounding factors [age, ethnicity, parity, multiple
  gestation pregnancies, diabetes mellitus, body mass index (BMI) or chronic
  hypertension].
-  Reported odds ratios (OR) or risk ratios (RR) with 95% confidence interval (CI).
-  Follow-up (in case of cohort studies and clinical trials).
Statistical analysis
Because of the high level of clinical heterogeneity in periodontal disease definitions, 
it was not possible to apply statistical methods to estimate overall pooled risks of 
periodontal disease from the selected observational studies. For the meta-analyis of 
the RCTs, the statistical software package ‘Stata’ was used (STATA 10.0 SE; Stata Corp., 
College Station, TX). Weighted rates together with random effects models were used 
to calculate the overall effects for the RCTs included. The Cochran’s Q test was used to 
test the homogeneity of the estimates of OR between studies.
RESuLTS 
Search results
Following the described search strategy, we found 331 articles. The reference lists of 
these papers and relevant reviews resulted in two additional papers. The screening by 
title and abstract resulted in 30 eligible articles (Fig. 1). 
  After full-text reading of these articles, four studies were excluded because they did 
not investigate the association between periodontal disease and preeclampsia33-36 and 
also four pathophysiological studies were excluded37-40. Furthermore, one prospective 
study41 was excluded because the identical study population had been used in a more 
recent study42 and two more studies43;44 that performed secondary analyses of the same 
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population. One case-control study45 was excluded because the population had been 
added to the sample of a later study46. A total of 18 studies fulfilled the inclusion and 
exclusion criteria and were assessed methodologically. 
Assessment of quality
Two observational studies47;48 were excluded from further analysis, because more 
than three items of the quality assessment checklist scored negative (Appendix 1, 
Tables S1-S3). Of the 12 observational studies included for further data analyses, three 
studies46;49;50 scored positive for all assessed items and were considered to have the 
highest level of quality with an estimated low risk of bias. Selection bias could not be 
excluded in six studies51-56. Of these, one study also provided insufficient information 
about study group characteristics52. Selective loss-to-follow-up could not be excluded 
in two of the cohort studies42;56. Blinding to outcome has not been reported in four 
studies42;53-55, and has not clearly been described in two studies51;57. Two studies52;53 did 
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- Review 
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- Oettinger-Barak et al (2005): Characteristics of the 
  study population not clearly defined, exposure not 
  assessed blinded to disease status, confounders not  
  taken into consideration, odds ratios not reported 
- Meurman et al (2006): Characteristics of the study  
  population not clearly defined, high risk on selection  
  bias, confounders not taken into consideration, odds  
  ratios not reported 
- Herrera et al (2009): Patients, therapists and effect  
  examiners not blinded to treatment, groups not  
  comparable at trial entry 




































clearly define preeclampsia51;58, while Shetty et al55 did not clearly specify the adopted 
periodontal disease definition in their statistical analysis. 
  One RCT59 was excluded from further analyses, because more than three items of 
the quality assessment scored negative (Appendix 1, Table S4). All three RCTs included 
were largely comparable in methodological quality. Clearly, blinding of patients and 
dental therapists to treatment was impossible, since treatment consisted of manual 
periodontal therapy. Two studies60;61 did not clearly specify whether staff members who 
included patients were blinded to randomization order.
 A total of 15 articles fulfilled the inclusion criteria and passed the quality assessment. All 
studies appeared to be published in peer-reviewed journals between January 2003 and 
August 2010. Below, each study is described and summarized in Tables 2 and 3.
 Cross-sectional studies
Castaldi et al52 examined the periodontal condition of 1562 women within 48 h after 
delivery. Of the total population included, 157 (10%) women were diagnosed with 
preeclampsia. The periodontal investigators were blinded for pregnancy outcomes. 
Gingivitis was found in 34.3% and severe periodontal disease in 17.5% of the women. 
After adjusting for smoking during pregnancy, no association was found between 
either gingivitis or severe periodontal disease and preeclampsia. The authors did not 
report to have adjusted for other confounding factors.
Case-control studies
 In a matched case-control study, Canakci et al (Canakci et al. 2004) examined within 
48 h prior to delivery, the periodontal condition of 41 preeclamptic women and 41 
normotensive healthy pregnant women. Cases and controls were individually matched 
for age, parity, gravidity, smoking and prenatal care. Periodontal disease was present in 
46.3% of women with preeclampsia and in 21.9% of controls. After adjusting for serum 
cholesterol levels, serum triglycerides levels and maternal body weight, the conditional 
multiple logistic regression analysis showed that preeclampsia was associated with 
periodontal disease.
  Contreras et al53 carried out a case-control study that included 130 pregnant women 
with preeclampsia and 243 healthy pregnant women. In both groups the periodontal 
status was determined between 26 and 36 weeks of pregnancy. Chronic periodontal 
disease was significantly more prevalent in the preeclamptic group (63.8%) compared 
with the control group (36.6%). When periodontal disease was further stratified in 
severity, incipient periodontal destruction was present in 42.3% of cases, compared 
with 27.2% of controls, whereas moderate-to-severe periodontal destruction was 
observed in 21.5% of cases, compared with 9.5% of controls. The authors did not report 
to have adjusted for confounding factors.
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  Khader et al49 conducted a blinded case-control study amongst 115 preeclamptic 
women and 230 healthy controls within 24 h after delivery. Only insured, non-smoking 
and non-alcohol drinking women were included in this study. After confounding for 
maternal age, parity, (family) history of preeclampsia, family history of cardiovascular 
disease, pre-pregnancy BMI, twin birth and self-reported emotional stress during 
pregnancy, no statistical differences were found between cases and controls concerning 
any of the eight periodontal parameters investigated.
  The association between periodontal disease and early-onset preeclampsia (<34 
weeks of pregnancy) was tested in a case-control study conducted by our own group54. 
The periodontal condition of 17 early-onset preeclamptic women and 35 women with 
uncomplicated pregnancies was examined in a period of 3-28 months postpartum. 
Severe periodontal disease was present in 82% of the post-preeclamptic women and in 
37% of the controls. After adjusting for age, BMI, smoking and educational level, severe 
periodontal disease was associated with preeclampsia.
  The aim of a case-control study performed by Canakci et al51 was to correlate the 
severity of periodontal disease to the severity of preeclampsia. Dental and periodontal 
examinations were performed in 20 mild preeclamptic, 18 severe preeclamptic and 21 
healthy pregnant women within 48 h preceding delivery. Mild periodontal disease was 
found in 16.7% of the severe preeclamptic women, in 25% of the mild preeclamptic 
women and in 28.6% of the controls. Severe periodontal disease was detected in 72.2% 
of the severe preeclamptic women, in 50% of the mild preeclamptic women and in 
33.3% of the controls. After adjusting for age, smoking, body weight, socioeconomic 
status and educational level, the results showed that severe periodontal disease was 
associated with both mild and severe preeclampsia.
  Siqueira et al46 performed a matched case-control study on 125 preeclamptic 
women and 375 healthy controls within 48 h after delivery. The frequency of 
periodontal disease before matching was significantly higher among the preeclamptic 
women (56.7%) than among the control group (39%). After matching and adjusting for 
maternal age ≥30 years, chronic hypertension, primiparity, previous pre-term birth and 
prenatal visits, periodontal disease remained associated with preeclampsia. However, 
when periodontal probing depth (PPD) and clinical attachment level (CAL) were tested 
with cut-off points of ≥5 mm or ≥7 mm, the ORs for preeclampsia were not significant, 
indicating that periodontal breakdown in itself was not associated with preeclampsia 
in this study.
  A recent epidemiological study was conducted by Lohsoonthorn et al50, who 
examined the periodontal condition of 150 preeclamptic and 150 healthy controls 
within 48 h after delivery. In the preeclamptic group, 49.3% of the women had mild 
periodontitis, 21.3% had moderate periodontitis and severe periodontitis was present 




































mild periodontitis, while moderate periodontitis was present in 20.7% and severe 
periodontitis in 4.7% of the women. After adjusting for maternal age, educational 
attainment, parity, pre-pregnancy BMI, annual household income, employment during 
pregnancy, marital status, onset of pre-natal care, alcohol use and smoking during 
pregnancy, no association between periodontal disease and preeclampsia was found. 
In addition to their periodontal disease definition62, the authors evaluated whether the 
previously found associations between periodontal disease and preeclampsia were 
due to differences in adopted periodontal disease definitions. Therefore they used 
definitions used by Canakci et al57, Contreras et al53, Lopez et al63 and Boggess et al42 on 
their dataset. In this Thai population, none of the definitions used by the other authors 
showed a significant association between periodontal disease and preeclampsia. 
  In a study conducted by Nabet et al58, the association between periodontitis and 
pre-term delivery (<37 weeks of gestation) was analysed according to the causes of pre-
term birth. For this purpose, 1108 cases with pre-term delivery (liveborn child between 
22-36 weeks of gestation) and 1094 controls with deliveries at term (≥37 weeks of 
gestation) were included in the study. One hundred and ninety-eight (18.1%) of the 
cases were induced pre-term deliveries due to preeclampsia. Periodontal examinations 
were performed within 2-4 days after delivery. Localized periodontitis was found 
in 13.6% of the cases and in 10.8% of the controls, while generalized periodontitis 
was present in 20.7% of the cases and in 10.8% of the controls. After adjusting for 
maternal age, parity, nationality, educational level, marital status, employment during 
pregnancy, BMI before pregnancy and smoking status, an association was observed 
between generalized periodontitis and induced pre-term birth due to preeclampsia.
  The most recently conducted case-control study so far was conducted by Shetty 
et al55, who examined the periodontal condition of 30 preeclamptic women and 100 
healthy pregnant controls at recruitment (26-32 weeks of gestation) and within 48 h 
after delivery. At enrolment, 100% of the cases and 78% of the controls were diagnosed 
with periodontal disease (CAL ≥3 mm). After adjusting for maternal age, body weight, 
occupation, education and income, severe periodontal disease (CAL >5 mm) both at 
enrolment as well as at delivery was associated with an increased risk of preeclampsia. 
There were no significant differences in disease progression between cases and 
controls.
Cohort studies
 As part of a prospective cohort study on the effect of maternal periodontal disease 
on obstetric outcomes (the Oral Conditions and Pregnancy Study, OCAP)41, Boggess et 
al42 examined the periodontal condition of 850 pregnant women at enrolment (before 
26 weeks’ gestation) and followed them until delivery. Thirty-nine women (4.6%) 
developed preeclampsia. At enrolment, 58.4% of the women were diagnosed with mild 
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periodontitis and 14.7% had severe disease. In order to determine periodontal disease 
progression, a second periodontal examination was performed in 763 of the women 
within 48 h after delivery. At this time, 37.3% of the women had mild periodontal 
disease and 13.1% had severe periodontal disease. Periodontal disease progression 
occurred in 26.6% of the women. After adjusting for maternal age, race, insurance 
status, delivery at <37 weeks’ gestation and smoking during pregnancy, the authors 
found that women were at a higher risk of developing preeclampsia if they had severe 
periodontal disease at delivery or periodontal disease progression during pregnancy. 
Periodontal disease at enrolment, however, was not associated with an increased risk of 
developing preeclampsia. 
  As part of a large multi-centre prospective cohort study (the Periodontal Infection 
and Prematurity Study, PIPS), the risk of adverse pregnancy outcomes in women with 
periodontal disease compared with those without disease was assessed by Srinivas et 
al56. In this study, 311 pregnant women with periodontal disease between 6 and 20 
weeks of gestation and 475 without periodontal disease were included. Periodontal 
examinations were performed by trained nurses. Sixteen women (5.2%) with periodontal 
disease developed preeclampsia, while in the periodontally healthy group 32 women 
(6.7%) developed preeclampsia. After adjusting for maternal age, race, tobacco, obesity 
and chronic hypertension, the authors found no association between the presence of 
periodontal disease during pregnancy and preeclampsia.
RCTs
 In an intervention study conducted by Michalowicz et al60, the effect of periodontal 
treatment on pregnancy outcomes was examined. Eight hundred and twelve pregnant 
women with periodontal disease were randomly assigned to two groups between 
13 and 17 weeks of gestation. Periodontal disease was assessed at trial entry, at 21-
24 weeks’ gestation and at 29-32 weeks’ gestation. The treatment group received 
periodontal therapy before 21 weeks of gestation, which consisted of up to four sessions 
of scaling and rootplaning (SRP). Treatment participants also received monthly tooth 
polishing, oral hygiene instruction and if needed, SRP was provided to the treatment 
group until delivery. The control group received only a brief examination at monthly 
follow-ups and received periodontal treatment after delivery. Although the primary 
outcome of this study was gestational age at the end of pregnancy (pre-term birth), the 
authors also evaluated preeclampsia as one of the secondary outcomes. Periodontal 
treatment during pregnancy did not significantly alter the rate of preeclampsia, despite 
the improvement of the periodontal status.
  Offenbacher et al61 also studied the effects of periodontal treatment on the 
frequency of pre-term birth as the primary outcome and preeclampsia as one of the 




































Oral Therapy to Reduce Obstetric Risk Study (MOTOR)]. One thousand seven hundred 
and sixty eligible pregnant women with at least 20 teeth present and diagnosed with 
periodontal disease were randomly assigned to receive periodontal treatment either 
before 23 6/7 weeks of gestation (treatment group) or after delivery (control group). 
Periodontal examinations were performed at baseline and at delivery. Periodontal 
treatment included up to four sessions of SRP, full-mouth tooth polishing and 
oral hygiene instruction. There were no significant differences in the frequency of 
preeclamptic pregnancies when comparing the women in the treatment group with 
those in the control group.
  Newnham et al64, investigated whether periodontal treatment prevented major 
pregnancy complications, with pre-term birth as the primary outcome, and low birth 
weight and preeclampsia as secondary outcomes. For this purpose, 1078 pregnant 
women were allocated at random to receive periodontal treatment at ±20 weeks of 
gestation (treatment group) or after delivery (control group). Periodontal examinations 
were performed at trial entry (between 12 and 20 weeks gestation). Periodontal 
treatment included up to three sessions of SRP, removing of overhanging restorations 
and comprehensive oral hygiene instructions. Patients were advised to additionally 
rinse with 0.12% chlorhexidin. At gestational week 28, further examinations were 
performed and a 3-week follow-up periodontal treatment was offered to the treatment 
group if necessary, and monthly motivation and oral hygiene instruction was provided. 
Periodontal examinations were repeated at 32 and 36 weeks’ gestation. Although 
periodontal treatment during pregnancy significantly improved the periodontal status, 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































After combining the data from the RCTs, the pooled RR of preeclampsia was 1.0 (95% CI 
0.78-1.28) (Fig. 2). Statistical heterogeneity is Cochran’s Q= 3.24 (df=2, p=0.198).
DISCuSSION
The present review summarizes the results of observational studies and RCTs 
investigating the relationship between periodontal disease and preeclampsia. It shows 
that an association between periodontal disease and preeclampsia was seen in eight 
observational studies while four of the observational studies failed to find such an 
association. None of the RCTs showed a reduction in preeclamptic pregnancies after 
periodontal treatment during pregnancy. 
  The reasons for the heterogeneity in findings among the observational studies 
cannot precisely be determined, because several methodological differences may 
have biased study outcomes. To be able to assess the methodological quality of the 
studies, we used specific study-design-related forms based on the Dutch Cochrane 
Collaboration checklists. Although all studies fulfilled the minimum score of our 
quality assessment, differences in quality between the studies may contribute to the 
heterogeneity in results. However, even within the three case-control studies with the 
Fig. 2. Fixed effect analysis of the meta-analyses of randomized-controlled trials.
244 45
highest methodological quality (plusses on all items), no homogeneity was observed 
between the results: Khader et al49 and Lohsoonthorn et al50 failed to find an association, 
while Siqueira et al46 reported a positive association between periodontal disease and 
preeclampsia. Moreover, although both cohort studies scored seven plusses (out of nine 
items) on the quality assessment, one cohort study42 reported a positive association, 
while the other cohort study 56 found no association between the two diseases. Thus, 
the observed heterogeneity cannot be explained by methodological quality alone, as 
there appears to be no relation between the quality of the studies included and their 
results.
  One of the pertinent issues is the potential lack of power calculation, as only five 
out of 12 observational studies reported to have performed power calculations. This 
problem can be circumvented by performing a meta-analysis. However, we were not 
able to do this due to the methodological differences among the observational studies, 
which is the most obvious limitation of this review. One other important limitation 
of this review is the variety in clinical disease definitions for periodontal disease. At 
least nine different periodontal disease definitions were adopted throughout the 15 
studies reviewed. Because the strength of the association between periodontal disease 
and pregnancy outcomes may depend upon the periodontal disease definition65, it is 
difficult to compare study outcomes.
  Moreover, although commonly accepted periodontal definitions take mean PPD 
and CAL (or specific cut-off points for PPD and CAL) as a means to classify periodontitis, 
PPD and CAL are linear measures that do not necessarily reflect active periodontal 
disease and do not quantify the total inflammatory burden66. In order to estimate 
active periodontal disease, also bleeding on probing (BOP) should be included in 
the periodontal assessment. It is important to observe that all studies that included 
BOP in their periodontal disease definition found an association between periodontal 
disease and preeclampsia42;51;53;54;57. In contrast, four out of seven studies that did 
not include BOP in their definition failed to find an association49;50;52;56. Therefore, the 
adopted criteria for defining periodontal disease in the studies reviewed may not 
provide the proper tool to draw a decisive conclusion on periodontitis as a risk factor 
for preeclampsia. Furthermore, eight of the observational studies excluded third molar 
periodontal pathology from the analysis46;49-51;54;55;57;58. It is possible that exclusion of 
third molar pathology, which has recently been associated with pre-term birth67 has 
led to an underestimation of periodontal disease and therefore may have biased study 
outcomes. 
  Periodontal disease as well as preeclampsia are of a multifactorial nature, and both 
diseases share some common risk factors, like ethnicity68;69. Although periodontal 
disease was associated with preeclampsia in certain populations (i.e. Turkish, Dutch and 




































definition. Thus, in certain ethnic populations, other factors, e.g. genetically determined 
host responses, might be involved. Some of the studies did not clearly report the 
ethnicity of their populations51;52;58, or included heterogeneous populations42;46;53;56. 
 Also, smoking and obesity may influence the severity of both conditions70-74. Smoking 
increases the risk of periodontal disease75, but paradoxically decreases the risk of 
preeclampsia76-78. Although most studies reported to have controlled for smoking 
or excluded smoking during pregnancy, smoking behaviour was only reported 
dichotomously (yes/no). Therefore, smoking behaviour may have had some residual 
confounding effects on the strength of the association. Furthermore, three of the 
studies did not report or adjust for BMI in their analyses46;52;53.
  All observational studies met the minimum criteria for defining preeclampsia79. 
However, a distinction can be made between early-onset preeclampsia (gestational age 
<34 weeks) and late-onset preeclampsia (gestational age >34 weeks)80;81. The two forms 
differ in pathogenesis, genetic risk and inheritance30;81. Indeed, in the study of Shetty et 
al55, a remarkably high incidence of periodontal disease was observed in early-onset 
preeclamptic women. This could indicate that an association between periodontal 
disease and preeclampsia may only be evident in certain forms of preeclampsia. 
Concerning the RCTs, none of the studies reported a clear definition for preeclampsia. 
Because Offenbacher et al61 performed therapy up to 24 weeks’ gestation, it cannot be 
excluded that some of the women assigned to the treatment group already developed 
early-onset preeclampsia before intervention. This may have biased study outcomes.
  Inconsistent findings in the observational studies may also be due to differences 
in the time points of the periodontal screening. The periodontal disease status was 
examined at different time points during pregnancy or post-partum, ranging from 
before 26 weeks of gestation to 3-28 months postpartum. The long time span between 
outcome and exposure in the study of Kunnen et al54 may have allowed for changes in 
the periodontal condition. Moreover, one may argue that in this study, preeclampsia 
was the exposure and the periodontal status the outcome. Therefore, this study may 
suggest that preeclampsia induced periodontal disease rather than that periodontal 
disease induced preeclampsia. Also, the timing of periodontal treatment may not 
have been optimal. The clinical symptoms of preeclampsia are thought to be late 
manifestations of pathological processes in the first half of pregnancy24;80. Therefore, 
periodontal therapy at ±20 weeks of gestation may be too late in pregnancy to prevent 
preeclampsia. Moreover, translocation of microorganisms from the periodontal 
infection to the placental tissues may have occurred before therapy.
  Although the present review does not undisputedly show that periodontal disease 
induces preeclampsia; there are various indications that periodontal disease may play 
a role in the pathogenesis of preeclampsia. Key pathogens associated with periodontal 
disease in adult subjects are the gram-negative microorganisms Aggregatibacter 
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actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Tannerella 
forsythia, Fusobacterium nucleatum and the gram-positive Parvimonas micra82. Some 
studies found a higher prevalence of P. gingivalis, Eikenella corrodens and T. forsythia39;53 
or P. micra54 in subgingival plaque samples of preeclamptic women as compared with 
healthy pregnant controls. These bacteria produce a variety of pro-inflammatory 
factors, e.g. lipopolysaccharide (LPS)83-86, which may further activate the normal 
inflammatory response during pregnancy, ultimately resulting in preeclampsia. Indeed, 
infusion of low doses of Escherichia coli LPS into pregnant rats leads to activation of the 
inflammatory response and subsequently to a preeclampsia-like syndrome87. Whether 
LPS of gram-negative oral pathogens is also capable of provoking preeclampsia-like 
symptoms is under investigation. Also, the bacteria themselves may also enter the 
circulation and affect the inflammatory response or tissues directly. Barak et al37 found 
increased bacterial counts for all important periodontal pathogens in placentas of 
women with preeclampsia. The presence of periodontal pathogens in placental tissues 
of preeclamptic pregnancies may imply a role for these bacteria in the pathogenesis of 
preeclampsia.
  Interestingly, prospective studies that performed periodontal examinations 
before 26 weeks of gestation failed to find an association42;56. In fact, although 
Boggess et al reported that periodontal disease at delivery or periodontal disease 
progression during pregnancy was associated with preeclampsia, periodontal disease 
at enrolment (gestational age <26 weeks) was not associated with an increased risk 
of developing preeclampsia42. This may suggest that periodontal disease does not 
induce preeclampsia. Although these studies were not designed to demonstrate that 
preeclampsia is a risk factor for the induction of periodontal disease, the possibility can 
not be ruled out that the preeclamptic state itself may have induced or aggravated 
periodontal problems, as was suggested above for the study of Kunnen et al54. This is 
in line with the two-hit model of Golub et al88. In this model, the first hit is initiated 
by detrimental microbial products arising from the periodontal biofilm. The second 
hit is the generalized inflammatory disease (in this case preeclampsia) with increased 
circulating levels of pro-inflammatory cytokines. Together these two hits could lead to 
an increase of local inflammatory mediators and effector molecules including matrix 
metalloproteinases, and finally to periodontal breakdown.
  The present review shows that in order to further evaluate the relationship 
between periodontal disease and preeclampsia, there is great need for larger studies, 
with standardized protocols. It is especially important to use a universal standardized 
periodontal disease definition that includes the inflammatory burden and assesses 
the risk of systemic effects of periodontitis. Interestingly, such a model has recently 
been developed by Nesse et al: the PISA method (Periodontal Infected Surface Area)66. 




































millimetres and can therefore quantify the total inflammatory burden. Also, RCTs 
should be performed that have preeclampsia as primary outcome. Moreover, it is 
recommended that future studies focus on dissecting the biological mechanisms that 
may link both conditions. Additional studies in terms of virulence properties of oral 
pathogens and subsequent host responses to these pathogens during pregnancy as well 
as pathophysiological studies investigating foetal exposure to periodontal microbiota 
and maternal immune responses are warranted. Since there is convincing evidence in 
non-pregnant individuals that systemic antibiotics improves periodontal health and has 
a long-term reducing effect on the bacterial infection89, future research on the effects 
of periodontal therapy during pregnancy may include the prescription of antibiotics.
CLINICAL RELEvANCE
Scientific rationale for the study: Periodontal disease has been proposed to contribute to 
the pathogenesis of preeclampsia. Therefore, we reviewed the scientific evidence of the 
relationship between periodontal disease and preeclampsia.
Principal findings: There are indications of an association between periodontal disease 
and some forms of preeclampsia. This is most obvious in early-onset preeclampsia. 
However, it is unclear whether periodontal disease plays a causal role in preeclampsia, 
for this review not only shows that periodontal therapy performed at about 20 
weeks of gestation did not reduce preeclamptic rates but also studies focusing 
on the periodontal condition at enrolment, i.e. before preeclampsia had occurred, 
failed to show an association. Therefore, periodontal disease at delivery may be the 
consequence of the preeclamptic state rather than vice versa. Inconsistent findings 
among the observational studies may be due to a large variety in periodontal disease 
definitions and timing of screening. 
Practical implications: 
Periodontal treatment during pregnancy did not seem to influence the risk of 
preeclampsia. Larger RCTs with standardized protocols and preeclampsia as the 
primary outcome, as well as pathophysiological studies are required to determine 
whether the observed relationship between preeclampsia and periodontal disease 
in some studies is causal or simply associative. So far, periodontal treatment during 
pregnancy, if needed, is not contraindicated.
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SuPPORTING INfORMATION
Appendix 1, Supplemental Table S1: Dutch Cochrane Collaboration quality assessment 
checklist for case-control studies.
Appendix 1, Supplemental Table S2: Dutch Cochrane Collaboration quality assessment 
checklist for cohort-studies.
Appendix 1, Supplemental Table S3, Quality assessment checklist for cross-sectional 
studies, adapted from the Dutch Cochrane Collaboration quality checklist for cohort 
studies.
Appendix 1, Supplemental Table S4: Dutch Cochrane Collaboration quality assessment 
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Supplemental Table S1. Quality assessment of the case-control studies* 
 
Study Canakci  Oettinger- Contreras Khader Kunnen Canakci Siqueira Lohsoon-  Nabet Shetty 
 et al  Barak et al et al et al et al et al et al thorn et al  et al et al 
Quality criteria (2004) (2005) (2006) (2006) (2007) (2007) (2008) (2009)  (2010) (2010) 
       
Are the characteristics of  
the study group 
clearly defined? +  – + + + + + +  + + 
 
Are the characteristics of  
the control group  
clearly defined? +  – + + + + + +  + + 
 
Can selection bias sufficiently  
be excluded? +  + – + – – + +  + – 
 
Are the exposure and method  
of assessment clearly defined  
(periodontal disease)? +  + + + + + + +  + – 
 
Are the outcome and method  
of assessment clearly defined  
(preeclampsia)? +  + + + + +/– + +  +/– + 
 
Is the exposure assessed blinded  
to disease status? ?  – – + – ? + +  +/– – 
 
Are the most important confounders  
identified and are these taken into  
consideration with respect to 
the study design and analysis? +  – – + + + + +  + + 
 
Reported odds ratios or risk ratios  
with 95% CI? +  – + + + + + +  + + 
 
*Quality assessment according to the Dutch Cochrane Collaboration checklist for case-control studies.  
Five or more plusses: methodologically acceptable. 
  
 
Supplemental Table S2. Quality assessment of the cohort studies* 
 
Study Boggess et al Meurman et al Srinivas et al 
Quality criteria (2003) (2006) (2009)     
    
Are the characteristics of the comparative study  
groups clearly defined? + – + 
 
Can selection bias sufficiently be excluded? + – – 
 
Are the exposure and method of assessment  
clearly defined (periodontal disease)? + + + 
 
Are the outcome and method of assessment 
clearly defined (preeclampsia)? + + + 
 
Is the outcome assessed blinded to the exposure status? – + + 
 
Is there a sufficient follow-up? + + + 
 
Can selective loss-to-follow-up 
sufficiently be excluded? – + – 
 
Are the most important confounders identified 
and are these taken into consideration with respect  
to the study design and analysis? + – + 
 
Reported odds ratios or risk ratios with 95% CI? + – + 
 
*Quality assessment according to the Dutch Cochrane Collaboration checklist for cohort studies. 








































Supplemental Table S3. Quality assessment of the cross-sectional study* 
 
Study Castaldi et al  
Quality criteria (2006)      
    
Are the characteristics of the comparative study  
groups clearly defined? –  
 
Can selection bias sufficiently be excluded? – 
  
Are the exposure and method of assessment  
clearly defined (periodontal disease)? +  
 
Are the outcome and method of assessment 
clearly defined (preeclampsia)? +  
 
Is the outcome assessed blinded to the exposure status? +   
 
Are dropouts and reasons for dropout reported? +  
 
Are the most important confounders identified 
and are these taken into consideration with respect  
to the study design and analysis? –  
 
Reported odds ratios or risk ratios with 95% CI? + 
 
*Quality assessment adapted from the Dutch Cochrane Collaboration checklist for cohort studies. 





Supplemental Table S4. Quality assessment of the randomized-controlled trials* 
 
Study Michalowicz et al Herrera et al Offenbacher et al Newnham et al 
Quality criteria (2006) (2009) (2009) (2009)  
    
Was the assignment of patients to the intervention 
randomized? + + +  + 
 
Were staff members who included patients 
aware of the randomization order? ? + ?  + 
 
Were patients blinded to the treatment? – – –  – 
 
Were dental therapists blinded to the treatment? – – –  – 
 
Were effect examiners blinded to the treatment? + – +  + 
 
Were the groups comparable at trial entry? + – +  + 
 
Is there a sufficient number of patients 
with a completed follow-up? + ? +  + 
 
Are all the included patients analysed in the 
group of randomization? + + +  + 
 
Apart from the intervention, did both groups  
receive equal treatment? + + +  + 
 
*Quality assessment according to the Dutch Cochrane Collaboration checklist for randomized-controlled trials. 
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Objective: Preeclampsia is a complication of pregnancy characterised by systemic 
vascular dysfunction and pathological changes in placental arteries. Growing evidence 
of chronic infection as an aetiological factor in vascular diseases prompted us to study 
maternal periodontal disease in subjects with early-onset preeclampsia (<34 weeks).
Methods: A case-control study was carried out on 17 early-onset preeclamptic 
women and 35 controls with uncomplicated pregnancies in a period of 3-28 months 
postpartum. All were Caucasians. Full mouth periodontal examinations were performed 
to determine the periodontal condition. Subgingival plaque samples were analysed by 
anaerobic culture techniques for the presence of 7 bacterial periodontal pathogens. 
Potential confounders as age, smoking, educational level and body mass index were 
determined.
Results: Severe periodontal disease was found in 82% of the preeclamptic and in 37% 
of the control group (p=0.009). After adjusting for age, smoking and educational level, 
the odds ratio was 7.9 (95% CI: 1.9-32.8). The periodontopathic microorganism M. micros 
was more prevalent in the case group (p=0.040) while C. rectus was more prevalent in 
the control group (p=0.047).
Conclusion: These results indicate that Caucasian women with a recent history of early-




There is growing evidence that periodontal disease is associated with adverse 
pregnancy outcome, e.g. preterm birth, low birthweight, miscarriage and preeclampsia 
as reviewed by Xiong and co-workers1. So far, most studies have been focused on 
the role of periodontal disease in preterm birth2-6, including intervention studies 
suggesting that periodontal treatment reduces the risk of preterm birth7;8. Results 
of recent investigations have suggested that periodontal disease is more prevalent 
in preeclampsia9-12. Preeclampsia is a multisystemic maternal vascular disease with 
endothelial dysfunction, clinically manifest during the second half of pregnancy by 
hypertension, proteinuria and varying dysfunction of major organs as the liver, the 
kidneys and the brain. It is a major cause of both maternal and foetal mortality and 
morbidity13-15. Early-onset preeclampsia is a severe form of preeclampsia, occurring 
before 34 weeks of pregnancy and very often accompanied by restricted foetal 
growth16 which is thought to be the result of insufficient placentation in the first half of 
pregnancy. 
 Until now, the mechanisms causing the maternal vascular abnormalities during 
the second half of pregnancy have not been fully clarified. The current opinion is that 
several mechanisms can result in the final common pathway of maternal endothelial 
dysfunction17;18. There is considerable evidence that one of these mechanisms is an 
exaggerated inflammatory response19-21. Chronic inflammation including periodontal 
disease, has been linked to atherosclerosis, another manifestation of vascular 
endothelial disease22-24. This prompted us to study maternal periodontal disease in 
subjects with early-onset preeclampsia (<34 weeks). Periodontal disease as well as 
preeclampsia are of multifactorial nature, including e.g. ethnicity and socioeconomic 
status. The reported studies on periodontitis and preeclampsia were carried out in 
ethnically heterogenous populations. The aim of the present study was to investigate 
the periodontal condition in a homogenous Caucasian population with a recent history 
of early-onset preeclampsia. To exclude direct possible hormonal influences caused by 
pregnancy, we compared the periodontal condition of women with a recent history 




A case-control study was carried out in the northern part of the Netherlands to compare 
the periodontal status between women with previous early-onset preeclampsia (N=17) 
and women with an uncomplicated pregnancy (N=35) in a period of 3-28 months 
postpartum. Women who previously were referred to the Department of Obstetrics & 



























































Preeclampsia was defined according to the criteria of the International Society for the 
Study of Hypertension in Pregnancy: the appearance of a diastolic blood pressure 
≥90 mmHg measured at 2 occasions at least 4 hours apart in combination with 
proteinuria (≥300 mg/24 hours or 2+ dipstick) developing after a gestational age of 20 
weeks in a previously normotensive woman. Early-onset preeclampsia was defined as 
preeclampsia occurring before 34 weeks of pregnancy. Healthy controls were recruited 
by advertisements in local news papers. Only women of Caucasian origin were included. 
All women have been under a pregnancy control program during their pregnancy by 
midwives or general physicians. Women with pre-existing hypertension (blood pressure 
before 20 weeks of gestation ≥140/90 mmHg or using anti-hypertensive medication), 
diabetes mellitus, renal disease, cardiovascular disease or any systemic illness, multiple 
pregnancy or post partum thyroiditis were excluded from the study. Patients who had 
received periodontal treatment in the past or patients on antibiotic medication during 
pregnancy or the post-partum period were also excluded, as well as women who were 
pregnant or breast feeding in the preceding three months before study-inclusion. 
All participants received information about the purpose of the study and provided 
informed consent before participation. After investigation, the subjects were informed 
about their periodontal status and advised on further treatment if indicated.
Data collection
Obstetric and medical history, educational level and health behaviour data of the 
preeclamptic women were obtained from the medical records of the Department of 
Obstetrics & Gynecology. Data of the control group were collected by questionnaire. 
This questionnaire was designed to gather data on medical history, previous pregnancy 
history (including gestational age at delivery, onset of delivery, birth weight and 
gender of the neonate), educational level, smoking habits and health behaviour data. 
Educational level was used as marker for socioeconomic status. Oral hygiene behaviour 
data were obtained by patient interview at the first visit.
Periodontal examinations
Participants underwent a full periodontal examination by one certified dental hygienist 
(AK). Clinical examinations were performed to determine the following variables: plaque 
index, bleeding on probing (BOP), pocket probing depth (PPD), clinical attachment 
level (CAL) and gingival recessions (GR). PPD and GR were measured in millimeters 
(to the nearest millimeter) with a Williams UNC-15 periodontal probe at six sites per 
tooth, excluding the third molars. PPD was defined as the distance from the gingival 
margin to the bottom of the pocket. GR was calculated from the distance from the 
cementoenamel junction (CEJ) to the gingival margin. CAL was measured in millimeters 
at two sites per tooth (buccal and lingual) and was defined as the distance from the 
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CEJ to the bottom of the pocket. CAL was calculated by distracting the distance of the 
gingival margin to the CEJ from the PPD, or in case of visible CEJ: PPD plus GR. BOP was 
expressed as the percentage of sites showing bleeding on probing. The periodontal 
condition was determined by the sum of all pockets with PPD ≥4 mm and BOP. The 
periodontal condition was further stratified in severity according to the criteria used by 
Boggess et al9. Periodontal health was defined as absence of pocket probing depths ≥4 
mm. Mild periodontal disease was defined as 1 up to 15 tooth sites with ≥4 mm pocket 
depth and BOP. Severe periodontal disease was defined as ≥15 tooth sites with ≥4 mm 
pocket depth and BOP. 
Microbiological procedures
In each subject gingival crevicular fluid samples were collected from the deepest 
periodontal pocket in each quadrant (for a total of 4 samples) after periodontal 
examination. Sterile paperpoints were inserted to the bottom of the periodontal 
pockets for 10 seconds and pooled in reduced transport fluid (Syed & Loesche25) and 
analysed by anaerobic culture techniques for the presence and levels of Actinobacillus 
actinomycetemcomitans (Aa), Porphyromonas gingivalis, (Pg), Prevotella intermedia (Pi), 
Tannerella forsythensis (Tf ), Micromonas micros (Mm), Fusobacterium nucleatum (Fn) and 
Campylobacter rectus (Cr).
 After vortexing for 30 secs, samples were tenfold serially diluted in RTF and 100 ul of 
appropriate dilutions were plated on non-selective 5% horse blood agar plates (Oxoid 
no. 2, Oxoid Ltd., Basingstoke, England) supplemented with haemin (5 mg/L) and 
menadione (1 mg/L) for enumuration of the total anaerobic bacterial count and to test 
for the presence and relative proportions of specific periodontal pathogens. Samples 
were also plated onto tryticase soy serum-bacitracin-vancomycin plates (TSBV, Slots26) 
for the isolation and enumeration of Actinobacillus actinomycetemcomitans. TSBV plates 
were incubated in air plus 5% CO2 at 37ºC for 5 days. Blood agar plates were incubated 
for 14 days at 37ºC in 80% N2, 10% CO2 and 10% H2. 
Data processing and statistical analyses
All data were stored in and analysed using SPSS 12.0. Univariate association between 
periodontal disease and presence or absence of preeclampsia (nominal data) was 
assessed using chi-square test. Differences between the case and the control group were 
in case of normally distributed continuous data analysed by Student’s t-test, and in case 
of nominal data by the chi-square test. Pearson correlation coefficients were calculated 
to assess the association between the periodontal condition and postpartum period. 
Multivariate logistic regression analysis was used to determine the association between 
periodontal disease and preeclampsia adjusted for potential confounders (smoking, 
body mass index (BMI), socioeconomic status and age). From the logistic regression 
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 Table 1. Maternal and obstetric characteristics of preeclamptic women and  
non-preeclamptic women 
 
 Preeclampsia Controls p value  
 (N = 17) (N = 35)  
 
Age (year)  29.5 (5.1) 31.7 (4.2) 0.095  
Body Mass Index (kg/m²)  27.8 (6.6) 24.3 (3.9) 0.051 
Family history of CVD  13 (77%) 11 (31%) 0.002 
Primigravida  16 (94%) 35 (100%) 0.147 
Gestational age at delivery (weeks)  30.7 (2.8) 39.9 (1.4) <0.001 
Birthweight child (gr.)  1133 (300) 3532 (417) <0.001 
Smoking during pregnancy  3 (18%) 3 (9%) 0.337 
Educational level    0.020 
 Very low  0 (0%) 2 (5.7%)  
 Low  1 (5.9%) 1 (2.9%) 
 Moderate  11 (64.7%) 8 (22.9%) 
 High  5 (29.4%) 24 (68.6%) 
Interval delivery to day of study (months) 14.0 (8.2) 15.7 (5.8) 0.434 
 
Values are expressed as means (SD) or number (%) unless otherwise stated. 





























































analysis odds ratios were calculated with 95% confidence interval (CI). p<0.05 was 
accepted as statistically significant.
RESuLTS
Of a total of 25 women with a history of early-onset preeclampsia who were asked to 
participate, 17 agreed to participate in the study. There was no evidence for selection 
bias in recruitment; in particular, participants and non-participants were of similar age 
and parity, and they had similar blood pressure before the index pregnancy. Of the 36 
controls, one woman was excluded because of recent antibiotic medication.
 Table 1 shows the maternal and obstetric characteristics of the participants. There 
were no differences between case- and control group, with exception of educational 
level and family history of cardiovascular disease. 
The results of the periodontal examinations are presented in Table 2. The periodontal 
condition in the preeclamptic group was significantly worse compared with the controls. 
Severe periodontal disease was found in 14 of the 17 (82%) preeclamptic women and 
in 13 of the 35 (37%) women in the control group. Mild periodontal disease was found 
in three of the 17 (18%) preeclamptic women and in 21 of the 35 (60%) women in the 
control group (p=0.009). One person in the control group was periodontally healthy. 
After adjusting for age, BMI, smoking and educational level, the odds ratio was 7.9 (95% 
CI: 1.9-32.8) (Figure 1). 
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Table 2. Periodontal and clinical dental variables in preeclamptic and  
non-preeclamptic women 
 
 Preeclampsia Controls p value 
 (N = 17)  (N = 35)  
 mean (SD) mean (SD) 
 
Mean PD (mm) 2.94 (0.37) 2.57 (0.31) 0.000 
PD ≥ 4 mm 30.18 (18.48) 15.23 (13.12) 0.001 
PD 4 mm 19.53 (8.57) 11.00 (7.77) 0.001 
PD 5 mm 7.82 (7.33) 3.37 (5.59) 0.019 
PD 6 mm 2.82 (4.49) 0.86 (2.58) 0.050 
Mean CAL (mm) 1.38 (0.63) 1.10 (0.45) 0.073 
% sites with bleeding 55.81 (20.41) 45.71 (20.45) 0.101 
% sites with plaque 78.71 (15.18) 77.84 (17.11) 0.858 
Tooth loss* 0.59 (0.80) 0.54 (1.12) 0.882 
 
*Number of teeth lost excluding third molars. 





To assess bias caused by possible third molar defects or eruption problems, we also 
determined the periodontal condition with exclusion of the distal sides of the second 
molars. Severe periodontal disease was then found in 13 of the 17 (76%) preeclamptic 
women and in 12 of the 35 (34%) women in the control group while mild periodontal 
disease was found in four of the 17 (24%) preeclamptic women and in 22 of the 35
3











Odds ratio for severe periodontal disease = 7.9 (95% CI: 1.9-32.8).
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(63%) women in the control group (p=0.016). The odds ratio then became 6.2 (95% CI: 
1.7-23.3). No association was found between postpartum period and the periodontal 
condition.
 There was no significant difference in the presence of periodontopathic micro-
organisms between cases and controls, with exception of M. micros, which was detected 
more frequently in the case group (p=0.040) and C. rectus, which occurred more often 
in the control group (p=0.047) (Table 3). Two of the microbiological samples were lost 
during transport.
DISCuSSION
This study shows that Caucasian, western European women with a recent history of 
early-onset preeclampsia have a worse periodontal condition compared with healthy 
controls. These findings are consistent with previous findings that periodontal disease 
is associated with preeclampsia9-12. Caution is needed in interpreting these results due 
to the limited number of cases. Until now, no conflicting results have been reported in 
past studies on an association between preeclampsia and periodontal disease. This is 
in contrast with studies on an association between periodontal disease and preterm 
birth, where findings throughout the years have not been consistent. Several potential 
biases have been noted among past studies, with the most important being the great 
variation in periodontal disease definitions1. To overcome this problem, we tried to 
obtain consistency by stratifying periodontal disease according to the definitions used 
by Boggess et al9. Classifying periodontal disease on PPD ≥4 mm, however, might not 
Table 3. Prevalence of periodontopathic micro-organisms in preeclamptic  
and non-preeclamptic women 
 
Micro-organism Preeclampsia Controls p value 
 (N = 17) (N = 35) 
 n (%) n (%) 
 
Red complex 
P. gingivalis 1 (6.7) 2 (5.7) 0.777 
T. forsythensis 12 (80) 22 (62.9) 0.283 
 
Orange complex 
P. intermedia 3 (20) 7 (20) 0.709 
F. nucleatum 15 (100) 34 (97.1) 0.158 
M. micros 15 (100) 25 (71.4) 0.040 
C. rectus 1 (6.7) 5 (14.3) 0.047 
 
Green complex 














be discriminating enough with respect to the severity of periodontal disease and might 
lead to overestimation of the disease. In this respect it is interesting to mention a recent 
study in which different periodontal measurements and/or definitions are compared 
in relation to earlier observed associations between periodontal disease and risk 
of myocardial infarction27. Results of this case-control study show that the observed 
associations remained consistent across different periodontal measurements/
definitions. The association was strongest when PPD was used to measure periodontal 
disease.
 Furthermore, our study was carried out postpartum, while the studies in the USA9, 
Turkey10, Israel12 and Colombia11 were carried out during pregnancy. This and the 
wide periodontal examination period (3-28 months postpartum) in our study merit 
discussion. The periodontal status after delivery might have changed over this period 
of time. None of the women in the case or control group reported specific periodontal 
treatment. With no intervention it is unlikely to expect spontaneous improvement 
in periodontal condition or bacterial load28. Since we excluded women who were 
pregnant of breast-feeding within three months prior to study-inclusion, hormonal 
influences on the periodontal condition are no longer to be expected. No correlation 
was found among the postpartum period and the periodontal condition. This suggests 
that there has been no systematic improvement or worsening of the periodontal 
condition postpartum. However, periodontal disease status might have worsened in 
the individual patient throughout the postpartum period.
 The background of the connection between periodontal disease and preeclampsia 
is far from clear. There are several possibilities. Firstly, preeclampsia and periodontal 
disease have risk factors in common. Although we accounted for these common risk 
factors by exclusion of patients of black race and patients with diabetes mellitus, and 
by correction for low socioeconomic status in the statistical analyses, we can not rule 
out the possibility of an unknown factor that predisposes to both preeclampsia and 
periodontal disease. This unknown factor might be a genetic one involved in the process 
of atherosclerosis, since a family history of cardiovascular disease was more prevalent 
in the preeclamptic group and a history of preeclampsia as well as periodontal disease 
increase the risk of atherosclerotic manifestations29-33. Remarkably, the prevalence 
of smoking is high and nearly the same in the preeclamptic group as in the control 
group. Smoking, however, is a risk factor for periodontal disease34, poor foetal growth35 
and preterm birth36, but seems to reduce the risk of developing preeclampsia37. This 
unexpected high rate of smoking in the preeclamptic group could have contributed to 
the high prevalence of severe periodontal disease in this group. 
 Secondly, it is possible that preeclampsia leads to an aggravation of pre-existing 
periodontal problems or even co-induces periodontal disease38. Alterations in the 



























































strate altered Th1-cytokine and CD4 cell expression in preeclampsia39-41. Th1-cytokines 
and CD4 cells play an important role in controlling ongoing infections and the host’s 
tissue destruction seen in periodontal disease progression42. 
 Thirdly, pre-existing (severe) periodontal disease might play a role in the initiation 
and progression of early-onset preeclampsia, since the presence of a chronic infection 
during pregnancy is thought to be a risk factor for preeclampsia43;44. It has been 
hypothesised that periodontal disease generates an inflammatory reaction leading 
to elevated systemic levels of cytokines, such as tumour necrosis factor-alpha (TNF-α), 
prostaglandin E2 (PGE2), interleukin-1β and interleukin-8
45. This host response to a long-
term exposure of periodontal pathogens may provoke systemic maternal and placental 
pro-inflammatory endothelial activation and dysfunction, which represent a significant 
risk factor for diseases of vascular origin, such as preeclampsia17;18;20;46.
 The prevalence of the periodontal pathogen M. micros was significantly higher in 
the preeclamptic group, while C. rectus was found more often in the control group. 
M. micros is a known bacterial marker for destructive periodontal disease in adult 
subjects47. The higher prevalence of M. micros in the preeclamptic group may be 
explained by the worse periodontal status in this group. M. micros and C. rectus are 
both members of the ‘orange’ complex, which is one of the two complexes thought 
to consist the major etiologic agents associated with periodontal disease48. Recently, 
Skuldbøl et al49 found M. micros significantly more often in the subgingival plaque of 
women with pre-term birth in comparison to women with term birth49. Buduneli et 
al50 and Madianos et al51 also evaluated the microbiological differences in subgingival 
plaque between preterm and full-term mothers. They found no significant differences 
in the prevalence of the individual periodontopathic micro-organisms between cases 
and controls, although Madianos found elevated levels of foetal IgM to C. rectus among 
the premature infants51. However, when multiple micro-organisms of the subgingival 
plaque were evaluated together, regression analysis indicated that the presence of both 
M. micros and C. rectus might lead to an increased risk on preterm birth50. The authors 
suggest that this might be explained by complex actions of different micro-organisms 
rather than the presence of individual species. The results of our present study are not 
congruent with the results of these articles and do not support this hypothesis. The role 
of M. micros in the development of preeclampsia remains therefore unclear.
 In case of a causal link between periodontal disease and preeclampsia, periodontal 
treatment is to be expected to reduce the risk of preeclampsia, like periodontal 
treatment reduces the risk of preterm birth7;8. This hypothesis needs to be tested. Since 
the host response to periodontal pathogens might play a key role in the development 
of preeclampsia, further research on the role of the inflammatory reaction as plausible 
mechanism is required. 
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 In summary, women with a recent history of early-onset preeclampsia have a 
worse periodontal condition. Thereby, patients and physicians should be aware of the 
possible relationship between periodontal disease and adverse pregnancy outcomes, 
such as preeclampsia.
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CLINICAL RELEvANCE
Scientific rationale for the study: Chronic inflammation, including periodontal disease, 
is thought to play a role in the development of preeclampsia, a serious pregnancy 
complication. We investigated the periodontal status in women with a recent history of 
severe early-onset preeclampsia and compared them to women with an uncomplicated 
pregnancy.
Principal findings: Women with a recent history of early-onset preeclampsia showed a 
worse periodontal condition, after adjusting for smoking, BMI, age and socioeconomic 
status.
Practical implications: Screening for periodontal disease and treatment of affected 
women might effectively prevent adverse pregnancy outcomes, such as preeclampsia, 
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Objective: Periodontitis, mostly associated with Porphyromonas gingivalis, has 
frequently been related to adverse pregnancy outcomes. We therefore investigated 
whether lipopolysaccharides of P. gingivalis (Pg-LPS) induced pregnancy complications 
in the rat. 
Methods: Experiment 1: pregnant rats (day 14) received increasing Pg-LPS doses (0.0-
50.0 µg/kg bw; n=2/3 p/dose). Maternal intra-aortic blood pressure, urinary albumin 
excretion, placental and foetal weight and foetal resorptions were documented. 
Experiment 2, 10.0 µg/kg bw (which induced the highest blood pressure together with 
decreased foetal weight in experiment 1) or saline was infused in pregnant and non-
pregnant rats (n=7/9 p/group). Parameters of experiment 1 and numbers of peripheral 
leukocytes as well as signs of inflammation in the kidney and placenta were evaluated. 
Results: Pg-LPS infusion in pregnant rats increased maternal systolic blood pressure, 
reduced placental weight (dose dependently) and decreased foetal weight and induced 
foetal resorptions. It, however, did not induce proteinuria or a generalised inflammatory 
response. No effects of Pg-LPS were seen in non-pregnant rats.
Conclusion: Pg-LPS increased maternal blood pressure, induced placental and foetal 
growth restriction and increased foetal resorptions, without inducing proteinuria and 




Porphyromonas gingivalis has been identified as a major aetiological factor in 
the pathogenesis of periodontitis1. Periodontitis is not only a local infection, but 
periodontal pathogens, especially P. gingivalis2, can also be found at distant sites3 or 
induce changes in systemic inflammatory parameters4, for instance increased plasma 
C-reactive protein (CRP) levels5 as well as activated inflammatory cells and endothelial 
cells6. Indeed, periodontitis has been associated with various systemic diseases, such as 
atherosclerosis, myocardial infarction and cardiovascular diseases (CVD)7. The systemic 
nature of periodontitis can also be seen from the putative relationship between 
maternal periodontitis and poor obstetric outcome8-10. 
 A large number of observational studies showed a relationship between pregnancy 
outcome and periodontal disease. Periodontal disease during pregnancy has been 
associated with preterm birth, which is defined as a delivery before 37 weeks of 
gestation10, low birth weight, which is defined as infants with birth weights of <2500 g9, 
miscarriage or stillbirths10 and preeclampsia8. Preeclampsia is one of the most important 
pregnancy complications in the western world and is characterised by maternal 
hypertension and proteinuria clinically manifest during the second half of pregnancy11. 
It has been suggested that the chronic general low-grade inflammation which is seen 
in patients with periodontitis may play a role in the pathogenesis of these pregnancy-
related pathologies12. Although the exact relationship between periodontitis and 
pregnancy complications and mechanisms needs to be established, it seems likely that 
P. gingivalis is involved in inducing adverse pregnancy outcomes, since P. gingivalis has 
the capacity to disseminate from the oral cavity to the foetoplacental unit13-17. In animal 
experiments, P. gingivalis has been found in placental tissues after intravenous infection 
and appeared to induce lesions similar to human chorioamnionitis and placentitis18. 
 Moreover, P. gingivalis in mice and rats was associated with foetal and placental 
growth restriction, increased foetal resorptions and foetal death19;20. P. gingivalis 
bacteria contain factors that are pro-inflammatory and can also potentially affect 
placental tissue. One of the most important factors is lipopolysaccharide (LPS)21. Indeed, 
intravenous infusion with LPS of P. gingivalis (Pg-LPS) in pregnant animals induced 
foetal growth restriction and foetal death22. Interestingly, pregnant individuals are 
extremely sensitive to LPS of Escherichia coli (Ec-LPS) and in recent animal studies, this 
LPS has been shown to induce not only placental effects23, but also peripheral effects 
such as hypertension, proteinuria and generalised inflammation24;25. 
 The aim of the present study therefore was to investigate whether Pg-LPS in 
pregnant rats also induced systemic complications, such as hypertension, proteinuria 

























































Handling of the rats
Animal experiments were conducted under protocols approved by the Animal Ethical 
Committee of the University of Groningen, the Netherlands. Female Wistar outbred 
rats (175-200 g) were obtained from Harlan Inc., Zeist, The Netherlands. Rats were 
maintained in a temperature- and light-controlled room (22°C, 12:12H light:dark cycle), 
with free access to standard laboratory chow and water. Animals were allowed seven 
days to acclimatise to the laboratory environment and were housed together until 
selection for experiments. After acclimatisation, vaginal smears were taken to follow 
oestrus cyclicity. On pro-oestrus, rats were housed overnight with two fertile Wistar 
outbred males. A positive vaginal smear for spermatozoa the next day was defined as 
day 0 of pregnancy. On day 0 of pregnancy and on diestrus-2 in non-pregnant control 
rats, a permanent cannula was surgically inserted into the right jugular vein under 
isoflurane/oxygen anaesthesia, according to standard methods26. This cannula allows 
stress-free infusion of either endotoxin or saline, and stress-free blood sampling. Rats 
were then housed individually and allowed to recover from surgery for 14 days. On day 
14 of pregnancy (14 days after surgery in non-pregnant rats), rats were infused with 
either with 2.0 ml endotoxin solution (concentrations ranging from 1.0 to 50.0 µg Pg-
LPS/kg bw in saline) or 2 ml saline alone during 1 hour via the permanent jugular vein 
cannula. Ultrapure lipopolysaccharide of Porphyromonas gingivalis (tlrl-pglps, strain 
ATCC 33277; InvivoGen, San Diego, USA) was used in this study.
Experimental design
Experiment 1: In this experiment, pregnant rats were infused with Pg-LPS at increasing 
doses from 0.0 to 50.0 µg Pg-LPS/kg bw (n=2/3 per dose) in order to establish a putative 
dose which would induce systemic, placental and foetal signs. Twenty four hour urinary 
albumin excretion was measured one day before infusion and at one and five days 
after infusion. On day 21, which is the end of pregnancy, and seven days after Pg-LPS 
infusion (in none of the rats parturition had started), rats were anaesthetised and aortic 
blood pressure was measured after which the rats were sacrificed by aortic puncture. 
Living foetuses and their placentas were collected and weighed. Total number of 
foetuses and the number of foetal resorptions were also counted. The percentage of 
foetal resorptions was calculated.
Experiment 2: From experiment 1 it appeared that Pg-LPS induced hypertension, 
decreased placental weight and increased the number of foetal resorptions. To further 
evaluate the effect of Pg-LPS on pregnant rats, in the second experiment, rats were 
infused with 10.0 µg/kg bw Pg-LPS, the dose that appeared to induce the highest blood 
pressure and also affected placental and foetal weight. The pregnant Pg-LPS (10.0 µg/
kg bw) group (n=9), as well as the pregnant control group were expanded, which was 
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infused with 2.0 ml saline alone (n=9). Blood pressure, albumin excretion, foetal and 
placental weight were measured as in experiment 1. In addition, in order to investigate 
possible effects of Pg-LPS on the inflammatory response, we evaluated the number of 
peripheral white blood cells (WBC) as well as differential WBC counts and also signs of 
inflammation in the placenta and the kidney were evaluated. We choose to study these 
organs, since these organs are usually affected in pregnancy complications, such as 
preeclampsia. To explore whether the response to Pg-LPS was specific for pregnancy, 
also two groups of non-pregnant rats were included which were infused with either 
Pg-LPS (10.0 µg/kg bw in 2 ml saline) (n=7), or with 2.0 ml saline alone (n=7) using an 
identical experimental setup.
Blood pressure
For measuring intra-aortic blood pressure, at the end of pregnancy, a midline ventral 
incision was made under standard isoflurane/oxygen anaesthesia and the abdominal 
aorta was exposed. Immediately after exposure of the aorta, a needle connected to 
the probe of a pressure recorder (Lifescope 9, Bedside monitor MU-832 RK, Nihon 
Kohden Corporation, Tokyo, Japan) was inserted into the abdominal aorta after which 
the systolic and diastolic blood pressure were recorded. Rats were bled immediately 
afterwards by aortic puncture.
Albumin excretion
One day before the start of the infusion, as well as one day and five days after the 
infusion, rats were placed in metabolic cages (from 10.00 AM until 10.00 AM the next 
day) to collect a 24 hour urine sample. Urinary volume was measured and urinary 
albumin levels were assayed by the rocket-electrophoresis technique using rabbit-anti-
rat albumin antiserum (Nordic Immunology, Tilburg, The Netherlands) according to the 
method of Laurell27.
Tissue preparations
Immediately after sacrifice, the pregnant uterus was transected longitudinally to 
determine the number of living foetuses and resorptions. Each living individual 
foetus was weighed. In order to investigate if leukocyte infiltration occurred not only 
in placental tissue, but also in maternal tissue, from each dam, according to standard 
procedures, three representative placentas (from live foetuses) with associated 
mesometrial triangle were harvested, cut sagittally into two halves and snap frozen in 
isopentane (-80°C) and stored at -80°C for later analysis. Remaining placentas from the 
living foetuses (without mesometrial triangle) were weighed individually. Also from 
each dam, the left kidney was removed and collected. Kidney fragments were snap 
























































White blood cell counts
Blood samples (0.1 ml in 12% ethylenediaminetetraactetate (EDTA)) were drawn from 
the permanent jugular vein cannula on day 14 (just prior to the start of the infusion), 
on day 15, 16, 19 and on day 21 between 09.00 and 11.00 AM. Twenty microlitre of 
blood was used to determine total WBC count on a microcell counter (model Sysmex 
pocH-100i Haematology Analyser, Sysmex Corp., Kobe, Japan). In order to determine 
differential WBC counts from each blood sample, a smear was made on a microscope 
slide and stained using the Giemsa method (1:10 dilution; Merck) for 20 minutes28. 
After evaluation of 200 cells per smear, relative and absolute numbers of granulocytes, 
lymphocytes and monocytes were calculated according to standard methods.
Immunohistochemistry
Cryostat placenta sections (along with the mesometrial triangle) and kidney sections 
(5 µm) were cut using a Leica CM1900 cryostat (Leica Microsystems, Wetzlar, Germany). 
The sections were collected on silane coated glass slides (Starfrost, Waldemar Knittel, 
Braunschweig, Germany) and allowed to air dry at room temperature and then stored 
at -20°C for later analysis. 
Staining for granulocytes and monocytes/macrophages
Glomerular and placental sections were stained for granulocytes and monocytes/
macrophages using primary monoclonal antibodies against rat granulocytes (His48; 
Becton Dickinson, NJ, USA) and primary monoclonal antibodies against rat monocytes/
macrophages (ED1/CD68; AbD Serotec, Düsseldorf, Germany, dilution 1:100) according 
to standard protocols. Briefly, after drying in air, sections were fixed in pre-cooled 
acetone (4ºC) for 10 minutes. Subsequently, sections were air dried and then incubated 
with the first antibody for one hour in the dark at room temperature. After washing 
in phosphate-buffered saline (PBS), endogenous peroxidase activity was blocked by 
incubation of the slides for 20 minutes in methanol supplemented with 3% hydrogen 
peroxide (H2O2). Thereafter, sections were incubated with normal rabbit serum (DAKO, 
Glostrup, Denmark, dilution 1:10) for 30 minutes. Then without rinsing, sections were 
incubated for 30 minutes with a Peroxydase-conjugated secondary antibody rabbit-
anti-mouse (DAKO, Glostrup, Denmark, dilution 1:50). After washing in PBS, the reaction 
product was visualised using 3-amino-9-ethyl-carbazole (AEC; Sigma-Aldrich, St. Louis, 
MO, USA), counterstained with hematoxylin (1 min.) and embedded in Kaiser’s glycerin-
gelatin. Control sections not incubated with the primary antibody were consistently 
negative.
Evaluation of kidney sections
Kidney sections of each individual rat were quantitatively scored by light microscopic 
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examination. Sections stained for the presence of granulocytes and monocytes/
macrophages were quantified by counting the total number of positive cells in 100 
glomeruli per section, as described previously29. Results were expressed as the median 
of number of positive cells per glomerulus.
Evaluation of placental sections
Granulocyte and monocyte/macrophage infiltration were evaluated in the placentas 
and their associated mesometrial triangle by light microscopic examination.
Statistics
Statistical analysis was performed using SPSS 20 software for Windows. Results are 
expressed as individual values or illustrated in box and whisker plots. In experiment 1, 
Pearson correlation coefficients were calculated to evaluate the relationship between 
dose of Pg-LPS and blood pressure, placental weight or foetal weight. R2 and the slope 
were calculated and it was tested whether the slope was statistically significantly 
different from zero. A slope which was different from zero indicated a dose response 
effect. If no dose response effect was observed, an effect of Pg-LPS was evaluated by 
grouping the data of all Pg-LPS infused rats together. These grouped data of the Pg-LPS 
infused rats were then compared with the saline infused rats using the Mann-Whitney 
U test. Before starting experiment 2, a power analysis was performed using maternal 
blood pressure as our main endpoint. The power analysis was based on the blood 
pressure data of experiment 1, with a mean systolic blood pressure of control pregnant 
rats of 86.3 mmHg and a variance of 12%. Based on the systolic blood pressure of Pg-
LPS infused rats (Figure 1a), a 25% increase in mean systolic blood was expected. Using 
a power of 0.9 and a probability level of 0.05, power analysis showed that a minimum 
of 6 rats per group should be included. In experiment 2, differences between groups 
were tested by using the Mann-Whitney U test. Nominal pregnancy outcome data 
(number of resorptions and/or number of foetuses with growth restriction) were tested 
by using the Fisher’s exact test. Post-infusion albumin excretion, total WBC counts and 
differential WBC counts were tested versus pre-infusion values using the Wilcoxon 
Signed Rank test. In the case of multiple comparisons, Bonferroni correction was used. 
P<0.05 was accepted as statistically significant.
RESuLTS
Experiment 1
Systolic and diastolic blood pressure and urinary albumin excretion
Figures 1 (a, b) show the aortic systolic and diastolic blood pressure of pregnant rats at 
gestational day 21, which is seven days after infusion with increasing doses of Pg-LPS 
























































systolic blood pressure (R2=0.039, p=0.29) or diastolic blood pressure (R2=0.013, p=0.56) 
was observed. However, when all Pg-LPS infused rats were grouped together, both 
diastolic and systolic blood pressure of Pg-LPS infused rats were significantly higher 
as compared with saline infused rats (p<0.05, Mann-Whitney U test). Urinary albumin 
excretion after infusion with increasing doses of Pg-LPS in pregnant rats is presented 
in Figure 1c. Pregnant rats did not exhibit increased albumin excretion after infusion 
with saline or Pg-LPS at any dose tested at one day after infusion (gestational day 15) 
or five days after infusion (gestational day 19) as compared with pre-infusion values 
(gestational day 13). 
Placental and foetal weight
After infusion with 0.0-50.0 µg/kg bw Pg-LPS, a decreasing mean placental weight was 
observed with increasing Pg-LPS doses (R2=0.218, p=0.005) (Figure 2a). There was no 
Figure 1. (a) Individual intra-aortic systolic blood pressure (b) and diastolic blood pressure of pregnant 
rats under standard isoflurane/oxygen anaesthesia on gestational day 21, seven days after infusion 
with increasing doses of Pg-LPS (0-50.0 μg/kg bw, n=2/3 p. dose). Closed triangles: saline control rats; 
open dots: Pg-LPS infused rats (R2=Pearson correlation coefficients; p<0.05 indicates that slopes are 
significantly different from zero); (c) individual 24 hour urinary albumin excretion of pregnant rats 
after infusion with increasing doses of Pg-LPS (0-50.0 μg/kg bw, n=2/3 p. dose) at gestational day 
13 (pre-infusion values: closed dots), gestational day 15 (one day after infusion: closed squares) and 
gestational day 19 (five days after infusion: closed triangles). 
78 79
significant dose response effect of increasing Pg-LPS doses and mean foetal weight 
(R2=0.015, p=0.49) (Figure 2b). No significant differences in foetal weight were observed 
between saline infused rats and all Pg-LPS infused rats grouped together. 
Foetal resorption
Table 1 shows the total number of foetuses as well as percentages of foetuses resorpted 
(disintegrated and assimilated dead foetuses in the uterus) in the animals infused with 
the different doses of Pg-LPS. As can be seen from this table, foetal resorption was 
exclusively found after infusion with doses of Pg-LPS at or above 7.5 μg/kg bw.
4
Figure 2. Placental (a) and foetal (b) weight after sacrifice at gestational day 21, seven days after 
infusion with increasing doses of Pg-LPS (0-50.0 μg/kg bw, n=2/3 p. dose). Each triangle/dot 
represents the mean placental or foetal weight per individual mother. Closed triangles: saline infused 
control rats; open dots: Pg-LPS infused rats (R2=Pearson correlation coefficients; p<0.05 indicates 
that slopes are significantly different from zero).
Table 1. Foetal resorptions at gestational day 21 following 









  0.0 3 0/32 0 
  1.0 3 0/31 0 
  3.0 3 0/34 0 
  5.0 3 0/39 0 
  7.5 2 2/25 8.0 
10.0 3 2/35 5.7 
12.5 2 1/27 3.7 
15.0 3 0/39 0 
17.5 2 1/26 3.8 
20.0 2 1/21 4.8 
25.0 2 0/25 0 
30.0 3 8/29 27.6 
40.0 2 0/24 0 
50.0 2 1/22 4.5 
























































Systolic and diastolic blood pressure and urinary albumin excretion
As infusion of 10 µg/kg bw Pg-LPS appeared to induce increased blood pressure 
together with decreased foetal weight, we chose this dose of LPS to further evaluate 
the effect of this LPS on pregnant animals. Figures 3 (a, b) show the aortic systolic and 
diastolic blood pressure of non-pregnant and pregnant rats after infusion with saline or 
10.0 µg/kg bw Pg-LPS. It can be seen from these figures that infusion with 10.0 µg/kg 
bw Pg-LPS significantly increased systolic blood pressure in pregnant rats as compared 
with the saline infused pregnant controls (p<0.05, Mann-Whitney U test). This increase 
in systolic blood pressure after infusion with 10.0 µg/kg bw Pg-LPS did not occur in 
non-pregnant rats. 
Figure 3. (a) Median and 25th and 75th percentiles of intra-aortic systolic and (b) diastolic blood pressure 
under standard isoflurane/oxygen anaesthesia of non-pregnant and pregnant rats after infusion 
with saline or 10.0 μg Pg-LPS/kg bw, seven days after infusion (gestational day 21 of pregnant rats). 
Open bars: saline infused control rats; black bars: Pg-LPS infused rats; (c) median and 25th and 75th 
percentiles of 24 hour albumin excretion of non-pregnant and pregnant rats after infusion with saline 
or 10.0 μg Pg-LPS/kg bw. Open bars: day 13 (pre-infusion values); dotted bars: day 15 (one day after 
infusion); striped bars: day 19 (five days after infusion). Error bars demonstrate 1.5 interquartile range 
and outlier values are represented as individual black dots. * Significantly increased vs saline infusion 
(Mann-Whitney U test; p<0.05).
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No significant differences were observed in diastolic blood pressure in non-pregnant 
or pregnant rats infused with 10.0 µg/kg bw Pg-LPS vs saline infusion. Figure 3c shows 
24 hour albumin excretion of non-pregnant and pregnant rats after infusion with saline 
or 10.0 µg/kg bw Pg-LPS. There was no difference in urinary albumin excretion after 
infusion with saline or 10.0 µg/kg bw Pg-LPS in non-pregnant or pregnant rats one day 
after infusion (gestational day 15 in pregnant rats) or five days after infusion (gestational 
day 19) as compared with pre-infusion values.
Placental and foetal weight
Infusion with 10.0 µg/kg bw Pg-LPS into day 14 pregnant rats significantly decreased 
placental weight as compared with the saline infused controls (median 0.5 [interquartile 
range (IQR) 0.1] gr saline vs median 0.4 [IQR 0.1] gr Pg-LPS, p<0.05, Mann-Whitney U 
test) (Figure 4a). Although there were no differences in median foetal weight between 
the Pg-LPS infused rats and the saline controls, there was a substantial amount of 
smaller than normal foetuses in the litter of the Pg-LPS infused group, as can be seen 
from Figure 4b. We therefore analysed the numbers of foetuses that were more than 
two standard deviations (2 SD) from the normal mean (4.75 ± 0.50 g; i.e. less than 3.75 
g) and defined them as foetal growth restricted. Of 102 foetuses in the Pg-LPS infused 
group, 11 foetuses were growth restricted, while in the control group, only two of the 
103 foetuses showed growth restriction. The number of growth restricted foetuses 
were significantly increased in LPS infused pregnant rats as compared to saline infused 
pregnant rats (p<0.05, Fisher’s exact test).
4
Figure 4. Median and 25th and 75th percentiles of placental (a) and foetal (b) weight after sacrifice 
at gestational day 21, seven days after infusion with saline or 10.0 μg Pg-LPS/kg bw. Error bars 
demonstrate 1.5 interquartile range and outlier values are represented as black dots. Open bars: 
saline infused control rats; black bars: Pg-LPS infused rats. * Significantly decreased vs saline infusion 
























































In saline control rats, no foetal resorptions were observed. However, after infusion with 
10.0 µg/kg bw Pg-LPS foetal resorptions were observed: of the total of 109 foetuses in 
9 mothers, 7 foetuses were resorbed (p<0.05, Fisher’s exact test). 
Inflammatory parameters
Total WBC and granulocyte, monocyte and lymphocyte counts
Figure 5a shows total numbers of WBC as well as the differential counts for granulocytes, 
monocytes and lymphocytes at gestational day 14, i.e. before the infusion with 10.0 μg/
kg bw Pg-LPS or saline. Total WBC counts before infusion were not significantly different 
in day 14 pregnant rats as compared with non-pregnant rats. In pregnant rats, total 
numbers of lymphocytes were decreased while total numbers of granulocytes were 
increased as compared with non-pregnant controls (p<0.05, Mann-Whitney U test). 
 Figures 5 (b, c) show the pre-infusion and post-infusion total WBC counts in non-
pregnant rats and pregnant rats after infusion with 10.0 μg/kg bw Pg-LPS or saline. In 
both non-pregnant and pregnant rats, no differences between pre-infusion (gestational 
day 14 in pregnant rats) WBC counts and WBC counts on days 15, 16, 19 and 21 (i.e. 
one, two, five and seven days post-infusion, respectively) were observed in either the 
Pg-LPS treated rats or saline treated rats. There were no effects of infusion of either 
saline or 10.0 μg/kg bw Pg-LPS on the percentages of monocytes, lymphocytes and 
granulocytes in both non-pregnant and pregnant rats (results not shown).
Glomerular granulocyte and monocyte/macrophage infiltration
Figures 5 (d, e) show the number of glomerular granulocytes and glomerular monocytes/
macrophages in non-pregnant and pregnant rats after infusion with saline or with 
10.0 µg/kg bw Pg-LPS. We observed no effect of Pg-LPS on glomerular granulocyte or 
monocyte/macrophage number.
Placental granulocyte and monocyte/macrophage infiltration 
In control placental tissues, only a few scattered granulocytes and monocytes/
macrophages were present in the labyrinth and in the spongiotrophoblast layer. In 
the decidua basalis as well as in the mesometrial triangle, in particular in the central 
part of the mesometrial triangle and in close proximity of the spiral arteries, ED1 
positive monocytes/macrophages were observed (Figure 6a). Granulocytes were 
found scattered in the mesometrial triangle (Figure 6b). However, when comparing 
the placental tissues of the 10.0 µg/kg bw Pg-LPS infused rats with the saline infused 
controls, no differences between the groups were observed in numbers of granulocytes 
and monocytes/macrophages (results not shown).
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4
Figure 5. (a) Median and 25th and 75th percentiles of total and differential white blood cell counts (WBC) in 
non-pregnant and pregnant rats (gestational day 14), prior to infusion with saline or 10.0 μg Pg-LPS/kg bw; 
(b, c) median and 25th and 75th percentiles of total white blood cell (WBC) counts in non-pregnant (b) and 
pregnant (c) rats at day 14 (pre-infusion), and at days 15, 16, 19 and 21 of pregnancy (post-infusion days 
1, 2, 5 and 7 respectively) after infusion of saline (closed triangles) or 10.0 μg Pg-LPS/kg bw (open dots); 
(d) median and 25th and 75th percentiles of number of granulocytes and (e) monocytes/macrophages per 
glomerulus in non-pregnant and pregnant rats, seven days after infusion with saline or 10.0 μg Pg-LPS/kg 
bw (gestational day 21 of pregnant rats). Error bars demonstrate 1.5 interquartile range and outlier values 
are represented as black dots. Open bars: saline infused control rats; black bars: Pg-LPS infused rats.
Figure 6. Photomicrographs of parts of the mesometrial triangle of a control pregnant rat at day 21 
of pregnancy, stained for the presence of monocytes/macrophages (ED1; a) or for the presence of 
granulocytes (His48; b). ED1 positive cells were found throughout the mesometrial triangle, but 
especially around the spiral arteries (S). Less His48 positive cells were found in the mesometrial triangle, 
























































This study was set up to evaluate a causal relationship between Pg-LPS and pregnancy 
complications. Therefore, it was examined whether Pg-LPS infusion in pregnant 
rats could induce maternal hypertension, proteinuria and foetal or placental growth 
restriction and general inflammation. Rats were infused at day 14 of pregnancy, since 
this is in accordance with previous studies24;29. For these previous studies, this time 
point was chosen, since at day 14 of pregnancy the chorioallantoic placenta is fully 
developed, while the trophoblast invasion into the decidua and mesometrial triangle 
starts around that day30;31. Our results showed that Pg-LPS infusion in day 14 pregnant 
rats increased maternal systolic blood pressure, decreased placental weight and slightly 
decreased foetal weight (only in experiment 2) and also slightly increased the number 
of foetal resorptions, but did not induce albuminuria. Moreover, in the present study, 
no signs of placental or renal inflammation were seen, and also there were no signs 
of inflammation in the peripheral circulation (no increase in white blood cell counts 
or changes in white blood cell populations). Therefore, in this study we observed 
no generalised inflammatory response in pregnant rats after infusion of Pg-LPS. The 
effects of Pg-LPS appeared to be specific for pregnant rats, since hypertension was not 
induced in non-pregnant animals. 
 Our findings of increased blood pressure, decreased foetal weight and increased 
number of foetal resorptions may originate from the placenta as placental weight was 
dose dependently decreased by Pg-LPS infusion. The reason for the decreased placental 
weight remains unclear from this study. Since we did not observe local inflammation 
in the placental tissues, Pg-LPS may have had a direct effect on the placenta. The fact 
that placental weight was dose dependently decreased may support this suggestion. 
Pg-LPS is a Toll-like receptor 2 (TLR2) ligand32 and placental trophoblast cells express 
TLR233. It has been demonstrated in vivo and in vitro that activation of TLR2 receptors 
on trophoblast cells can evoke cell death pathways34 and trophoblast apoptosis35. It 
can be hypothesised that the reduction in placental size may be associated with an 
increased resistance to blood flow in the placental arteries. Increased arterial resistance 
may result in reduced transport of oxygen and nutrients to the foetus and in some 
foetuses to foetal demise or death23. It is suggested that reduced placental perfusion in 
humans enhances the release of pro-inflammatory factors, such as cytokines, soluble 
endoglin (sEng), the soluble form of the vascular endothelial growth factor (VEGF) 
receptor (sFlt-1) and placental growth factor (PlGF). Although these factors may be 
involved in endothelial dysfunction, subsequently leading to hypertension36, they are 
also involved in inducing generalised inflammation. Since in the present study there 
were no signs of systemic inflammation, it seems unlikely that the placenta released 
such pro-inflammatory factors into the maternal circulation.
 It can be hypothesised that the increase in blood pressure in the present study may 
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have been a compensatory attempt to maintain perfusion in the affected placentas. 
Such an adaptive role for the foetus has also been suggested to occur in humans 
in the face of uteroplacental dysfunction37. Indeed, maternal hypertension during 
pregnancy has been associated with improved neonatal health37;38. The observation 
that antihypertensive therapy of mild-to-moderate hypertension during pregnancy 
appeared to impair intrauterine foetal growth further supports this hypothesis39;40. In 
the present study, even in the face of hypertension, foetal growth restriction or foetal 
death still occurred in some foetuses, suggesting that also other factors may play a 
role. Alternatively, it is also possible that the increased systolic blood pressure was 
the consequence of a direct effect of Pg-LPS on the endothelium, for it has recently 
been shown that exposure to Pg-LPS increases the sensitivity of contractile responses 
mediated by endothelin-1 (ET-1) in cultured rat coronary arteries41. Since ET-1 is a 
strong vasoconstrictor produced by endothelial cells that has been associated with 
hypertension during pregnancy in both animal and human studies42, this may also be 
a possible mechanism by which Pg-LPS directly increased systolic blood pressure in 
pregnant rats in the present study.
 Previously, our laboratory established a model for preeclampsia24 by infusion 
of low doses of LPS (1.0 μg/kg bw) of E. coli in pregnant rats. These rats developed 
not only hypertension and a slightly decreased foetal weight, but in contrast to the 
present study, also proteinuria and generalised inflammation24;29;43. These differences in 
responses to both LPS species may be due to differences in signaling via TLRs. LPS from 
E. coli signals through TLR4, which leads to predominantly pro-inflammatory cytokine 
production44. Indeed, these animals showed a generalised inflammatory response24;29;43. 
The detrimental effects of this pro-inflammatory response induced by E. coli LPS were 
better observed after infusion of a slightly higher dose of this LPS (6.5 μg/kg bw), which 
induced septic-like signs, such as hypotension and maternal illness and increased 
numbers of foetal resorptions24. 
 In contrast, Pg-LPS signals via TLR232, and in vitro stimulation of whole blood with 
Pg-LPS induced a lower pro-inflammatory cytokine production as compared with in 
vitro stimulation with E. coli LPS45. Interestingly, increasing the dose of Pg-LPS from 
10.0 µg/kg bw to 50.0 µg/kg bw did not result in a further rise in blood pressure or 
foetal resorptions, a further decrease in foetal weight, or in other septic-like signs 
as compared with 10.0 µg/kg bw Pg-LPS. Since in vitro this Pg-LPS induced a dose 
dependent increase in cytokine production of monocytes45, suggesting that also in this 
in vivo study higher Pg-LPS doses induced higher cytokine production. This lack of dose 
dependency, therefore, remains to be investigated.
 Although various clinical and epidemiological studies suggest a relationship 
between periodontitis and pregnancy complications, there are not many animal or in 
























































indicate that Pg-LPS may be (one of ) the causal mechanisms between periodontitis 
and adverse pregnancy outcomes. By affecting placental growth, Pg-LPS may be one 
of the contributing factors by which the periodontal infection causes unfavourable 
pregnancy outcomes including foetal demise and maternal hypertension. The results 
of the present study do not confirm a causal relationship between periodontitis and 
preeclampsia, for we did not observe albuminuria or inflammation. This study also 
shows that the effects of Pg-LPS appear relatively mild as compared with effects of 
E. coli LPS, suggesting that E. coli LPS may be more harmful for pregnancy than Pg-LPS. 
 In summary, this study showed that Pg-LPS infusion in pregnant rats increased 
maternal systolic blood pressure, impaired placental growth and slightly decreased foetal 
weight and also slightly increased numbers of foetal resorptions. Pg-LPS infusion did not 
induce albuminuria, a systemic maternal inflammatory response, or local inflammation 
in the kidneys or placentas. The present data provide a next step in the identification 
of the mechanism in the relationship between periodontitis and adverse pregnancy 
outcomes. The study undertaken suggests that Pg-LPS may be causally involved in 
some pregnancy complications, such as hypertension, foetal growth restriction, foetal 
death or miscarriage (in this rat model represented as foetal resorptions). However, a 
causal relationship of Pg-LPS with preeclampsia seems unlikely from the present study. 
Further research is therefore needed to identify the exact pathogenic mechanisms by 
which P. gingivalis or its products induce pregnancy complications, including placental 
and foetal growth restriction or maternal hypertension. 
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Objective: Pregnant individuals are more sensitive to various bacteria or their products. 
Pregnant individuals also respond differently to different bacteria or their products. 
Therefore, in the present study, we evaluated whether the increased sensitivity of 
pregnant individuals to bacterial products, and the different responses of pregnant 
individuals to different bacteria was associated with differences in whole blood 
cytokine production upon stimulation with bacteria or their products.
Study Design: Blood samples were taken from healthy pregnant and non-pregnant 
women and ex vivo stimulated with bacteria or LPS from P. gingivalis (Pg) or E. coli for 24 
hrs. TNF-α, IL-1ß, IL-6, IL-12 and IL-10 were measured using a multiplex luminex system.
Results: We observed a generally lower cytokine production after stimulation with Pg 
bacteria or it’s LPS as compared with E. coli bacteria. However, there was also an effect 
of pregnancy upon cytokine production: in pregnant women the production of IL-6 
upon Pg stimulation was decreased as compared with non-pregnant women. After 
stimulation with E. coli, the production of IL-12 and TNF-α was decreased in pregnant 
women as compared with non-pregnant women.
Conclusion: Our results showed that cytokine production upon bacterial stimulation 
of whole blood differed between pregnant and non-pregnant individuals, showing that 
the increased sensitivity of pregnant individuals may be due to differences in cytokine 
production. Moreover, pregnancy also affected whole blood cytokine production upon 
Pg or E. coli stimulation differently. Thus, the different responses of pregnant individuals 
to different bacteria or their products may result from variations in cytokine production.
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INTRODuCTION
Periodontal diseases are a group of diseases caused by inflammation and destruction of 
the supporting and investing structures of the teeth and the periodontal tissues1. The 
infection in the oral cavity can lead to systemic inflammation resulting in adverse medical 
outcomes. Indeed, associations between periodontal disease and cardiovascular 
disease (CVD)2, stroke3, glycemic control in diabetes4 and rheumatoid arthritis5 have 
been found. It has also become evident that periodontitis during pregnancy may 
result in adverse outcome; the presence of periodontitis during pregnancy has been 
associated with IUGR6 or preterm birth7. Although there are many bacterial species 
present in the infected oral cavity, P. gingivalis (Pg) has most frequently been associated 
with systemic disease8. This is probably due to the fact that this bacterium has the 
capacity to disseminate into the peripheral circulation and cause inflammation at other 
sites8.
 The mechanism responsible for the association between periodontitis and 
pregnancy complications remains to be unraveled, but a route via the peripheral 
circulation to the placenta is likely to be involved9;10. Plausibly, also activation of the 
systemic inflammatory response by oral bacteria, such as Pg or their products, is 
involved. It is well known that pregnancy is a pro-inflammatory condition11, with 
phenotypically activated monocytes and changes in monocyte function, such as 
cytokine production12;13. Therefore, it seems likely that during pregnancy the systemic 
inflammatory response to bacteria and their products is different as compared with 
this response in non-pregnant individuals. Indeed, pregnant individuals are much more 
sensitive to one of the E. coli products, lipopolysaccharide (LPS), than non-pregnant 
individuals14. For instance it has been shown that infusion of a low dose of E. coli LPS 
(1.0 μg/kgbw) induced hypertension and proteinuria in pregnant animals only; non-
pregnant rats did not develop these signs15.
 Interestingly, infusion of a low dose of Pg-LPS into pregnant rats in identical 
circumstances induced hypertension, but not proteinuria. Moreover, while only slightly 
increased doses of E. coli LPS induced hypotension, maternal illness and resorption of 
most of the fetuses15, increasing doses of Pg-LPS did not induce more severe effects 
than the low dose of Pg-LPS (Kunnen et al, submitted). This suggests that pregnant 
individuals are not only more sensitive to bacterial products, but also that the 
sensitivity of pregnant individuals to different bacteria or their products differs. In the 
present study, we evaluated whether the increased sensitivity of pregnant individuals 
to bacterial products, and the different sensitivities of pregnant individuals to different 
bacterial products was due to differences in cytokine production of leukocytes upon 
stimulation of whole blood with bacterial products. To this end, we compared cytokine 
production following stimulation of whole blood of pregnant and non-pregnant 
women with Pg or E. coli bacteria and their LPS and measured production of the pro-









































































To compare whole blood cytokine production in non-pregnant and pregnant women 
following stimulation with Pg or E. coli bacteria or their LPS, we stimulated whole blood 
of non-pregnant and pregnant women with bacteria of Pg or E. coli or their LPS. After 
24 hrs. of stimulation, we measured the production of pro-inflammatory and anti-
inflammatory cytokines in the plasma using a multiplex Luminex system.
Subjects
This study was approved by the local ethics committee and a written informed consent 
was obtained from each subject before participation. Participants (pregnant and non-
pregnant, healthy Caucasian women between 20 and 40 years) were recruited from 
the Department of Obstetrics and Gynecology, University Medical Center Groningen 
or recruited from the hospital staff. Exclusion criteria for both groups were: smoking, 
hypertension, chronic diseases, flu-like symptoms or fever, treatment with antibiotics 
within 14 days prior to blood sampling or an DPSI score of 3+ or 4 after periodontal 
screening, which is indicative for destructive periodontal disease16. Furthermore, 
pregnant women were checked until the end of pregnancy and no pregnancy 
complications were observed.
Whole blood (10 ml; lithium-heparin vacutainer tube (Becton Dickinson, Rutherford, 
NJ)) was obtained by venous puncture from 16 primigravid women at 30 weeks of 
gestation (range 28-32 weeks) and from 15 nulligravid women with regular menstrual 
cycles (26-32 days) in their follicular phase (day 8-10), to minimize variations due to 
hormonal changes.
Bacteria
E. coli ATCC 25922 was grown on 5% sheep blood agar plates (Mediaproducts 
Groningen, The Netherlands) in air with 5%CO2 at 37ºC for 1 day. P. gingivalis ATCC 
33277 (A.J. van Winkelhoff, Department of Oral Microbiology, Academic Center 
for Dentistry Amsterdam, The Netherlands) was grown on Brucella blood agar 
(Mediaproducts), supplemented with 5% sheep blood, 5 mg/L hemin and 1 mg/L 
menadione in an anaerobic chamber with 5%CO2, 10%H2 and 85%N2 at 37ºC. After 1 
day (E. coli) or 4-7 days (Pg), one bacterial colony was inoculated in Todd-Hewitt-broth 
(BBL Microbiology Systems), supplemented with hemin (5 mg/L), menadione (5 mg/L) 
and glucose (2 mg/L) for one day (E. coli) or one week (Pg). The bacterial cultures were 
harvested by centrifugation at 2773 g for 10 minutes at 4ºC. The pellet was washed 
twice in phosphate-buffered saline (PBS). The number of bacteria was evaluated by 
means of a microscope after gram-staining and resuspended in PBS at a concentration 
corresponding of approximately 1x108 bacteria/ml and stored at -80ºC.
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Lipopolysaccharides
P. gingivalis LPS ATCC 33277 (Ultra-Pure, Cat.#: tlrl-pglps, Lot.#: 28-06-PGLPS, InvivoGen, 
San Diego, USA); E. coli LPS (055:B5, BioWhittaker, Walkersville MD, USA).
Stimulation of whole blood with bacteria and LPS
After sampling, 250 μl of blood was mixed with 250 μl of bacterial cultures of E. coli or Pg 
(final numbers: 5x107 bacteria/ml). Furthermore, 250 μl of blood was mixed with 250 μl 
RPMI (Invitrogen, California, USA) and LPS (E. coli or Pg) was added (final concentration: 
2 μg/ml). Negative controls were incubated in the absence of bacteria or LPS. Samples 
were incubated for 24h at 37°C in a 5%CO2 humidified atmosphere. After stimulation, all 
samples were pipetted into 1.5 ml eppendorf tubes and centrifuged for 10 minutes at 
316 g (4°C). The plasma was centrifuged again for 5 minutes at 1972 g (4°C) and frozen 
at -80°C.
Determination of plasma cytokine production
Cytokine levels in whole blood were measured using a Bio-PlexTM premixed cytokine 
assay, human 5-plex group I; cat. #: M50019PLCW, control 5016683 (Bio-Rad Laboratories, 
Hercules, USA), to measure TNF-α, IL-1β, IL-6, IL-10 and IL-12(p70), according to the 
manufacturers instruction manual. Raw data (mean fluorescence intensity, MFI) were 
analyzed using STarStation V2.3.
TLR labeling
Immediately after sampling, 500 μl of whole blood was mixed with 500 μl of RPMI 
and incubated with PerCp–labeled mouse-anti-human-CD14 (clone TüK4; Invitrogen 
Corporation, Breda, The Netherlands) together with FITC-labeled mouse-anti-human-
TLR2 (clone TL2.1; eBioscience, Breda, The Netherlands) and PE-labeled mouse-anti-
human-TLR4 (clone HTA 125; eBiosciences), or with anti-CD14 together with TLR2 and 
TLR4 isotype controls for 30 minutes at room temperature (RT) in the dark. After 5 
minutes incubation with lysing buffer (Becton Dickinson, CA, USA) at RT in the dark, 
tubes were centrifuged (5 minutes at 467 g) and aspirated. After washing with washing 
buffer (PBS with 0.5% bovine serum albumin and 0.1% sodium azide), cells were fixed 
with 0.5% paraformaldehyde and kept at 4°C in the dark until flow cytometry, within 
24h after labeling.
Flow Cytometry
Cells were analyzed by flow cytometer (FACS Calibur; Becton Dickinson, NJ, USA). For 
each individual, 100.000 leukocytes were acquired whilst life gating on leukocytes 
using forward and side-scatter characteristics. Data were saved for later analysis using 







































































During analyses a gate was set on the leukocytes in the forward-sidescatter plot. This 
gate was copied to a sidescatter-CD14 plot, in which monocytes (CD14 positive cells), 
granulocytes (CD14 negative cells with high SSC) and lymphocytes (CD14 negative cells 
with low SSC) were gated. Total numbers of monocytes, granulocytes and lymphocytes 
were derived by multiplying the percentage of the subpopulations with the total WBC 
count (microcell counter model Sysmex pocH-100i Haematology Analyser, Sysmex 
Corp., Kobe, Japan). Thereafter, CD14 positive cells were copied to a TLR2/TLR4 plot. 
Using the isotype control sample, gates were set in the TLR2/TLR4 plot so that at least 
99% of the isotype controls were negative for TLR2/TLR4 expression. This gate was 
then used to identify the percentages of TLR4/TLR2 double positive, TLR2 single and 
TLR4 single positive monocytes as well as their mean fluorescent intensity (MFI), in the 
antibody incubated samples.
Data analysis
All figures expressed individual results (line: mean or median, depending on normality 
of the data). Normality of the data was tested using the Kolmogorov-Smirnov test. In 
the blood stimulation experiments, effects of the reproductive state (non-pregnant 
vs. pregnant) or effects of the bacteria or LPS species (E. coli vs. Pg) were tested using 
two-way ANOVA followed by Bonferroni post-tests. In case data were not normally 
distributed, before using the two-way ANOVA, data were log transformed, which led 
to normal distribution of data. For data on number of WBC and the differential cell 
counts and data on TLR expression, differences between pregnant and non-pregnant 
women in were evaluated using the Student’s t-test. In all cases, the significance level 
was p<0.05.
RESuLTS
Whole blood cytokine production following bacterial stimulation
Figure 1 shows that for all cytokines tested, in pregnant and in non-pregnant women, 
E. coli bacteria induced a stronger cytokine production as compared with Pg bacteria 
(Two-way ANOVA and Bonferroni posttest, p<0.05). An effect of pregnancy was also 
observed: the concentration of IL-12 following E. coli stimulation was significantly lower 
in pregnant blood as compared with non-pregnant blood (p<0.05). The concentration 




Figure 1: Cytokine concentrations following stimulation with bacteria.
Concentrations (ng/ml) of IL-1β, IL-6, IL-12, TNF-α and IL-10 in plasma of pregnant and non-pregnant 
women following stimulation of whole blood with E. coli (black dots) or P. gingivalis (Pg) (open dots) 
bacteria (5*107 bacteria/ml) for 24 hr. *significantly different from E. coli (two-way ANOVA followed 
by Bonferroni post-tests, p<0.05)) a: significantly different from pregnant women after the same 
stimulation (two-way ANOVA followed by Bonferroni post-tests, p<0.05)
Figure 2: Cytokine concentrations following stimulation with LPS.
Concentrations (ng/ml) of IL-1β, IL-6, IL-12, TNF-α and IL-10 in plasma of pregnant and non-pregnant 
women following stimulation of whole blood with E. coli (black dots) or P. gingivalis (Pg) (open dots) 
LPS (2 μg/ml) for 24 hr. *significantly different from E. coli (two-way ANOVA followed by Bonferroni 
post-tests, p<0.05)) a: significantly different from pregnant women after the same stimulation 






































































Whole blood cytokine production following LPS stimulation
Also stimulation of blood of pregnant and non-pregnant women with E. coli LPS 
induced significantly higher production of all cytokines tested as compared with Pg- 
LPS (Two-way ANOVA and Bonferroni posttest, p<0.05). Moreover, concentrations of 
IL-12 and TNF-α after stimulation with E. coli LPS were significantly lower in pregnant as 
compared with non-pregnant women. The concentration of IL-6 was significantly lower 
in pregnant vs. non-pregnant women following stimulation with Pg-LPS (fig 2).
Ratio of IL-12/IL-10, TNF-α/IL-10, IL-6/IL-10
Stimulation with E. coli bacteria resulted in a significantly higher IL-12/IL-10, TNF-α/
IL-10 ratio and a significantly lower IL-6/IL-10 ratio as compared with stimulation with 
Pg bacteria (fig 3A) in both pregnant and non-pregnant women. Pregnant women 
showed a decreased IL-12/IL-10 ratio after stimulation with E. coli bacteria (fig 3A) and 
a decreased IL-6/IL-10 ratio following Pg bacterial stimulation as compared with non-
pregnant women.
 After LPS stimulation, we observed a higher IL-12/IL-10 ratio after E. coli LPS 
stimulation vs. Pg-LPS in blood of pregnant women and a lower IL-6/IL-10 ratio after E. 
coli LPS stimulation vs. Pg-LPS stimulation in blood of both pregnant and non-pregnant 
women. The IL-12/IL-10 ratio was decreased in pregnant vs. non-pregnant women for 
both types of LPS, while only for Pg-LPS the TNF-α/IL-10 and the IL-6/IL-10 ratio was 
decreased in pregnant vs. non-pregnant women (fig 3B).
Figure 3A: Pro-inflammatory/anti-inflammatory cytokine ratio following stimulation with bacteria.
Ratio of IL-12/IL-10, TNF-α/IL-10 and IL-6/IL-10 cytokine production in plasma of pregnant and non-
pregnant women following stimulation of whole blood E. coli (black dots) or P. gingivalis (Pg) (open 
dots) bacteria (5*107 bacteria/ml) for 24 hr. *significantly different from E. coli (two-way ANOVA 
followed by Bonferroni post-tests, p<0.05)). a: significantly different from pregnant women after the 
same stimulation (two-way ANOVA followed by Bonferroni post-tests, p<0.05)
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Changes in white blood cells counts and TLR2 and TLR4 expression in pregnant women
As cytokine production in the plasma may depend on the number of leukocytes, we 
measured WBC counts and percentages of leukocyte subsets in the blood samples 
(Table 1). A significant increase in total number of WBC, monocytes and granulocytes 
was seen during pregnancy as compared with the follicular phase (p<0.05, Student’s 
t-test).
Since TLR2 and TLR4 are the main TLRs recognizing bacteria and LPS17, we measured 
expression of these receptors on monocytes, the most important cells responsible 
for bacteria and LPS recognition. The percentage of TLR2+ monocytes decreased in 
pregnant vs. non pregnant women (fig 4A; Student’s t-test, p<0.05), while the mean 
fluorescent intensity (MFI), a measure for expression of TLR2 per cell, was not affected 
5
Figure 3B: Pro-inflammatory/anti-inflammatory cytokine ratio following stimulation with LPS.
Ratio of IL-12/IL-10, TNF-α/IL-10 and IL-6/IL-10 cytokine production in plasma of pregnant and 
non-pregnant women following stimulation of whole blood E. coli (black dots) or P. gingivalis (Pg) 
(open dots) LPS (2 μg/ml) for 24 hr. *significantly different from E. coli (two-way ANOVA followed 
by Bonferroni post-tests, p<0.05)). a: significantly different from pregnant women after the same 
stimulation (two-way ANOVA followed by Bonferroni post-tests, p<0.05)
Table 1: total white blood cell count and differential cell counts 
 
  WBC Granulocyte Monocyte Lymphocyte 
  Count (*109/L) count (*109/L) count (*109/L) count (*109/L) 
  (mean±SEM) (mean±SEM) (mean±SEM) (mean±SEM) 
Pregnant 9.96±0.62* 7.02±0.56* 0.62±0.07* 2.31±0.17 
Non-pregnant 5.69±0.21 2.89±0.25 0.35±0.03 2.44±0.15 
 







































































by pregnancy. The percentage TLR4+ monocytes and TLR4 MFI of monocytes was not 
different between pregnant and non-pregnant women (fig 4B).
The percentage of double positive cells was also not affected by pregnancy (56.41±4.42 
in pregnant vs. 57.85±4.48 in non-pregnant women; not shown).
COMMENT
The present study was conducted to evaluate the effect of pregnancy and different 
bacteria and their products on leukocyte cytokine production. We stimulated whole 
blood of pregnant and non-pregnant women with bacteria or LPS from E. coli or Pg. 
There was a generally lower cytokine production after stimulation with Pg bacteria 
or it’s LPS as compared with E. coli bacteria or it’s LPS in both non-pregnant and 
pregnant women. We also observed an effect of pregnancy upon cytokine production. 
In pregnant women the production of IL-6 upon Pg stimulation was decreased as 
compared with non-pregnant women, while the production of IL-12 and TNF-α was 
decreased in pregnant women as compared with non pregnant women following 
stimulation with E. coli. This illustrates that pregnancy affects cytokine responses upon 
Figure 4: Expression of TLR2 and TLR4 in pregnant and non-pregnant women.
Expression of TLR2 and TLR4 on monocytes of pregnant (open squares) and non-pregnant women 
(black squares). A: Percentage of TLR2 positive monocytes (left graph) and mean fluorescent intensity 
of TLR2 staining of monocytes (right graph). B: Percentage of TLR4 positive monocytes (left graph) and 
mean fluorescent intensity of TLR4 staining of monocytes (right graph). *: significantly increased vs 
pregnant women (student’s t-test, p<0.05)
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Pg or E. coli stimulation differently and suggests that the varying responses during 
pregnancy upon different bacteria or their products may result from differences in 
cytokine production. The increased sensitivity of pregnant women to bacteria or their 
products may also result from differences in cytokine production.
 We found a marked lower cytokine production and a relatively higher production 
of pro-inflammatory cytokines induced by Pg bacteria/LPS in comparison with E. coli 
bacteria/LPS in both pregnant and non-pregnant women. An important mechanism 
by which a decreased cytokine response upon LPS/bacterial stimulation could be 
explained is by decreased expression of pattern recognition receptors (PPR), amongst 
which Toll-like receptors (TLR) are the best studied18. These TLR recognize so-called 
DAMPs (danger-associated molecules)19. PAMPs (pathogen-associated-molecules), are 
of subtype of DAMPS; they arise from pathogens, and alarm an individual to intruding 
pathogens19. LPS or other bacterial factors are PAMPs which are recognized by TLR2 and 
TLR417. As TLR2 is involved in recognition of Pg-LPS20;21 and TLR4 in recognition of E. coli 
LPS21, differences in expression between TLR2 and TLR4 on monocytes may result in 
different cytokine production following stimulation with these bacteria/LPS. However, 
despite the lower cytokine production after Pg bacteria/LPS, TLR2 is higher expressed 
by monocytes as compared with TLR4. Differences in TLR expression could also explain 
differences in responses of pregnant vs. non-pregnant women to Pg or E. coli LPS. We 
found a decreased expression of TLR2 on monocytes of pregnant vs. non-pregnant 
women, with no changes in TLR4 expression. Although production of some cytokines 
were decreased during pregnancy after stimulation with Pg-LPS, this was not the case 
for all cytokines. Further research is warranted to evaluate the role of TLRs on cytokine 
production in pregnant women.
 The finding that cytokine production after stimulation with Pg bacteria/LPS is 
generally lower as compared with stimulation with E. coli bacteria/LPS in non-pregnant 
women is in line with previous studies22;23. Our study for the first time shows these 
differences in pregnant women. Such lower cytokine production and lower pro-
inflammatory cytokine ratio following stimulation with Pg-LPS, as compared with E. coli 
LPS, may be involved in the in vivo differences in responses of pregnant women or 
animals to these LPS species: while E. coli LPS induces a preeclampsia-like syndrome15, 
Pg LPS only induced hypertension [Kunnen et al, accepted for publication, Oral Diseases 
2013]. Apparently, a preeclampsia-like syndrome is induced by pro-inflammatory 
cytokines, which is in line with the fact that the pro-inflammatory TNF-α also induced 
a preeclampsia-like syndrome24. The differences in cytokine production following 
stimulation with Pg bacteria vs. E. coli bacteria may suggest that pregnant women do 
also respond differently to these bacteria. Infections with E. coli bacteria usually result 
in maternal symptoms of illness, such as fever25;26. Although it has been shown that Pg 







































































such dissemination does not result in maternal illness. The present study suggests 
that these different maternal responses towards E. coli infection and Pg infection may 
(partly) result from differences in cytokine production following recognition of the 
bacteria. However, other mechanisms, such as differences in numbers of circulating 
bacteria between E. coli and Pg infection, may also play a role.
 The differences in IL-6 production between the two strains are smaller as compared 
with the other cytokines. This is reflected in an increased IL-6/IL-10 ratio following Pg 
bacteria/LPS stimulation as compared with E. coli bacteria/LPS stimulation. These results 
are in line with the fact that IL-6 plays an important role in periodontal disease. IL-6 is 
an important cytokine with diverse functions. It regulates the immune response and 
leukocyte recruitment27, but can also affect bone formation28. It has also been shown 
that IL-6 has potent anti-inflammatory properties, as it can inhibit the production of 
TNF-α29 and can increase the production of IL-10 and IL-1ra30. Therefore the relatively 
high production of IL-6 induced by stimulation with Pg bacteria or LPS may, next to 
the relatively low overall cytokine production, be involved in the different response of 
individuals to these bacteria or its LPS.
 Interestingly, despite the fact that pregnant women are much more sensitive to 
LPS, the production of cytokines following LPS (of both species) stimulation is either 
similar or decreased in pregnant women as compared with non-pregnant women. This 
suggests that pregnant women may be more sensitive to the effects of these cytokines. 
This is in line with earlier results from our lab31. If results would have been presented 
as amount of cytokines per monocyte, the differences would even be more extreme 
(results not shown), since the number of monocytes is increased in blood of pregnant 
women. Thus, as has also been shown previously13, monocytes of pregnant women 
produce less cytokines upon a similar LPS or bacterial stimulus than monocytes of non-
pregnant women. Such a decreased production of cytokines by pregnant monocytes 
may be due to their increased activational status: monocytes of pregnant women show 
increased CD14, CD11b and CD64 expression and decreased CD62L expression12. This 
may result in an endotoxin tolerant state, similar to the “endotoxin tolerance” seen in 
monocytes from septic patients32.
 In summary, the generally lower production of cytokines as well as the decreased 
pro-inflammatory ratio after Pg stimulation vs. E. coli stimulation in pregnant women 
may be responsible for the differences in the in vivo response upon the bacteria and 
their products in these individuals. Although pregnant women are extremely sensitive 
to LPS, the production of IL-12, TNF-α and IL-6 upon stimulation with bacteria or LPS 
were decreased, suggesting that pregnant women are more sensitive to these cytokines. 
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Objective: Although the exact reason is not known, encapsulated gram-negative 
Porphyromonas gingivalis strains are more virulent than non-encapsulated strains. Since 
difference in virulence properties may be due to difference in cytokine production 
following recognition of the bacteria or their products by the host inflammatory 
cells, we compared cytokine production following stimulation with bacteria or 
lipopolysaccharides (LPS) of a non-encapsulated and an encapsulated P. gingivalis 
strain (K¯ and K1).
Design: Tumour necrosis factor-alpha (TNF-α) production following stimulation of the 
cell-line Mono Mac 6 with bacteria or LPS of both P. gingivalis strains was determined 
using flow cytometry. Furthermore, we investigated the effects of the two P. gingivalis 
strains or their LPS on TNF-α and Interleukin (IL-1β, IL-6, IL-12 and IL-10) production in 
whole blood using Luminex. In both experiments, Escherichia coli bacteria and LPS were 
used as a reference.
Results: Both P. gingivalis strains induced lower cytokine production than E. coli with the 
exception of IL-6. P. gingivalis K1 bacteria elicited a higher overall cytokine production 
than P. gingivalis K¯. In contrast, P. gingivalis K1 LPS stimulation induced a lower cytokine 
production than P. gingivalis K¯ LPS.
Conclusions: Our findings suggest that the encapsulated P. gingivalis K1 bacteria 
induce higher cytokine production than the non-encapsulated P. gingivalis K¯. This was 
not due to its LPS. The stronger induction of cytokines may contribute to the higher 
virulence of P. gingivalis K1.
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INTRODuCTION
Periodontitis is a multifactorial, polymicrobial infection of the tissues surrounding the 
teeth, caused by a mixed microflora consisting of gram-negative and gram-positive 
micro-organisms. It is a chronic inflammatory disease involving complex interactions 
between the micro-organisms and immune response of the host and is characterised 
by collagen destruction and alveolar bone resorption1. 
 An important gram-negative strict anaerobic micro-organism associated with 
periodontal breakdown and with the capacity to modulate inflammatory responses is P. 
gingivalis2;3. Several encapsulated and non-encapsulated serotypes of P. gingivalis have 
been described4-6. Encapsulated P. gingivalis serotypes are more virulent in experimental 
infections and cause a more invasive type of infection, whereas non-encapsulated P. 
gingivalis cause a more localised infection7. The exact reason for the higher virulence of 
encapsulated strains is not known, but may result from different cytokine production 
following recognition of the encapsulated or non-encapsulated bacteria by the host 
immune system8;9. P. gingivalis strains contain a variety of components on their cell 
surface, like lipopolysaccharides (LPS), lipoproteins and fimbriae, as well as capsular 
components, which may activate inflammatory cells, such as monocytes, and induce 
cytokine production2. Especially LPS is known as a potent stimulator of the host 
inflammatory response10 and is thought to be a main virulence factor2. Therefore, we 
hypothesised that encapsulated and non-encapsulated P. gingivalis do induce different 
production of cytokines upon stimulation of inflammatory cells and that this may be 
due to their LPS. 
 Monocytes are the main regulators of the inflammatory response11 by their ability 
to recognise bacteria and their products by pattern recognition receptors (PRRs), 
like Toll-like receptors (TLRs) and NOD-like receptors (NLRs)12. Upon recognition of 
bacteria or their products by these PRRs, monocytes start producing cytokines13. In 
the present study, we investigated whether encapsulated and non-encapsulated P. 
gingivalis strains induced different cytokine production in monocytes. First we used 
a monocyte cell line, Mono Mac 6 (MM6), to study whether there are differences in 
cytokine responses of monocytes per se to the encapsulated and non-encapsulated 
P. gingivalis strains. We used TNF-α as a marker of cytokine production, since TNF-α is 
the most important regulatory pro-inflammatory cytokine, which is first produced by 
monocytes/macrophages upon bacterial or LPS stimulation14. Since this experiment 
showed different TNF-α responses to especially the LPS of the two P. gingivalis strains, in 
a second experiment, we incubated whole blood to simulate the natural environment15, 
with bacteria or LPS and measured production of the pro-inflammatory cytokines 
TNF-α, IL-1β, IL-6, IL-12 and the anti-inflammatory cytokine IL-10. In both experiments, 
we used E. coli bacteria or its LPS as a reference, since this species is known to be a 








































































Experiment 1: The first aim was to compare the pro-inflammatory properties of 
P. gingivalis K¯, P. gingivalis K1 and E. coli bacteria on monocytes per se. Therefore, 
we first evaluated the production of TNF-α after stimulation of MM6 cells18 with the 
bacteria using flow cytometry. To study whether differences in virulence are the result 
of differences in pro-inflammatory potency of their LPS, we also determined TNF-α 
production by MM6 cells after stimulation with LPS of P. gingivalis (K¯ and K1) as well as 
with E. coli LPS.
Experiment 2: Since in experiment 1 we found differences in TNF-α production by MM6 
cells after stimulation with the LPS of the two P. gingivalis strains, we continued to 
study the production of other pro- and anti-inflammatory cytokines, now using whole 
blood, which simulates the in vivo situation better. For this experiment, whole blood of 
15 healthy individuals was stimulated with bacteria as well as with LPS of P. gingivalis 
K¯, P. gingivalis K1 and E. coli. The production of TNF-α, IL-1β, IL-6, IL-12 and IL-10 was 
measured using the Luminex system. 
Bacterial strains and growth conditions
E. coli ATCC 25922 was grown on 5% sheep blood agar plates (Mediaproducts, Groningen, 
The Netherlands) in air with 5% carbon dioxide (CO2) at 37ºC for 1 day. Bacterial strains 
of P. gingivalis ATCC 33277 (K¯), which has been shown to be non-encapsulated19 and 
P. gingivalis W50 (K1), which has been shown to have a capsule6;20, were generously 
provided by A.J. van Winkelhoff (Department of Oral Microbiology, Academic Center 
for Dentistry Amsterdam, The Netherlands). P. gingivalis K¯ and K1 were grown on 
Brucella blood agar (Mediaproducts, Groningen, The Netherlands), supplemented with 
5% sheep blood, 5 mg/l hemin and 1 mg/l menadione in an anaerobic chamber with 
an atmosphere of 5% CO2, 10% H2 and 85% N2 at 37ºC. After 4-7 days, one bacterial 
colony per strain was incubated in Todd-Hewitt broth (BBL Microbiology Systems), 
supplemented with hemin (5 mg/l), menadione (5 mg/l) and glucose (2 g/l) for one 
week. The bacterial cultures were harvested by centrifugation at 2773 × g for 10 minutes 
at 4ºC. The supernatant was decanted and the bacterial pellet was washed twice in 
phosphate-buffered saline (PBS). The number of bacteria was evaluated by means of a 
microscope after gram-staining and resuspended in PBS at a number corresponding to 
approximately 1x108 bacteria/ml. All cultures were stored at −20ºC until used.
 Lipopolysaccharides derived from E. coli 055:B5, (BioWhittaker, Walkersville, 
MD, USA); P. gingivalis ATCC 33277 (Ultra-Pure, Cat. #: tlrl-pglps, Lot. #: 28-06-PGLPS, 
InvivoGen, San Diego, USA) and P. gingivalis W50, a generous gift from M.A. Curtis (The 
Institute of Cell and Molecular Science; Barts and The London School of Medicine and 
Dentistry, UK) were used.
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Cell line and culture
The MM6 cell line was cultured in RPMI (Complete Roswell Park Memorial Institute) 1640 
medium (Invitrogen, California, USA) with 10% foetal calf serum (FCS), supplemented 
with 1% l-glutamin, 1% Na-pyruvate, 0.1% BME (2β-mercaptoethanol), 0.6% gentamycin 
sulfate and 0.05% fungizone (amfotericine B). Cell-suspensions were cultured at 37ºC 
with a 5% CO2 humidified atmosphere and diluted 1:5 in the culture medium for every 
3-4 days.
Experiment 1: TNF-α production after stimulation of MM6 cells
Before stimulation, MM6 cells were counted and diluted in RPMI to a cell concentration of 
4x109 cells/l. 2x108 MM6 cells/l were supplemented with 9% FCS and 2 ng/ml monensin 
(Sigma Aldrich, St. Louis, MO, USA) to inhibit intracellular transport of TNF-α through 
the ER-Golgi complex21. Immediately prior to use, the stocks of 1x108 bacteria/ml of 
E. coli, P. gingivalis K¯ and P. gingivalis K1 were thawed and used undiluted or diluted 
in PBS (10, 100 and 1000 times). 250 μl of bacterial suspensions was added to 50 μl of 
the MM6 suspension to reach a final bacterial concentration in the tubes of 8.3x107, 
8.3x106, 8.3x105 and 8.3x104 bacteria/ml respectively. All cultures were incubated for 4 
h at 37°C in a 5% CO2 humidified atmosphere. Similarly, MM6 cells were incubated with 
increasing concentrations (0.005, 0.05, 0.25, 0.5, 1.0, 1.5 and 2.5 µg/ml) of P. gingivalis 
K¯ LPS, P. gingivalis K1 LPS or with E. coli LPS. For negative control (unstimulated MM6 
cells), MM6 cells were incubated in the absence of bacterial or LPS challenge.
Sample labelling
After incubation, 200 µl of both stimulated and unstimulated MM6 cells were fixed 
in 1 ml 2% paraformaldehyde (PFA) in PBS for 5 minutes. Then, after centrifugation at 
467 × g for 5 minutes, the pellet was resuspended in 1 ml 0.1% saponin solution (Sigma 
Aldrich, St. Louis, MO, USA) in washing buffer [PBS with 0.5% bovine serum albumin 
(BSA) and 0.1% sodium azide] for 5 minutes in order to permeabilise the MM6 cells. 
After centrifugation (5 minutes at 467 × g) and aspiration, the cells were incubated 
with PE-labelled mouse-anti-human TNF-α antibody (BD Pharmingen, San Diego, 
USA), 1:10 diluted with 0.1% saponin solution in washing buffer for 30 minutes at room 
temperature in the dark. The MM6 cells were then washed again with 1 ml 0.1% saponin 
solution in washing buffer, and after centrifugation and aspiration, the cells were fixed 
with 200 µl 0.5% PFA in PBS and were kept in the dark at 4ºC until measured by flow 
cytometry, within 24 h after labelling.
Flow cytometry
MM6 cells were analysed using the FACS Calibur flow cytometer (Becton Dickinson, NJ, 
USA). Flow cytometry results were analysed using Winlist 6.0 software (Verity Software 







































































Five thousand MM6 cells were acquired by live gating on the total MM6 population 
using forward- and sidescatter characteristics. This gate was copied to a single 
parameter histogram, to determine intracellular TNF-α production of the MM6 cells. 
Using the unstimulated control sample, a linear gate was set in the histogram so that at 
least 99% of the unstimulated MM6 cells were negative for TNF-α production. This gate 
was then copied to the histogram for stimulated MM6 cells. The percentage of positive 
cells was evaluated from the histogram of the stimulated cells. Results are expressed as 
percentage of TNF-α positive cells. 
Experiment 2: cytokine production after stimulation of whole blood
Whole blood samples were obtained by venous puncture from 15 healthy females. 
Protocols for this study were approved by the local ethics committee and a written 
informed consent was obtained from each subject before participation. Since males and 
females do respond differently to endotoxin22, in order to obtain a homogenous study-
population, only Caucasian women between 20 and 40 years of age, with no known 
systemic diseases, were included in this study. Moreover, female hormonal fluctuations 
during the different phases of the ovarian cycle influence the sensitivity of monocytes 
to endotoxin23, therefore, for all individuals, blood was drawn in the follicular phase of 
the menstrual cycle. Immediately after blood sampling, all participants were submitted 
to a periodontal examination by a certified dental hygienist (A.K.) using the Dutch 
Periodontal Screening Index (DPSI) to establish the periodontal condition24. To avoid 
the risk of including participants with a generalised inflammatory response due to 
periodontitis, we excluded subjects with a DPSI score of 3+ or 4, which is indicative for 
destructive periodontal disease24. Blood samples (10 ml) were collected in vacutainer 
tubes containing lithium heparin (Becton Dickinson, Rutherford, NJ, USA). The stock 
bacterial cultures were thawed. Immediately after sampling, 250 μl of undiluted 
stock bacterial cultures of E. coli, P. gingivalis K¯ or P. gingivalis K1 were mixed with 250 
μl of heparinised blood (final numbers: 5x107 bacteria/ml). Furthermore, 250 μl of 
heparinised whole blood was mixed with 250 μl RPMI and LPS of E. coli, P. gingivalis K¯ or 
P. gingivalis K1 was added (2 μg/ml). Negative controls were incubated in the absence 
of bacterial or LPS challenge under similar circumstances. All samples were incubated 
for 24 h at 37°C in a 5% CO2 humidified atmosphere. After stimulation, all samples 
were pipetted into 1.5 ml Eppendorf tubes and centrifuged for 10 minutes at 316 × g 
(4°C). The plasma was then pipetted into new 1.5 ml Eppendorf tubes and centrifuged 
again for 5 minutes at 1972 × g (4°C). Supernatants were frozen at −80°C until cytokine 
concentrations were measured using Luminex.
Determination of extracellular cytokine production in whole blood
Cytokine levels in whole blood were measured using a Bio-PlexTM premixed cytokine 
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assay, human 5-plex group I; Cat. #: M50019PLCW, control 5016683 (Bio-Rad Laboratories, 
Hercules, USA). This customised kit simultaneously measured human TNF-α, IL-1β, 
IL-6, IL-10 and IL-12 (p70). Standard curves for each cytokine were generated using the 
reference cytokine concentrations supplied in this kit. Assay buffer, plasma and duplex 
standards were pipetted into the wells according to the manufacturers’ instruction 
manual. In brief, after prewetting the wells of a 96-well filter plate with assay buffer, 50 
µl of coupled beads were added to the wells and washed twice with assay buffer using 
a vacuum manifold (Millipore, MA, USA). 50 µl of 1:3 diluted plasma (sample diluent 
supplied in the kit) and standards were pipetted into the wells and incubated for 30 
minutes with the coupled beads. The wells were then washed three times and 25 µl of 
detection antibody was subsequently added. After 30 minutes incubation, the wells 
were again washed three times and incubated for 10 minutes with 50 µl streptavidin-PE. 
After 10 minutes of incubation, the wells were washed three times in order to remove 
the unbound streptavidin-PE. Finally, 125 µl of assay buffer was added to each well after 
which the beads were analysed using the Luminex LX100TM multiplex assay detection 
system. Raw data (mean fluorescence intensity, MFI) were analysed using STarStation 
V2.3.
Data analysis
Statistical analysis was performed using GraphPad Prism 5 for Windows (Graphpad 
Software, San Diego, CA, USA). Normality tests were performed using the Shapiro-
Wilk test. Values were given as mean ± standard error of the mean (SEM) for normally 
distributed variables. Not normally distributed data were presented as box and whisker 
plots showing the median values, interquartile and full ranges of value. Outliers were 
defined as data points greater than 1.5 the interquartile range from the median value. 
To evaluate differences between the dose response curves of the various bacterial and 
LPS stimulations, we calculated the area under the curve (AUC). Statistical comparisons 
between the AUCs after the various bacterial and LPS stimulations were performed 
using the unpaired Student’s t-test with Bonferroni’s correction. Differences in cytokine 
concentrations in plasma after stimulation with the different bacterial species as well 
as after the different LPS stimulations were evaluated by using Wilcoxon’s Signed Rank 
test with Bonferroni’s correction. Pro- or anti-inflammatory ratios were calculated by 
dividing the pro-inflammatory cytokine production (TNF-α and IL-12) by the anti-
inflammatory cytokine production (IL-10). The ratios between the various bacterial and 
LPS stimulations were evaluated by using Wilcoxon’s Signed Rank test with Bonferroni’s 








































































Experiment 1: TNF-α production after stimulation of MM6 cells
MM6 cells exposed to only medium showed no TNF-α producing MM6 cells. Stimulation 
with increasing numbers of bacteria of P. gingivalis K¯ and P. gingivalis K1 showed a 
dose-dependent increase in the percentage of TNF-α positive monocytes (Fig. 1(a)). 
Differences in dose response curves after the various bacterial stimulations were 
calculated using the AUC (Fig. 1(a), inset). A significantly higher AUC was observed after 
stimulation with bacteria of E. coli as compared with P. gingivalis K¯ and P. gingivalis 
K1 (p<0.05). No differences in the AUC between P. gingivalis K¯ and P. gingivalis K1 
stimulation were observed. 
 
Fig. 1 – (a) Mean ± SEM percentages of TNF-α positive MM6 cells after stimulation with increasing 
numbers of bacteria from P. gingivalis K¯ (Pg K¯) or P. gingivalis K1 (Pg K1), with E. coli (Ec) as reference 
strain and (b) mean ± SEM percentages of TNF-α positive MM6 cells after stimulation with increasing 
concentrations of LPS from Pg K¯, Pg K1 and from Ec as reference strain. Inserts: mean area under the 
curve (AUC) ± SEM of TNF-α positive MM6 cells after stimulation with increasing numbers of bacteria 
from Pg K¯, Pg K1 and Ec, or with increasing concentrations of LPS from Pg K¯, Pg K1 and Ec. 
(*) Significantly different (unpaired Student’s t-test with Bonferroni’s correction; p<0.05). 
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The percentages of TNF-α positive MM6 cells increased after stimulation with 0.005 
µg/ml E. coli LPS, and then remained constant following stimulation with higher 
concentrations (Fig. 1(b)). Stimulation with increasing concentrations of P. gingivalis 
K¯ LPS and K1 LPS induced a dose-dependent increase of TNF-α positive MM6 cells, 
starting at concentrations higher than 0.05 µg/ml LPS. As can be depicted from Fig. 1(b) 
(inset), a significantly higher AUC was observed after E. coli LPS stimulation as compared 
with both P. gingivalis strains (p<0.05). Also, a significantly higher AUC after stimulation 
with LPS of P. gingivalis K¯ as compared with P. gingivalis K1 was observed (p<0.05).
Experiment 2: cytokine production after stimulation of whole blood
No cytokines were detected in plasma from unstimulated blood samples (data not 
shown). Apart from IL-6 production after P. gingivalis K1 stimulation, stimulation with 
E. coli induced an overall higher cytokine production as compared with P. gingivalis 
K¯ and P. gingivalis K1 stimulation (p<0.05) (Fig. 2). Furthermore, stimulation with 
P. gingivalis K¯ resulted in a significantly lower overall cytokine production than P. 
gingivalis K1 (p<0.05, for all cytokines tested).
 Cytokine production was higher after whole blood stimulation with E. coli LPS, as 
compared with the LPS of P. gingivalis K¯ and P. gingivalis K1 (p<0.05, for all cytokines 
tested) (Fig. 3). Stimulation with P. gingivalis K¯ LPS induced a significant higher overall 
cytokine production than P. gingivalis K1 LPS (p<0.05, for all cytokines tested). 
6
Fig. 2 – Median, 25th and 75th percentiles and 1.5 interquartile range (error bar) of secretion of TNF-α, 
IL-1β, IL-10, IL-12 and IL-6 in human whole blood following stimulation with 5x107 bacteria/ml of E. coli 
(Ec), P. gingivalis K¯ (Pg K¯) or P. gingivalis K1 (Pg K1). Outlier values are represented as individual 






































































We observed that cytokine production was induced differently following exposure 
to the various bacteria or LPS. Therefore, we determined the ratio between pro-
inflammatory and anti-inflammatory cytokines after the various stimulations.
 The TNF-α/IL-10 ratios after both P. gingivalis bacterial stimulations were lower than 
after E. coli stimulation (p<0.05) (Fig. 4(a)). There were no differences in the TNF-α/IL-10 
ratios between the two P. gingivalis bacterial strains. Fig. 4(b) shows the TNF-α/IL-10 
ratios after the various LPS stimulations. No differences in the TNF-α/IL-10 ratios were 
observed between stimulation with LPS of E. coli as compared with both P. gingivalis 
strains. However, a higher TNF-α/IL-10 ratio was observed after P. gingivalis K¯ LPS 
stimulation as compared with P. gingivalis K1 (p<0.05). 
 IL-12 is an important pro-inflammatory cytokine associated with aggressive 
periodontal disease25, forming a link between innate and adaptive immunity26. 
Therefore, we calculated the ratios of IL-12/IL-10 after the various stimulations. A 
significantly higher IL-12/IL-10 ratio was seen after stimulation with E. coli bacterial 
stimulation as compared with both P. gingivalis strains (p<0.05) (Fig. 5(a)). No significant 
differences in the IL-12/IL-10 ratios between the two P. gingivalis strains were observed 
after bacterial stimulation. Fig. 5(b) shows the IL-12/IL-10 ratios after the various LPS 
stimulations. There were no differences in the IL-12/IL-10 ratios between the various 
stimulations. 
Fig. 3 – Median, 25th and 75th percentiles and 1.5 interquartile range (error bar) of secretion of TNF-α, 
IL-1β, IL-10, IL-12 and IL-6 in human whole blood following stimulation with 2 μg/ml LPS of E. coli (Ec), 
P. gingivalis K¯ (Pg K¯) or P. gingivalis K1 (Pg K1). Outlier values are represented as individual points: ●. 
(*) Significantly different (Wilcoxon’s Signed Rank test with Bonferroni’s correction; p<0.05).
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DISCuSSION
This study was undertaken to investigate whether differences in virulence properties 
between P. gingivalis K¯ and P. gingivalis K1 may be due to differences in their capacities 
to induce cytokine production by monocytes. As expected, we showed that bacteria and 
LPS of both P. gingivalis strains were less potent inducers of cytokines as compared with 
our reference strain E. coli. In line with our hypothesis, we found prominent differences 
in cytokine production following incubation with P. gingivalis K¯ vs. P. gingivalis K1 
bacteria or LPS. P. gingivalis K¯ bacteria in general induced a lower cytokine production 
as compared with P. gingivalis K1. This difference can not be due to differences in 
6
Fig. 5 – Median, 25th and 75th percentiles and 1.5 interquartile range (error bar) of IL-12/IL-10 ratios: (a) 
following stimulation with 5x107 bacteria/ml of E. coli (Ec), P. gingivalis K¯ (Pg K¯) or P. gingivalis K1 (Pg 
K1) and (b) after stimulation with 2 μg/ml LPS of Ec, Pg K¯ or Pg K1. Outlier values are represented as 
individual points: ●. (*) Significantly different (Wilcoxon’s Signed Rank test with Bonferroni’s correction; 
p<0.05).
Fig. 4 – Median, 25th and 75th percentiles and 1.5 interquartile range (error bar) of TNF-α/IL-10 ratios: (a) 
following stimulation with 5x107 bacteria/ml of E. coli (Ec), P. gingivalis K¯ (Pg K¯) or P. gingivalis K1 (Pg 
K1) and (b) after stimulation with 2 μg/ml LPS of Ec, Pg K¯ or Pg K1. Outlier values are represented as 






































































cytokine stimulation by their LPS, since P. gingivalis K¯ LPS induced a higher cytokine 
production as compared with LPS of P. gingivalis K1.
  The minor differences in results between experiments 1 and 2 can be explained 
by the use of different experimental protocols, i.e. use of MM6 vs. whole blood, use 
of intracellular cytokine production vs. extracellular production, 4 h stimulation vs. 
24 h. Despite these minor differences, in both experiments, we found a higher overall 
cytokine production and higher TNF-α/IL-10 and IL-12/IL-10 ratio after E. coli bacterial 
stimulation as compared with P. gingivalis bacterial stimulation. This higher pro-
inflammatory cytokine production following E. coli stimulation was expected, since 
it is a well-established fact that E. coli is a more potent inducer of pro-inflammatory 
cytokines than P. gingivalis both in vivo17 and in vitro16. The production of IL-6, however, 
appeared to be much more similar between E. coli bacteria and the P. gingivalis species. 
This may have an in vivo relevance, since IL-6 plays an important role in regulating the 
immune response and leukocyte recruitment27. It also stimulates bone resorption by 
stimulating the formation and activation of osteoclasts28. IL-6 may therefore play an 
important role in the pathogenesis of periodontal diseases. 
  In addition, the overall decreased production of all cytokines by inflammatory 
cells after bacterial stimulation with P. gingivalis K¯ as compared with P. gingivalis K1 is 
in line with previous findings8;9. The higher total cytokine production may play a role 
in the more invasive character of the infection following P. gingivalis K1 infection in 
vivo. Increased cytokine production may enhance the spreading of the infection by 
activating other leukocytes in the environment and by attracking these cells to the 
site of infection28. Various bacterial substances may be responsible for the differences 
in cytokine induction after P. gingivalis K¯ compared with P. gingivalis K1 stimulation. 
The type of fimbriae of P. gingivalis K1 (type IV fimA) has been reported to induce a 
much stronger systemic inflammation in a mouse model as compared with the type of 
fimbriae of P. gingivalis K¯ (type 1 fimA)29. Differences in cysteine proteinase structure 
may also have accounted for the observed variety in cytokine production between 
the two P. gingivalis strains30. Furthermore, the presence of capsular polysaccharides 
in the bacterial suspension of P. gingivalis K1 could have contributed to the observed 
differences between the bacterial strains. The capsule of P. gingivalis K1 has been shown 
to reduce phagocytosis in vivo, providing the bacterium with a mechanism to evade 
internalisation and clearance by host inflammatory cells31. A decreased phagocytosis of 
these bacteria may result in increased numbers of bacteria which can be recognised by 
monocytes, leading to increased cytokine production. However, recent studies looking 
at cytokine production by inflammatory cells after stimulation with encapsulated P. 
gingivalis and non-encapsulated mutants have shown higher cytokine production 
in the non-encapsulated mutant31;32. Additional in vivo studies are thus needed to 
elucidate the role of the capsule of P. gingivalis in host recognition and subsequent 
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inflammatory responses. 
  Differences in chemical characterisation and biologic properties of the LPS33 may 
also have played a role, since the LPS is considered as one of the most important 
pro-inflammatory molecules of gram-negative bacteria2. Although E. coli LPS and P. 
gingivalis LPS differ in chemical structure of the lipid A species34, and signal through 
different Toll-like receptors (TLR2 for LPS of P. gingivalis35 and TLR4 for LPS of E. coli36,37), 
we found no differences in the IL-12/IL-10 and TNF-α/IL-10 ratio between P. gingivalis 
LPS vs. E. coli LPS. Our results are thus not in line with the suggestion that TLR2 is a weak 
inducer of pro-inflammatory cytokines38. It, however, corroborates the suggestion 
that TLR2 activation may also induce strong type 1 helper T cell (TH1) responses
39 and 
indicates that TLR2 activation may induce pro-inflammatory or immunomodulatory 
signalling38;40.
  From our results, it is unlikely that LPS of the P. gingivalis strains is responsible for the 
observed differences in cytokine production following stimulation with P. gingivalis K¯ 
and K1 bacteria. In contrast to P. gingivalis bacterial stimulation, we observed a higher 
overall cytokine production after incubation with P. gingivalis K¯ LPS versus incubation 
with P. gingivalis K1 LPS and a higher TNF-α/IL-10 ratio. Our results are in agreement 
with a study of Bramanti et al.33, who also showed higher TNF-α and IL-1β production 
after stimulation of inflammatory cells with LPS of P. gingivalis K¯ as compared with 
LPS of P. gingivalis K1. This may be due to differences in the chemical properties of 
the LPS between these two P. gingivalis strains, since variations in carbohydrate and 
galactosamine composition and lipid A proportion between the strains have been 
observed33. Therefore, our findings do not support the idea that the LPS of P. gingivalis 
plays an important role in the observed variations in virulence properties between 
the species2. Other bacterial products than LPS seem to be responsible for the higher 
cytokine production following stimulation with P. gingivalis K1 bacteria compared with 
P. gingivalis K¯ bacteria.
  In summary, although E. coli bacteria were more potent inducers of cytokine 
production in whole blood, we also observed differences in cytokine production after 
stimulation with P. gingivalis K¯ vs. P. gingivalis K1: stimulation of whole blood with the 
encapsulated P. gingivalis K1 bacteria resulted in an overall higher cytokine production. 
This may be related to the increased virulence of the encapsulated P. gingivalis strain, 
since a higher cytokine production may result in the attraction of more and other 
leukocytes and increase the spreading of the inflammatory response. The reason why 
P. gingivalis K1 induced a higher cytokine production remains elusive from the present 
study, since the most obvious cytokine inducing substance from gram-negative 
bacteria and thus P. gingivalis, its LPS, did not induce a higher cytokine production as 
compared with LPS from P. gingivalis K¯. Therefore, future studies need to be directed 






































































between the higher cytokine production of P. gingivalis K1 and its higher virulence 
properties. 
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The purpose of the present thesis was to evaluate the putative association between 
periodontitis and preeclampsia. First, we evaluated epidemiological and scientific 
evidence for such a relationship in the literature and conducted a case-control study, 
in which we compared the periodontal condition of women with a recent history of 
preeclampsia and women with uncomplicated pregnancies. Then we studied in the 
rat whether P. gingivalis LPS, as an important antigen in periodontal infections, could 
induce pregnancy complications, including preeclampsia. We observed that infusion 
of LPS from P. gingivalis into pregnant rats induced hypertension, decreased placental 
and foetal weight and induced foetal resorptions. The response of pregnant rats to 
P. gingivalis LPS was different from the response of pregnant rats to the well established 
pro-inflammatory LPS of E. coli, which induces a preeclampsia like syndrome, including 
hypertension, proteinuria and generalised inflammation. This difference in response 
may be induced by variations in cytokine production. Therefore we incubated whole 
blood of pregnant women with LPS as well as bacteria of P. gingivalis and E. coli and 
measured cytokine production and also compared the response of human leukocytes 
to a non-virulent and a virulent serotype of P. gingivalis.
Epidemiological associations
Adverse pregnancy outcomes including preterm delivery, foetal growth restriction 
and preeclampsia affect a significant number of pregnancies, often accompanied with 
both maternal and foetal morbidity and mortality1-3. Infections and subsequent host 
inflammatory processes remain important risk factors for pregnancy complications 
and continue to be investigated as a potential causative factor for adverse pregnancy 
outcomes, especially in pregnancies complicated with preeclampsia4;5. The possible 
relationship between periodontitis and preeclampsia has been studied in various 
populations, with conflicting findings6-26. Chapter 2 provides an overview of the 
primary studies conducted from 2003 until 2010. Analysis of the data showed that, 
although findings were not consistent, there are indications that periodontitis may 
be associated with preeclampsia. A meta-analysis conducted by Ide and Papapanou 
in 2013 confirmed significantly deeper probing depths and higher levels of gingival 
bleeding in preeclamptic pregnancies as compared with healthy controls27. Some of the 
conflicting findings observed in chapter 2 may be due to the fact that the association 
between periodontitis and preeclampsia was investigated in several ethnically different 
populations. Ethnicity has been shown to be a risk factor for both periodontitis as well 
as preeclampsia in the past28;29 and may therefore have biased study outcomes. Another 
major problem might have been the variation in defining periodontal disease. Until 
now there is no accepted ‘gold standard’ definition for periodontitis. It appears that the 
strength of the association between periodontitis and adverse pregnancy outcomes 
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may depend upon the adopted periodontitis definition30. When reviewing the available 
literature, it became apparent that a large variety of methods was adopted to define 
periodontitis as a risk factor for preeclampsia. It is of interest that all studies that, next to 
pocket probing depth and/or clinical attachment level also included bleeding on probing 
(BOP), indicating active inflammation, in their periodontal disease definition found an 
association between periodontitis and preeclampsia7;8;11;17;31. Because we were aware of 
this, in chapter 3 we tried to obtain consistency by stratifying periodontitis according to 
the definitions used by Boggess et al31 who also included BOP. Indeed, we confirmed a 
strong association between periodontitis and preeclampsia. In contrast, most studies 
that did not include BOP in their definition failed to find an association9;15;18;25. Therefore, 
the adopted criteria for defining periodontitis in the observational studies reviewed 
may not have provided the proper tool to draw a decisive conclusion on periodontitis 
as a risk factor for preeclampsia, because not always an active inflammatory process 
is involved. This emphasises the importance of a universal standardised periodontal 
disease definition that includes the inflammatory burden. Nesse et al therefore recently 
developed the PISA (Periodontal Infected Surface Area) definition for periodontal 
disease32. This model calculates the extension of the infected periodontal surface in 
square millimetres, reflecting the severity of the periodontal infection, and quantifies 
the total inflammatory burden. PISA has recently been shown to be a useful model 
to determine a dose-response relationship between the inflammatory burden posed 
by periodontitis and the level of glycated haemoglobin (HbA1c) in type 2 diabetes 
mellitus patients33. In fact, Nesse and coworkers compared several periodontal 
disease definitions and found that PISA reflected the inflammatory burden better 
than all other measures of periodontitis severity. Using PISA might be a major step 
forward in investigating the association between periodontitis and preeclampsia. 
The consensus report of the Joint European Federation of Periodontology (EFP) and 
American Academy of Periodontology (AAP) Workshop on Periodontitis and Systemic 
Diseases: Periodontitis and adverse pregnancy outcomes (2013) now also suggests the 
use of exposure-response relationship analyses, next to categorical assessments, when 
investigating the role of periodontitis in pregnancy complications34.
 Another point of consideration may be the fact that there are several classifications 
for preeclampsia in the literature: severe and mild preeclampsia (with a consensus 
threshold for severe preeclampsia, being systolic blood pressure of >160 mmHg and 
a diastolic blood pressure of >110 mmHg with proteinuria)35 and early-onset (<34 
weeks of gestation) and late-onset (>34 weeks of gestation) preeclampsia36;37. Early-
onset en late-onset preeclampsia are thought to be two different syndromes, for they 
differ in pathogenesis, genetic risk and inheritance37;38. Early-onset preeclampsia starts 
with abnormal placentation (placental preeclampsia) and is associated with reduced 















This abnormal placentation and foetal growth restriction is usually not seen in late-
onset preeclampsia (maternal preeclampsia). Late preeclampsia is considered to arise 
from the interaction between a normal placenta and maternal factors that predispose 
to microvascular diseases, such as diabetes mellitus and long-term hypertension36. In 
these metabotically or genetically predisposed women, the demands of the growing 
foeto-placental unit at the end of pregnancy exceeds the maternal resources40. Since 
in chapter 2 and in our case-control study described in chapter 3 it was shown that a 
remarkable high incidence of periodontitis was observed in early-onset preeclampsia, 
this could indicate that an association between the two diseases may only be evident 
in early-onset preeclampsia. Most of the studies included in the systematic review 
described in chapter 2, did not discriminate between early-onset and late-onset 
preeclampsia, which may have biased study outcomes. Therefore, like standardised 
periodontal disease definitions, also universal standardised preeclampsia definitions 
should be adopted in order to elucidate a relationship between the two diseases. 
 It can be concluded that periodontitis and preeclampsia may be associated 
depending on the inflammatory state of periodontitis and especially in women with 
early-onset preeclampsia. However, it is unclear whether periodontitis plays a causal 
role in the pathogenesis of preeclampsia, because studies focusing on the periodontal 
condition before 20 weeks of gestation, i.e. before the occurrence of the clinical 
symptoms of preeclampsia, failed to show an association25;31. Also in our case-control 
study (chapter 3), in which periodontitis was recorded 3-28 months after delivery, 
it can not be excluded that the preeclamptic state may have induced or aggrevated 
periodontitis rather than vice versa. However, none of these studies were designed 
to demonstrate that preeclampsia may have been a risk factor for the induction or 
progression of periodontitis. Therefore, from the observational studies described in 
chapter 2, it remains unclear whether the relationship between the two diseases is 
causal or just associative.
Efficacy of periodontal therapy on reducing preeclampsia during pregnancy
The question whether periodontitis plays a causal role in preeclampsia is reinforced by 
the observation that there appeared to be no beneficial effect of periodontal treatment 
at ±20 weeks of gestation on the risk of developing preeclampsia (chapter 2). However, 
it is of notice that although the periodontal intervention (primary mechanical therapy, 
i.e. scaling and root planing and improving oral hygiene) resulted in significant clinical 
improvement, in none of the treatment studies reviewed in chapter 2, the intervention 
completely restored periodontal health (defined as shallow probing depths of ≤3 mm 
in the absence of BOP). In fact, Offenbacher et al reported a further increase in incidence 
or progression in probing depth between baseline and delivery in 40% of the treatment 
group41. These findings suggest that primary mechanical therapy alone may not be 
128 129
adequate to control gingival inflammation during pregnancy. Success of mechanical 
therapy is largely dependent on whether specific pathogenic micro-organisms are (still) 
present at subgingival sites at the completion of the therapy42. Especially P. gingivalis 
has been shown to have the capacity to invade into the periodontal tissues43 and can 
be difficult to remove by scaling and root planing alone. Indeed, P. gingivalis has been 
associated with refractory and progressive periodontitis and is commonly found in 
sites that exhibit recurrence and progression44;45. Remarkingly, although observational 
studies showed a higher prevalence of P. gingivalis, E. corrodens, T. forsythia11;46 and 
P. micra17 (chapter 3) in the subgingival plaque of preeclamptic women, none of the 
treatment studies reviewed in chapter 2 investigated the bacterial composition of the 
subgingival microbiome before or after treatment. Therefore, in the treatment studies, 
residual existence of pathogens in the subgingival area, such as P. gingivalis, may have 
resulted in a persistent inflammatory process. A beneficial effect of periodontal therapy 
on pregnancy outcome is not to be expected if the intervention itself was not successful 
in returning the women to a healthy periodontal status, for it may not have adequately 
reduced the level of systemic burden. This may be an explanation for the observation 
that the treatment studies failed to reduce the risk on preeclampsia and emphasises 
the importance of determining the bacterial composition of women suffering from 
periodontitis during pregnancy. Thus, when periodontal pathogens like P. gingivalis 
are found in the subgingival plaque of pregnant women, adjunctive treatment, such 
as the use of antibiotics and/or periodontal surgery, may be necessary to successfully 
reduce the systemic burden posed by periodontitis. It is also possible that periodontal 
therapy at ±20 weeks of gestation was too late in pregnancy to prevent complications, 
for translocation of micro-organisms such as P. gingivalis, or bacterial products like LPS 
from the periodontal infection into the maternal circulation may already have occurred 
before therapy47;48. This may be of importance, since haematogenous transport of 
bacteria and/or pro-inflammatory mediators like LPS of gram-negative pathogens from 
sites of the periodontal infection into the maternal circulation and/or foeto-placental 
tissues may have provoked a systemic or local inflammatory response, thereby inducing 
pathological processes that led to these adverse outcomes49;50.
Biological mechanisms
Since especially P. gingivalis can disseminate into the maternal tissue and some studies 
found a higher prevalence of P. gingivalis in subgingival plaque samples of preeclamptic 
women as compared with healthy pregnant controls11;46, we studied the potential causal 
role of P. gingivalis in preeclampsia. To do so, we used pregnant rats, which were infused 
with LPS of P. gingivalis, the most prominent pro-inflammatory factor of this bacterium 
(chapter 4). We used the set up of a well established model for preeclampsia, in which 















micro-organism E. coli51. A rat model was chosen, because rats, just like humans, have a 
haemochorial placenta and deep trophoblast invasion in the mesometrial triangle52;53. 
We investigated whether LPS of P. gingivalis could induce hypertension and albuminuria, 
could decrease placental or foetal weight or could increase foetal resorptions. Moreover, 
since P. gingivalis LPS is highly pro-inflammatory54 and may provoke local and systemic 
inflammatory responses leading to pregnancy complications, including preeclampsia49, 
we also examined signs of peripheral inflammation, by measuring total leukocyte 
counts and differential leukocyte counts as well as signs of placental and glomerular 
inflammation. From our findings it was shown that infusion with LPS of P. gingivalis in 
pregnant rats increased maternal systolic blood pressure, induced placental and foetal 
growth restriction and increased the number of foetal resorptions. In contrast with the 
findings of Faas et al who used E. coli LPS51;55;56, we did not observe albuminuria. We did 
also not find signs of inflammation in the peripheral blood, in the placenta or in the 
kidney of pregnant rats after infusion of P. gingivalis LPS. 
 Because placental weight was negatively affected by P. gingivalis LPS, we hypothesise 
that the observed foetal and maternal pathology may have been of placental origin. 
Recently, it has been found that P. gingivalis bacteria can induce G1 arrest and increase 
apoptosis of extravillous trophoblast cells57. Extravillous trophoblast cells are not only 
essential for the physical adherence of the placenta to the uterine wall, but also invade 
and remodel the maternal uterine spiral arteries in the placental bed (the mesometrial 
triangle in the rat), which is crucial for normal growth and development of the foetus58. 
An increase in extravillous trophoblast apoptosis may lead to an impaired invasion 
pattern and impaired spiral artery remodeling52, to a small placenta and subsequently 
to impaired placental perfusion59. Impaired placental perfusion may result in reduced 
oxygen and nutrients to the foetus60 and in some foetuses to growth restriction or 
demise. Because P. gingivalis LPS is a TLR2 ligand61 and activation of TLR2 on extravillous 
trophoblast cells may induce apoptosis of these cells62, P. gingivalis LPS may have had a 
direct effect on trophoblast cells and induced increased trophoblast apoptosis. This may 
have resulted in decreased trophoblast invasion and placental and foetal pathology. 
This hypothesis needs to be tested in future studies. It also needs to be elucidated 
what mechanism caused the modest rise in maternal blood pressure in pregnant rats. 
Although P. gingivalis LPS might have had a direct effect on the maternal endothelium63, 
it is also possible that the increased blood pressure was a compensatory attempt of the 
mother to maintain normal blood flow to the foetus in the face of reduced placental 
perfusion. Such a mechanism has also been proposed to occur in humans64.
 The lack of dose dependency for effects of P. gingivalis LPS on foetal resorptions, 
foetal weight and maternal blood pressure in this model is interesting. Such a lack of 
dose dependency is in contrast with infusion of E. coli LPS, in which a dose dependent 
effect on foetal resorptions and foetal weight was observed51. The reason for lack of dose 
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dependency for P. gingivalis LPS is unclear. It is most likely not due to a lack of a dose 
dependent increase in cytokine production following P. gingivalis LPS infusion, since 
in chapter 6 we showed a dose dependent increase in cytokine production following 
stimulation of monocytes with P. gingivalis LPS. However, in chapter 5 we observed that 
P. gingivalis LPS induced a more anti-inflammatory cytokine ratio as compared with E. 
coli LPS in blood of pregnant women. If a similar anti-inflammatory cytokine pattern 
is observed in pregnant rats following P. gingivalis LPS infusion, the anti-inflammatory 
cytokines may have prevented LPS-induced foetal growth restriction and foetal loss 
in these animals65. Furthermore, in chapter 4, we infused P. gingivalis LPS with a single 
dose at gestational day 14. Although this is relatively late in pregnancy, we still found 
obvious effects. We chose gestational day 14, because in rat pregnancy, around that day 
the placenta is fully developed and will only grow in the last week, when trophoblast 
invasion into the mesometrial triangle begins52;53. As indicated before, this trophoblast 
invasion is necessary to maintain adequate placental perfusion in the last week of 
pregnancy. This allowed us to study the effect of the LPS on placental and foetal growth 
rather than on placental and foetal development. However, in humans, pregnant 
women with periodontitis may be exposed to P. gingivalis and/or LPS much earlier in 
pregnancy, most likely from the beginning of pregnancy. Therefore, for future studies, 
it would be interesting to infuse LPS at an earlier stage of rat pregnancy, for instance at 
day seven, three days after implantation of the blastocyst. A more severe response to 
the LPS could then be expected, since LPS, which may directly affect the trophoblast 
via TLR2, may also affect placental development. Moreover, pregnant women with 
periodontitis may be exposed to LPS more continuously. Such a permanent exposure 
to LPS may also result in more severe complications, for continuous LPS exposure may 
induce continuous apoptosis of trophoblasts. It is therefore also of interest to investigate 
the effects of chronic exposure to P. gingivalis LPS in pregnant animals, for instance by 
means of a mini osmotic pump which allows for a permanent systemic release of LPS 
into the circulation. 
 It is also of notice that, in chapter 4, increasing the dose of P. gingivalis LPS did not 
induce more severe maternal effects in pregnant rats than the lower dose of P. gingivalis 
LPS, again in contrast with E. coli LPS51. This may suggest that the sensitivity of pregnant 
individuals to different bacteria or their LPS differs. Such a variety in sensitivity to 
different LPS species may arise from different induction of cytokine production 
following contact of the LPS with leukocytes. We therefore evaluated whether the 
diverse effects of E. coli LPS and P. gingivalis LPS in the pregnant rat may be due to 
differences in cytokine production upon stimulation with LPS. For this purpose, blood 
was taken from pregnant individuals and was stimulated with LPS of P. gingivalis and 
LPS of E. coli. This is described in chapter 5. For comparison, we also included blood of 















with whole bacteria of P. gingivalis and E. coli. In general, we found that P. gingivalis (both 
the whole bacteria and the LPS) was a less potent inducer of both pro- and inflammatory 
cytokines than E. coli, in both blood of pregnant and non-pregnant women. Also, a 
generally lower pro-inflammatory cytokine ratio was observed following stimulation 
with bacteria/LPS of P. gingivalis as compared with E. coli. We hypothesise that this 
lower cytokine production and lower pro-inflammatory cytokine ratio following 
P. gingivalis LPS vs. E. coli LPS stimulation may be involved in the in vivo differences 
observed in chapter 4, in which infusion with LPS of P. gingivalis did not induce systemic 
inflammation and subsequent preeclamptic symptoms in pregnant rats. However, not 
all cytokine levels were equally affected by P. gingivalis or its LPS during pregnancy. For 
example, the production of IL-6 was reduced during pregnancy as compared with the 
non-pregnant situation after P. gingivalis stimulation. IL-6 is a multifunctional cytokine 
with both pro- and anti-inflammatory capacities66. This cytokine has an important role 
in the cytokine network that directs the shift from acute to chronic inflammation67 and 
is associated with several chronic inflammatory diseases68, including periodontitis69. 
IL-6 may also be a candidate player in several pregnancy complications, such as 
preterm delivery, miscarriage and also preeclampsia in both animals and humans70. 
The reason why especially the production of IL-6 upon P. gingivalis stimulation is 
decreased during pregnancy is unclear. Further studies will be necessary to elucidate 
the mechanisms responsible for the lower IL-6 production upon P. gingivalis stimulation 
during pregnancy, and whether this response is beneficial or detrimental to pregnancy.
 In chapter 4, we observed the well known pregnancy-induced increased sensitivity 
to LPS51;55;71, for the effects of P. gingivalis LPS on blood pressure were only observed in 
pregnant animals. This may be due to different cytokine responses upon LPS treatment 
of pregnant animals as compared with non-pregnant animals. Therefore, in chapter 
5, we compared cytokine production after stimulation of blood of pregnant women 
with cytokine production after stimulation of blood of non-pregnant women. In line 
with our expectation, pregnancy itself had an effect on cytokine production: the 
production of cytokines as well as the pro-inflammatory ratios of these cytokines after 
E. coli and P. gingivalis bacteria/LPS stimulation in general were comparable or lower in 
pregnant women than in non-pregnant women. Apparently, monocytes of pregnant 
women produce less cytokines upon bacterial/LPS stimulation than monocytes of 
non-pregnant women. Our findings are in line with previous findings of our laboratory, 
in which it was also observed that the percentages of IL-12 and TNF-α producing 
monocytes were lower upon LPS stimulation in pregnant women as compared with 
non-pregnant women72. Reduced cytokine production may be the consequence of an 
endotoxin tolerant state of activated monocytes, caused by factors in the plasma of 
pregnant women72 and suggests that pregnant women may be more sensitive to the 
effects of cytokines. This is in line with earlier results from our lab73. However, the exact 
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biological implication of this pregnancy-induced phenomenon remains to be further 
investigated.
 Finally, in chapter 6, we studied the cytokine response upon the different P. 
gingivalis phenotypes and their LPS, since it has been shown that the bacterial 
phenotype may influence inflammatory responses against these bacteria, even within 
the same bacterial species. It has been reported that there may be differences in pro-
inflammatory properties between LPS of different P. gingivalis serotypes74, and several 
P. gingivalis serotypes with paradoxically opposing (stimulatory versus suppressive) 
effects on host inflammatory responses do exist75. Therefore, our final aim was to further 
study the host response to P. gingivalis and its LPS on human cells. For this purpose, we 
investigated cytokine production in human whole blood following stimulation with 
bacteria or isolated LPS of two P. gingivalis serotypes [non-encapsulated P. gingivalis 
ATCC 33277 (K¯) and encapsulated P. gingivalis W50 (K1)] (chapter 6). These specific 
serotypes were chosen, because encapsulated P. gingivalis subtypes have been shown 
to be more virulent in experimental infections than non-encapsulated P. gingivalis 
subtypes76. Differences in virulence properties may result from different cytokine 
production following recognition of the encapsulated or non-encapsulated bacteria 
by the host immune system77;78. As described in chapter 6, both bacteria/LPS of both P. 
gingivalis serotypes were significantly less potent inducers of inflammatory cytokines 
than E. coli LPS. When comparing the two P. gingivalis serotypes, the LPS of P. gingivalis 
K¯ induced a higher cytokine production and a higher pro-/anti-inflammatory ratio 
than P. gingivalis K1, which is in line with previous findings74. It confirms that in our 
rat experiment (chapter 4), we used to the appropriate LPS to investigate the effects 
of this molecule on inflammatory processes during pregnancy. However, encapsulated
P. gingivalis K1 bacteria induced higher cytokine production than the non-encapsulated 
P. gingivalis K¯. Similar to the findings described in chapter 5, this was especially apparent 
in the production of IL-6. In fact, the production of IL-6 after P. gingivalis K1 bacterial 
stimulation was comparable with E. coli bacterial stimulation, which substantiates the 
general thought that P. gingivalis serotypes, by inducing IL-6, may play an important 
role in the pathogenesis of periodontitis. Interestingly, the LPS of both serotypes did 
not significantly contribute to the inflammatory capacity of P. gingivalis, when tested in 
non-pregnant individuals. Apparently, other pro-inflammatory factors, such as fimbriae, 
lipoproteins or capsular components may (also) be involved in the inflammatory 
capacity of P. gingivalis54. This may implicate that in future experimental studies, not 
isolated LPS alone but rather whole bacteria should be infused to further investigate 
the role of P. gingivalis in pregnancy complications. 
 The overall higher cytokine production following stimulation with P. gingivalis K1 
vs. P. gingivalis K¯ might be related to the higher virulence properties of P. gingivalis 















response. The higher inflammatory potential of P. gingivalis K1 may therefore play a 
role in the more invasive character of the infection following stimulation in vivo. This 
higher invasive capacity and observed higher inflammatory potential of P. gingivalis 
K1 might be highly relevant during pregnancy, for it may provide this serotype with a 
mechanism to disseminate into placental tissues more easily than non-encapsulated 
P. gingivalis serotypes. This implicates that not all P. gingivalis serotypes may be (equally) 
involved in pregnancy complications and emphasises the importance of using well 
defined bacterial subtypes when investigating the effects of P. gingivalis on pregnancy 
outcome. If such experimental studies would show that indeed not all P. gingivalis 
serotypes equally affect pregnancy outcome, then identifying the specific P. gingivalis 
serotypes in the subgingival plaque of pregnant women might become a next step in 
investigating a causal role of periodontitis in pregnancy complications. 
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CONCLuSIONS, fuTuRE PERSPECTIvES AND CLINICAL IMPLICATIONS
This thesis showed that periodontitis may be associated with pregnancy complications, 
such as preeclampsia, and also provides some new insights into the identification of a 
mechanism by which the periodontal infection may be involved in adverse pregnancy 
outcomes. Observational studies indicate that periodontitis may be associated with 
some forms of preeclampsia. This was most obvious in early-onset preeclampsia 
(chapter 2 and chapter 3). It is however questionable whether periodontitis is causally 
involved in preeclampsia, because this thesis not only showed that studies focusing 
on the periodontal condition before 20 weeks of gestation, i.e. before the clinical 
occurrence of preeclampsia, failed to find an association, also periodontal treatment 
performed at about 20 weeks of pregnancy did not reduce the risk on preeclampsia 
(chapter 2). Moreover, one of the most virulent antigens of the periodontal infection, 
P. gingivalis LPS, did not induce preeclamptic features or systemic inflammation in the 
pregnant rat (chapter 4), nor induced strong pro-inflammatory cytokine production 
in our in vitro and ex vivo experiments (chapter 5 and chapter 6). It therefore remains 
unclear whether the preeclamptic state predisposes to periodontitis or vice versa or 
that a confounding factor predisposes to both diseases.
 The rat experiment, however, demonstrated that the LPS of P. gingivalis may induce 
some pregnancy complications, such as hypertension, foetal growth restriction, foetal 
death or miscarriage. It is possible that LPS of P. gingivalis is involved in trophoblast 
apoptosis, although the exact mechanism by which this molecule is involved in obstetric 
complications remains to be established. It is widely appreciated that aberrations of 
the normal trophoblast invasion pattern into spiral arteries may lead to pregnancy 
complications in humans. Therefore, more comprehensive research to pathological 
mechanisms, and especially experimental research to the role of specific pathogenic 
micro-organisms in placental bed pathology, should be performed.
  Our findings indicate that haematogenous spread of P. gingivalis LPS in rats affects 
placental growth, which may be one of the causes of adverse obstetric outcomes. It 
needs to be established whether P. gingivalis or its LPS also affects placental growth in 
humans. It also needs to be established whether the association between P. gingivalis 
and adverse pregnancy outcomes may depend on the specific serotype present. Early 
detection and therapeutic elimination of P. gingivalis might then become important 
intervention strategies. In this thesis we chose to focus on P. gingivalis, because this 
micro-organism is one of the most important pathogens associated with severe 
periodontitis79, expresses appropriate virulence properties in animal studies80 and 
has been associated with foetal growth restriction and foetal resorptions in animal 
experiments in the past80-82. However, it is possible that other bacterial species from 
the periodontal infection, such as A. actinomycetemcomitans, T. forsythia, P. intermedia, 















complications, such as preeclampsia83;84. This should be investigated in future studies.
  Clearly, at this moment it is unknown whether periodontal therapy in early 
pregnancy or before conception will effectively reduce the risk on developing 
pregnancy complications. Therefore, there is great need for a large randomised study 
of preconception or interception screening and treatment of periodontitis. Such a 
study may also identify which patients would benefit from screening and treatment 
and which screening methods would be useful. Until then, the ‘Guidelines for Treating 
the Pregnant Patient’ of the American Academy of Periodontology85 remain applicable. 
In this statement it is recommended that preventive oral care should be performed 
as early as possible in pregnancy and if needed, scaling and root planing should 
be scheduled early in the second trimester. Preventive oral care during pregnancy 
should not only include training and motivation in oral hygiene practices, but also 
include education in periodontal self-assessment, so that the pregnant patient may 
recognise the obvious signs of gingival inflammation and seek the appropriate oral 
care, if necessary34. Irrespective of an aetiological role of periodontitis in pregnancy 
complications, the altered maternal immuno-responsiveness during pregnancy and 
the presence of P. gingivalis increases the susceptibility to gingival inflammation during 
pregnancy86;87. Since oral health is an integral part of general health, early detection 
and treatment of periodontal diseases remain unquestionably of benefit to the mother. 
Especially in the Netherlands, were both obstetric and oral care are very well organised, 
and periodontal screening is part of the routine annual dental check-up, it should be 
possible to screen and treat women in the reproductive age for periodontitis and follow 
them throughout gestation. Such a strategy clearly has the advantage of reducing the 
need for periodontal intervention during pregnancy, when women are at increased risk 
on developing gingival inflammation and/or worsening of the periodontal condition. In 
order to achieve this, not only a closer collaboration between professionals in obstetric 
care and oral care is necessary, but also public health officials should emphasise on 
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The general introduction (chapter 1) briefly describes the pathophysiology of periodontal 
diseases, the possible systemic consequences of the periodontal infection and also its 
putative role in pregnancy complications, with a special focus on preeclampsia. 
  It was first suggested in 2003 that periodontitis during pregnancy might be 
related with preeclampsia, a severe complication of pregnancy clinically manifest by 
hypertension and proteinuria during the second half of pregnancy. There is growing 
evidence that a chronic generalised inflammatory response is an important factor 
in the pathogenesis of preeclampsia. Periodontitis, as a chronic infection, might 
superimpose on the already pro-inflammatory state of normal pregnancy, thereby 
inducing preeclampsia. Periodontopathic bacteria or bacterial products from the oral 
cavity may also enter placental or foetal tissues via the maternal blood stream and 
induce inflammation at site. 
  Clearly, at the start of this thesis, there was little evidence to substantiate a 
relationship between periodontitis and preeclampsia. Therefore, the overall aim of this 
thesis was to investigate the nature of this putative relationship, and more specifically 
to explore epidemiological associations between periodontitis and preeclampsia, to 
investigate the effect of periodontal therapy on preeclamptic rates and also to explore 
pathological pathways that might explain such a relationship.
The review presented in chapter 2 aimed to systematically review the current available 
scientific evidence for an association between periodontal disease and preeclampsia. A 
search of the literature was performed in the computerised databases of MEDLINE via 
PubMed (1969-August 2010), EMBASE (1974-August 2010) and CINAHL (2003-August 
2010). Relevant studied performed in humans, published in English, German, French, 
Spanish and Dutch were included. Methodological quality was assessed by two 
reviewers independently using quality-assessment forms designed by the Dutch 
Cochrane Collaboration. Out of the primary eligible articles, 12 observational studies 
and three randomised-controlled trials (RCTs) fulfilled the inclusion and exclusion 
criteria. Eight of the observational studies reported a positive association, while four 
studies found no association. The most obvious association was observed between 
periodontitis and early-onset preeclampsia. However, it appeared difficult to 
compare the studies, due to variations in adopted definitions of periodontal disease 
and preeclampsia, timing of periodontal examination and inadequate control for 
confounders, such as ethnicity. Since studies focusing on the periodontal condition at 
enrolment, i.e. before preeclampsia had occurred, failed to show an association, it is 
unclear whether periodontal disease plays a causal role in preeclampsia. None of the 
RCTs reported reductions in preeclamptic rates after periodontal treatment performed 
at about 20 weeks of gestation. The meta-analysis showed a periodontal disease 
144 145
associated RR on preeclampsia of 1.0 (95% CI 0.78-1.28). It can therefore be concluded 
that periodontal therapy performed at about 20 weeks of gestation has no beneficial 
effect on pregnancy outcome.
Since variety in periodontitis and preeclampsia definitions as well as ethnicity may have 
confounded results in chapter 2, in our case-control study described in chapter 3, the 
periodontal condition and subgingival plaque composition of 17 Causasian women 
with a recent history of early-onset preeclampsia was compared with the periodontal 
condition of 35 Caucasian women with uncomplicated pregnancies. In order to obtain 
consistency in periodontal disease definitions, we stratified periodontitis as described 
by Boggess et al (2003). Full mouth periodontal examinations were performed to 
determine the periodontal condition and subgingival plaque samples were analysed 
for the presence of seven of the most important periodontopathic micro-organisms. 
Severe periodontitis was present in 82% of the preeclamptic women and in 37% of 
the controls. We found that, after adjusting for age, BMI, smoking and educational 
level, the periodontal condition of preeclamptic women was worse as compared to 
women with uncomplicated pregnancies and that severe periodontitis was associated 
with preeclampsia (adjusted OR 7.9, 95% CI 1.9-32.8). The periodontopathic micro-
organism M. micros (now referred to as P. micra) was more prevalent in the case group 
while C. rectus was more prevalent in the control group. The results indicated that 
the periodontal condition in Caucasian women with a recent history of early-onset 
preeclampsia was significantly worse as compared with the periodontal condition of 
women with uncomplicated pregnancies.
In order to investigate a causal role of periodontitis in pregnancy complications, in 
chapter 4 we performed an experimental animal study in which we studied the impact 
of P. gingivalis LPS infusion into pregnant rats. We investigated whether the most 
virulent component of P. gingivalis, its lipopolysaccharide, like LPS of E. coli, could induce 
pregnancy complications, including preeclamptic features, in the rat. For this purpose 
we conducted two experiments. In experiment 1, on gestational day 14, pregnant 
rats received increasing doses of P. gingivalis LPS (0.0-50.0 µg/kg bw LPS; n=2/3 for 
each dose). The following parameters were documented: maternal intra-aortic blood 
pressure, urinary albumin excretion, placental and foetal weight and number of foetal 
resorptions. In experiment 2, pregnant and non-pregnant rats were infused with 10.0 
µg/kg bw P. gingivalis LPS (which induced the highest blood pressure and reduced foetal 
weight in experiment 1), or saline alone (n=7/9 for each group). The same parameters 
of experiment 1 as well as numbers of peripheral leukocytes and signs of inflammation 
in the kidney and placenta were evaluated. The results of experiment 1 showed that 








well as number of foetal resorptions and reduced placental weight at most doses 
tested. We did not observe a reduction in foetal weight nor did the rats develop 
albuminuria. These findings were confirmed in experiment 2 after infusion with 10.0 
µg/kg bw P. gingivalis LPS (the dose that induced the highest blood pressure together 
with decreased foetal weight in experiment 1). However, after analysing the number 
of foetuses that were more than two standard deviations (2 SD) from the normal mean 
(4.75 ± 0.50 g; i.e. less than 3.75 g), it was shown that a significant higher number of 
foetuses were growth restricted in the P. gingivalis LPS infused group as compared with 
the saline controls. No signs of a generalised inflammatory response were observed, 
nor did we find indications for inflammation in the kidney or placenta. The increased 
blood pressure appeared to be specific for pregnant rats, since no effects of P. gingivalis 
LPS were seen in non-pregnant rats. It can be concluded that P. gingivalis LPS affects 
pregnancy by increasing maternal blood pressure, inducing placental and foetal growth 
restriction and by increasing the number of foetal resorptions. Therefore, P. gingivalis 
LPS may play a role in pregnancy complications induced by periodontitis. Unlike LPS of 
E. coli, P. gingivalis LPS does not appear to play a role in the pathogenesis of the maternal 
syndrome of preeclampsia, for we did not observe albuminuria nor inflammation.
Therefore, in chapter 5, we evaluated whether the observed different effects of P. 
gingivalis LPS and E. coli LPS on pregnancy may be due to differences in cytokine 
production upon recognition by leukocytes. For this purpose, blood samples were 
taken from 16 healthy pregnant and 15 healthy non-pregnant women and stimulated 
with bacteria and LPS of P. gingivalis ATCC 33277 and E. coli in an ex vivo laboratory 
study. After the stimulations, we measured cytokine production (TNF-α, IL-1β, IL-6, 
IL-12 and IL-10) using Luminex and TLR2/TLR4 expression on monocytes using flow 
cytometry. We also calculated pro-/anti-inflammatory ratios (IL-12/IL-10, TNF-α/IL-10 
and IL-6/IL-10). The results showed that in both pregnant and non-pregnant women, 
stimulation with P. gingivalis bacteria/LPS induced lower cytokine production and 
lower pro-inflammatory ratios than E. coli bacteria/LPS, with the exception of the IL-6/
IL-10 ratio, which was higher after P. gingivalis bacteria/LPS stimulation. There was 
also an effect of pregnancy on cytokine production: the concentration of IL-12 after 
E. coli bacterial stimulation and the concentration of IL-6 after P. gingivalis bacterial 
stimulation was lower in whole blood of pregnant women than in non-pregnant 
women. Similarly, as compared with non-pregnant women, in pregnant women the 
production of IL-12 and TNF-α was lower after stimulation with LPS of E. coli, and the 
production of IL-6 was lower after stimulation with P. gingivalis LPS. The percentage of 
TLR2 positive monocytes was lower in pregnant women vs. non-pregnant women. The 
generally lower cytokine production and lower pro-inflammatory ratio after P. gingivalis 
stimulation vs. E. coli stimulation during pregnancy may explain differences in response 
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upon bacterial recognition in the in vivo situation and suggest that pregnant women 
are more sensitive to the effects of cytokines like IL-12, IL-6 and TNF-α.
Strain dependent variations in virulence of P. gingivalis have been reported. This may 
be due to differences in cytokine production following recognition of the bacteria or 
their LPS by host inflammatory cells. Therefore, in order to further investigate virulence 
factors of P. gingivalis, in chapter 6, we compared cytokine production following 
stimulation with bacteria or LPS of two different P. gingivalis serotypes. We stimulated 
the cell-line Mono Mac 6 (MM6) as well as human whole blood from 15 healthy women 
with bacteria and isolated LPS of the non-encapsulated P. gingivalis ATCC 33277 (K¯) and 
the encapsulated P. gingivalis W50 (K1). In experiment 1, TNF-α production following 
stimulation of the cell-line Mono Mac 6 with bacteria or LPS of both P. gingivalis strains 
was determined using flow cytometry. In experiment 2, we investigated the effects of 
the two P. gingivalis serotypes or their LPS on TNF-α, IL-1β, IL-6, IL-12 and IL-10 production 
in whole blood collected from 15 healthy women using Luminex. In both experiments, 
E. coli bacteria and LPS were used as a reference. Both P. gingivalis serotypes induced 
lower cytokine production than E. coli, with the exception of IL-6 after P. gingivalis 
K1 bacterial stimulation. P. gingivalis K1 bacteria elicited a higher overall cytokine 
production than P. gingivalis K¯. In contrast, P. gingivalis K1 LPS stimulation induced 
a lower cytokine production than P. gingivalis K¯ LPS. Apparently,  other bacterial 
products than LPS seem to be responsible for the higher cytokine production following 
stimulation with P. gingivalis K1 bacteria as compared with P. gingivalis K¯ bacteria. This 
stronger cytokine production after stimulation with P. gingivalis K1 may contribute to 
its virulence properties because increased production of cytokines may recruit more 
leukocytes to the site of infection, thereby enhancing the local inflammatory process.
Finally, in chapter 7 the main research outcomes are discussed and perspectives for 
future research are described. From observational studies, including the case-control 
study conducted by our own group, there appears to be an association between 
periodontitis and some forms of preeclampsia, most evident early-onset preeclampsia. 
It is, however, questionable whether periodontitis is causally involved in preeclampsia, 
because studies that performed periodontal screening before 20 weeks of gestation 
(i.e. before the occurrence of the clinical symptoms of preeclampsia) failed to show an 
association. Also, periodontal therapy performed at about 20 weeks of gestation did 
not reduce the risk on preeclampsia. Therefore, it remains elusive whether periodontitis 
may induce preeclampsia or vice versa or that an unknown factor predisposes to both 
diseases. It can, however, not be excluded that periodontal therapy performed at about 
20 weeks of gestation may have been too late in pregnancy, for translocation of oral 








may already have occurred before therapy.
 The results of our animal study substantiated previous findings that LPS of P. 
gingivalis may be causally involved in pregnancy complications such as low birth weight 
and miscarriage, in this thesis presented as foetal resorptions in the rat. Although we 
observed a slight increase in maternal blood pressure, infusion with P. gingivalis LPS 
did not induce albuminuria or generalised inflammation. LPS of P. gingivalis therefore 
appears not be involved in the pathogenesis of preeclampsia. It can be hypothesised 
that the foetal pathology and increased blood pressure arose from the placenta as 
placental weight was decreased by P. gingivalis LPS infusion. P. gingivalis LPS may have 
directly affected placental growth by increasing trophoblast apoptosis. This in turn may 
have led to reduced oxygen and nutrient supply to the foetus and subsequently to 
growth retardation of the foetus. The slightly increased maternal blood pressure may 
have been a compensatory mechanism to restore oxygen and nutrient supply to the 
foetus and as such also be of placental origin. The exact mechanism by which LPS of 
P. gingivalis increased maternal blood pressure and reduced placental and foetal growth 
remains obscure from our experiment and needs further investigation. 
 Our in vitro and ex vivo blood experiments showed that both bacteria and LPS 
of P. gingivalis serotypes had lower pro-inflammatory capacity and induced lower 
cytokine production by monocytes than E. coli bacteria and LPS. This may explain why 
infusion with P. gingivalis LPS, in contrast with E. coli LPS did not induce preeclamptic 
features in our animal experiment. Interestingly, despite the fact that pregnant women 
are extremely sensitive to LPS, cytokine levels in blood of pregnant women after the 
various stimulations was similar or lower as compared with non-pregnant women. 
This may reflect an endotoxin tolerant state of activated monocytes during pregnancy 
and suggests that pregnant women may be more sensitive to the effects of cytokines. 
Further studies will be necessary to elucidate what mechanisms are responsible for the 
lower cytokine production upon LPS stimulation during pregnancy.
 
In conclusion, this thesis shows there are indications from observational studies that 
human periodontitis may be associated with some forms of preeclampsia. However, 
no beneficial effect of periodontal therapy on preeclamptic rate was observed, nor 
did P. gingivalis LPS induce preeclampsia or generalised systemic inflammation in the 
pregnant rat. Also, P. gingivalis bacteria or LPS did not induce a strong pro-inflammatory 
cytokine production in the in vitro en ex vivo blood experiments. It seems therefore 
unlikely that periodontitis plays a causal role in the pathogenesis of preeclampsia.
 Periodontitis may be involved in low birth weight and miscarriage by the presence 
of P. gingivalis LPS, as was shown in a rat experiment. It is of importance to elucidate 
the exact pathway by which P. gingivalis LPS interferes with pregnancy. Interestingly, in 
contrast with the common hypothesis, the detrimental effects of P. gingivalis LPS on foetal 
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development were not induced by activation of the inflammatory response. In fact, we 
showed in our ex vivo experiment that during normal pregnancy, cytokine production 
upon P. gingivalis LPS exposure is balanced towards a more anti-inflammatory ratio as 
compared with the non-pregnant situation. The exact mechanisms and implications 
of this pregnancy-related adaption of the inflammatory response to bacteria or LPS 
during pregnancy are intriguing and need further investigation. 
 At this moment there is no evidence to substantiate that periodontal treatment 
during pregnancy reduces the risk on pregnancy complications, except possibly for 
a subgroup of women with high risk of preterm birth. However, irrespective of an 
aetiological role of periodontitis in pregnancy complications, the state of pregnancy 
increases the susceptibility to gingival inflammation. Therefore, early detection and 
treatment of periodontal diseases prior to or during pregnancy remain unquestionably 























In de inleiding (hoofdstuk 1) wordt kort de pathofysiologie van parodontitis, de mogelijke 
systemische consequenties van de parodontale infectie, alsook de vermeende rol van 
parodontitis in zwangerschapscomplicaties beschreven, met een extra focus op pre-
eclampsie.
  In 2003 is voor het eerst gesuggereerd dat parodontitis tijdens de zwangerschap 
mogelijk ook een risicofactor voor pre-eclampsie zou kunnen zijn. Pre-eclampsie is 
een ernstige, levensbedreigende aandoening die zich kan openbaren vanaf de 20ste 
week van de zwangerschap met hypertensie en proteinurie. Er is groeiend bewijs dat 
een chronische infectie (en de ontstekingsreactie hierop) een belangrijke etiologische 
factor is in de pathogenese van pre-eclampsie. Mogelijk draagt parodontitis, als een 
chronische infectie, bij aan de al toegenomen pro-inflammatoire staat van de normale 
zwangerschap, met pre-eclampsie als gevolg. Het is ook mogelijk dat paropathogene 
bacteriën of bacteriële producten vanuit de mondholte via de bloedbaan de placentaire 
en/of foetale weefsels bereiken en ter plaatse een ontstekingsproces induceren. Ten 
tijde van de aanvang van dit proefschrift was er weinig bewijs voor een relatie tussen 
parodontitis en pre-eclampsie. Het overkoepelende doel van dit proefschrift was dan 
ook om de aard van deze relatie te onderzoeken, in het bijzonder de epidemiologische 
associatie, het effect van parodontale therapie op het aantal pre-eclamptische 
zwangerschappen alsook pathologische mechanismen te onderzoeken die een relatie 
zouden kunnen verklaren.
De studie die wordt beschreven in hoofdstuk 2 was gericht op het systematisch beoor-
delen van het beschikbare wetenschappelijke bewijs voor een verband tussen paro-
dontitis en pre-eclampsie. Daartoe werd gezocht in de geautomatiseerde gegevens-
bestanden van MEDLINE via PubMed (1969-augustus 2010), EMBASE (1974-augustus 
2010) en CINAHL (2003-augustus 2010). Relevante humane studies, gepubliceerd in het 
Engels, Duits, Frans, Spaans en Nederlands werden opgenomen. De methodologische 
kwaliteit van de primair geselecteerde studies werd door twee onderzoekers onafhanke-
lijk van elkaar beoordeeld, met behulp van kwaliteitsbeoordelingsformulieren van 
de Nederlandse Cochrane Collaboration. Van de primair geselecteerde onderzoeken 
voldeden 12 observationele studies en drie gerandomiseerde, gecontroleerde 
studies (RCT’s) aan de vooraf opgestelde inclusie- en exclusiecriteria. Acht van de 
observationele studies vonden een positieve associatie, terwijl vier studies geen 
associatie konden aantonen. De meest opvallende associatie werd gevonden tussen 
parodontitis en vroege pre-eclampsie (<34 weken zwangerschap). Het bleek echter 
moeilijk om de studies met elkaar te vergelijken, als gevolg van variaties in de gebruikte 
definities van parodontitis en pre-eclampsie, het tijdstip van parodontaal onderzoek en 
het ontbreken van voldoende controle voor confounders, zoals ethniciteit. Aangezien 
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studies die de parodontale status beoordeelden bij binnenkomst van de patiënt, d.w.z. 
voor pre-eclampsie was opgetreden, geen verband laten zien, is het onduidelijk of 
parodontitis een causale rol bij pre-eclampsie speelt. Geen van de geïncludeerde RCT’s 
rapporteerde een reductie in pre-eclamptische zwangerschappen na parodontale 
therapie uitgevoerd rondom 20 weken zwangerschap. De meta-analyse toonde een aan 
parodontitis gerelateerd gecombineerd relatief risico op pre-eclampsie van 1.0 (95% CI 
0.78-1.28). Er kan worden geconcludeerd dat parodontale therapie uitgevoerd rondom 
20 weken zwangerschap geen positief effect heeft op zwangerschapsuitkomsten.
Gezien het feit dat in hoofdstuk 2 de variatie in gebruikte definities voor parodontitis 
en pre-eclampsia, alsook ethniciteit mogelijk de uitkomsten hebben verstoord, is in 
de patiënt-controle studie zoals beschreven in hoofdstuk 3, de parodontale conditie 
en subgingivale plaque samenstelling van 17 Kaukasische vrouwen met een recent 
doorgemaakte pre-eclamptische zwangerschap vergeleken met de parodontale con-
ditie van 35 Kaukasische vrouwen met een ongecompliceerd verlopen zwangerschap. 
Om consistentie zoveel mogelijk te garanderen zijn de parodontale definities gebruikt 
zoals eerder beschreven in de studie van Boggess et al (2003). Een volledig parodontaal 
onderzoek in de gehele mond werd uitgevoerd om de parodontale conditie vast te 
stellen. Subgingivale plaque monsters werden onderzocht op de aanwezigheid 
van zeven van de meest belangrijke paropathogenen. Ernstige parodontitis werd 
aangetroffen in 82% van de pre-eclamptische vrouwen en in 37% van de vrouwen 
uit de controlegroep. Na correctie voor leeftijd, BMI, roken en opleidingsniveau bleek 
ernstige parodontitis geassocieerd met pre-eclampsie (gecorrigeerde OR 7.9, 95% CI 
1.9-32.8). De paropathogene bacterie M. micros (volgens recente taxonomie: P. micra) 
was verhoogd aanwezig in de onderzoeksgroep, terwijl C. rectus in hogere aantallen 
aanwezig was in de controlegroep. De resultaten laten zien dat de parodontale conditie 
van Kaukasische vrouwen met een recente geschiedenis van pre-eclampsie slechter is 
dan de parodontale conditie van vrouwen met een ongecompliceerde zwangerschap.
 
Om te onderzoeken of parodontitis een causale rol speelt in zwangerschaps-
complications, is in hoofdstuk 4 een experimentele dierstudie uitgevoerd, waarin is 
gekeken naar het effect van infusie van P. gingivalis LPS op zwangere ratten. In deze 
studie is onderzocht of de meest virulente component van P. gingivalis, het LPS, net zoals 
LPS van E. coli, zwangerschapscomplicaties, inclusief pre-eclamptische kenmerken, kon 
induceren in de rat. Voor dit doel zijn twee experimenten uitgevoerd. In experiment 1 
werden zwangere ratten op dag 14 van de zwangerschap geïnfundeerd met oplopende 
doseringen van P. gingivalis LPS (0.0-50.0 µg/kg bw LPS; n=2/3 per dosering). De 
volgende parameters werden gedocumenteerd: maternale intra-arteriële bloeddruk, 


















resorpties. In experiment 2 werden zwangere en niet-zwangere ratten geïnfundeerd 
met 10.0 µg/kg bw P. gingivalis LPS (de dosis die in experiment 1 de hoogste bloeddruk 
induceerde en het foetale gewicht reduceerde). Controle-ratten werden geïnfundeerd 
met fysiologisch zout (n=7/9 per groep). Naast de in experiment 1 onderzochte 
parameters, werden ook aantallen leukocyten in perifeer bloed en tekenen van 
ontsteking in de nier en placenta geëvalueerd. De resultaten van experiment 1 laten 
zien dat infusie met P. gingivalis LPS in zwangere ratten leidde tot verhoogde bloeddruk, 
een toename in het aantal foetale resorpties en een afname in placentair gewicht bij de 
meeste doseringen. Er was echter geen afname in foetaal gewicht, noch ontwikkelden 
de ratten albuminurie. Deze resultaten werden bevestigd in experiment 2 na infusie 
met 10.0 µg/kg bw P. gingivalis LPS. Echter, het aantal foetussen dat kleiner dan 2x de 
standaard deviatie (2 SD) van het normale gemiddelde was (4.75 ± 0.5 g; d.w.z. 3.75 gr), 
bleek significant hoger in de P. gingivalis LPS geïnfundeerde groep dan in de controle 
groep. Er werden geen tekenen van gegeneraliseerde ontsteking waargenomen 
en ook waren er geen indicaties van ontsteking in de nier en placenta. Gezien het 
feit dat er geen effect van P. gingivalis LPS op de bloeddruk bij niet-zwangere ratten 
was, is de toename in bloeddruk specifiek voor de zwangere ratten. Er kan worden 
geconcludeerd dat P. gingivalis LPS effect heeft op zwangerschap door het induceren 
van hypertensie en de placentaire en foetale groei negatief beïnvloedt alsook het 
aantal foetale resorpties doet toenemen. P. gingivalis LPS speelt daarom mogelijk een 
rol bij zwangerschapscomplicaties geïnduceerd door parodontitis. P. gingivalis LPS 
lijkt, in tegenstelling tot LPS van E. coli, geen rol te spelen in de pathogenese van pre-
eclampsie, omdat er geen tekenen van albuminurie of ontsteking optraden.
In hoofdstuk 5 is vervolgens gekeken of het verschil in effect van P. gingivalis LPS 
en E. coli LPS op de zwangerschap het gevolg zou kunnen zijn van verschillen in 
cytokineproductie na herkenning door leukocyten. Voor dit doel is bloed van 16 gezon-
de zwangere vrouwen en 15 gezonde niet-zwangere vrouwen gestimuleerd met 
bacteriën en LPS van P. gingivalis ATCC 33277 en E. coli in een ex-vivo laboratorium 
experiment. Na stimulatie is de cytokineproductie gemeten (TNF-α, IL-1β, IL-6, IL-
12 and IL-10) met behulp van Luminex en is de TLR2/TLR4 expressie op monocyten 
vastgesteld met behulp van flow cytometrie. Tevens zijn pro-/anti-inflammatoire 
ratios (IL-12/IL-10, TNF-α/IL-10 and IL-6/IL-10) berekend. Stimulatie met P. gingivalis 
bacteriën/LPS induceerde, zowel in zwangere alsook in niet-zwangere vrouwen, lagere 
cytokineproductie en lagere pro-inflammatoire ratios dan E. coli bacteriën/LPS, met 
uitzondering van de IL-6/IL-10 ratio die was verhoogd na P. gingivalis bacteriën/LPS 
stimulatie. Er was tevens een effect van de zwangerschap op de cytokineproductie: 
in het bloed van zwangere vrouwen werd een lagere concentratie van IL-12 gemeten 
na stimulatie met E. coli bacteriën en een lagere IL-6 concentratie na stimulatie met P. 
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gingivalis bacteriën dan in het bloed van niet-zwangere vrouwen. Overeenkomstig was 
de productie van IL-12 en TNF-α in het bloed van zwangere vrouwen na stimulatie met 
LPS van E. coli en de productie van IL-6 na stimulatie met P. gingivalis LPS lager dan in 
het bloed van niet-zwangere vrouwen. Het percentage TLR2 positieve monocyten was 
lager tijdens de zwangerschap dan in de niet-zwangere situatie. De lagere cytokine-
productie en lagere pro-inflammatoire ratio na stimulatie met P. gingivalis vs. E. coli 
tijdens de zwangerschap verklaart mogelijk de verschillen in respons na bacteriële 
herkenning in de in-vivo situatie en suggereert dat tijdens de zwangerschap, vrouwen 
gevoeliger zijn voor de effecten van cytokines zoals IL-12, TNF-α en IL-6.
Meerdere studies hebben laten zien dat er variatie is in virulentie tussen verschillende 
P. gingivalis serotypen. Dit is mogelijk het gevolg van verschil in cytokineproductie 
na herkenning van de bacteriën of het LPS door ontstekingscellen van de gastheer. 
Om de virulentiefactoren van P. gingivalis verder te onderzoeken is in hoofdstuk 6 
een experiment uitgevoerd waarin is onderzocht in hoeverre cytokineproductie 
van leukocyten verschilt na stimulatie met bacteriën en geïsoleerd LPS van twee 
verschillende P. gingivalis serotypen. Voor dit doel werd de Mono Mac 6 (MM6) cellijn, 
alsook bloedmonsters van 15 gezonde vrouwen gestimuleerd met bacteriën en LPS 
van de ongekapselde P. gingivalis ATCC 33277 (K¯) en de gekapselde P. gingivalis W50 
(K1). In experiment 1 werd de productie van TNF-α van de MM6 cellijn vastgesteld na 
stimulatie met bacteriën en LPS van beide P. gingivalis soorten met gebruikmaking 
van flow cytometrie. In experiment 2 werden de effecten van bacteriën of LPS van 
beide P. gingivalis serotypen op de productie van TNF-α, IL-1β, IL-6, IL-12 en IL-10 in 
bloed onderzocht met gebruikmaking van Luminex. Voor beide experimenten werden 
bacteriën en geïsoleerd LPS van Escherichia coli gebruikt als referentie. Beide P. gingivalis 
serotypen induceerden een lagere cytokineproductie dan E. coli, met uitzondering 
van IL-6 na stimulatie met P. gingivalis K1 bacteriën. Stimulatie met bacteriën van P. 
gingivalis K1 induceerde een hogere cytokineproductie dan stimulatie met bacteriën 
van P. gingivalis K¯. In tegenstelling, P. gingivalis K1 LPS induceerde een lagere 
cytokineproductie dan P. gingivalis K¯ LPS. Blijkbaar zijn andere bacteriële producten 
dan het LPS verantwoordelijk voor de hogere cytokineproductie na stimulatie met P. 
gingivalis K1 in vergelijking tot P. gingivalis K¯ bacteriën. De hogere cytokineproductie 
na stimulatie met bacteriën van P. gingivalis K1 draagt wellicht bij aan de virulentie-
eigenschappen van dit serotype, omdat een toename in de productie van cytokines 
mogelijk leidt tot de recrutering van meer leukocyten naar het gebied van de infectie, 
waardoor het lokale ontstekingsproces wordt versterkt. 
Tot slot worden in hoofdstuk 7 de belangrijkste onderzoeksresultaten bediscussieerd 


















inclusief de door ons uitgevoerde patiënt-controle studie, kan worden geconcludeerd 
dat er verband lijkt te bestaan tussen parodontitis en sommige vormen van pre-
eclampsie. Deze associatie is het duidelijkst bij vroege-pre-eclampsie. Het is echter de 
vraag of parodontitis causaal betrokken is in de pathogenese van pre-eclampsie. Studies 
die een parodontale screening hebben uitgevoerd rond 20 weken van de zwangerschap 
(d.w.z. voordat de klinische symptomen van pre-eclampsie zich openbaarden) lieten 
geen verband zien tussen de beide aandoeningen. Ook parodontale behandeling, 
uitgevoerd rond 20 weken van de zwangerschap, leidde niet tot een reductie van het 
risico op pre-eclampsie. Het is dus onduidelijk of de parodontale infectie pre-eclampsie 
induceert of vice versa, of dat een tot nu toe onbekende, mogelijk genetische, factor 
ten grondslag ligt aan beide aandoeningen. Het kan echter niet worden uitgesloten 
dat parodontale behandeling rond 20 weken van de zwangerschap te laat is om 
translocatie van paropathogene bacteriën, zoals P. gingivalis, in de maternale circulatie 
en naar de foeto-placentaire weefsels te voorkomen.
 De resultaten van het dierproefexperiment bevestigen eerdere bevindingen 
dat LPS van P. gingivalis een oorzakelijke bijdrage kan leveren aan het ontstaan van 
zwangerschapscomplicaties zoals een laag geboortegewicht en miskramen, in deze 
studie gerepresenteerd als foetale resorpties in de rat. Het LPS lijkt echter geen rol te 
spelen in de pathogenese van pre-eclampsie. Hoewel er een milde verhoging van de 
maternale bloeddruk werd gevonden, resulteerde infusie met LPS van P. gingivalis niet 
tot albuminurie of een gegeneraliseerde ontsteking. De foetale pathologie alsook de 
stijging in bloeddruk lijken van placentaire oorsprong zijn, omdat infusie met P. gingivalis 
LPS het placentaire gewicht negatief beïnvloedde. P. gingivalis LPS kan mogelijk de 
placentaire groei direct hebben beïnvloed door het induceren van apoptose van de 
trofoblast. Dit kan vervolgens hebben geleid tot een afgenomen toevoer van zuurstof 
en voeding naar de foetus, met als gevolg foetale groeivertraging. De milde stijging 
in bloeddruk kan ook een compensatiemechanisme van de moeder zijn geweest 
om de verstoorde zuurstof- en voedingstoevoer naar de foetus te herstellen. Het 
exacte mechanisme waarmee P. gingivalis LPS een stijging in maternale bloeddruk en 
placentaire en foetale groeivertraging heeft geïnduceerd blijft onopgehelderd in ons 
experiment en behoeft nader onderzoek.
 De in-vitro en ex-vivo bloed experimenten laten zien dat zowel bacteriën als 
ook LPS van P. gingivalis een lagere pro-inflammatoire capaciteit hebben en een 
lagere cytokineproductie induceren dan E. coli. Dit verklaart mogelijk waarom in ons 
ratexperiment infusie met P. gingivalis LPS, in tegenstelling tot E. coli LPS, geen pre-
eclampsie-achtige kenmerken induceerde. Het is opmerkelijk dat ondanks het feit dat 
zwangere vrouwen extreem gevoelig zijn voor endotoxine, de cytokineproductie in het 
bloed van zwangere vrouwen na de diverse stimulaties gelijk of lager was dan in het 
bloed van niet-zwangere vrouwen. Dit zou kunnen wijzen op een staat van endotoxine-
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tolerantie van monocyten tijdens de zwangerschap en suggereert dat zwangere 
vrouwen gevoeliger zijn voor de effecten van cytokines. Vervolgonderzoek moet 
uitwijzen welke mechanismen verantwoordelijk zijn voor de lagere cytokineproductie 
na LPS stimulatie tijdens de zwangerschap.
Dit proefschrift toont aan dat er mogelijk een associatie is tussen parodontitis en 
sommige vormen van pre-eclampsie in observationele studies. Deze associatie 
was het meest duidelijk met vroege pre-eclampsie. Echter, parodontale therapie 
uitgevoerd tijdens de zwangerschap leidde niet tot een reductie in het aantal pre-
eclamptische zwangerschappen. Ook induceerde P. gingivalis LPS in zwangere ratten 
geen pre-eclampsie-achtige verschijnselen of een gegeneraliseerde systemische 
ontstekingsreactie en werd er geen sterke pro-inflammatoire cytokineproductie 
opgewekt door P. gingivalis bacteriën of LPS in de in-vitro en ex-vivo experimenten. 
Het lijkt dan ook niet waarschijnlijk dat parodontitis een causale rol speelt in de 
pathogenese van pre-eclampsie.
 De parodontale infectie speelt mogelijk een rol bij laag geboortegewicht en 
miskramen in de aanwezigheid van P. gingivalis LPS, zoals is aangetoond in het 
ratexperiment. Het is van belang om het exacte mechanisme te ontrafelen waarmee 
P. gingivalis LPS interfereert met de zwangerschap. Opmerkelijk is dat, in tegenstelling 
tot de algemene hypothese, de schadelijke effecten van P. gingivalis LPS op de foetale 
ontwikkeling niet werden veroorzaakt door een geactiveerde ontstekingsreactie. 
Ook ons ex-vivo experiment laat zien dat blootstelling aan P. gingivalis LPS tijdens de 
normale zwangerschap, in vergelijking tot de niet-zwangere situatie, een verschuiving 
in cytokineproductie teweeg brengt richting een meer anti-inflammatoire ratio. De 
exacte mechanismen en implicaties van deze aan de zwangerschap gerelateerde 
aanpassing van de ontstekingsreactie op bacteriën of LPS tijdens zwangerschap zijn 
intrigerend en dienen nader te worden onderzocht.
 Op dit moment is er geen bewijs om te onderbouwen dat parodontale behandeling 
tijdens de zwangerschap het risico op zwangerschapscomplicaties reduceert, behalve 
mogelijk bij een subgroep van vrouwen met een hoog risico op vroeggeboorte. 
Echter, los van de mogelijkheid of parodontitis een etiologische rol speelt in zwanger-
schapscomplicaties, neemt tijdens de zwangerschap de gevoeligheid voor het ont-
wikkelen van parodontale ontstekingen toe. Om die reden blijft vroege detectie en 
behandeling van parodontale aandoeningen voorafgaand en tijdens de zwangerschap 














Het is nu dan toch echt klaar! Nu ik het dankwoord aan het schrijven ben vermoed ik, 
dat niet alleen ik, maar ook vele anderen met mij opgelucht zullen zijn dat dit boekje 
nu eindelijk af is. Ontzettend veel dank ben ik verschuldigd aan alle mensen die de 
afgelopen jaren betrokken zijn geweest bij dit onderzoekstraject… zonder hen was 
het nooit gelukt om het tot een goed einde te brengen! Aan mijn promotores en co-
promotores: ik ben er ongelofelijk trots op dat ik in zo’n multidisciplinair team heb 
mogen participeren en dat ik de afgelopen jaren jullie promovenda heb mogen zijn!
Prof. dr. F. Abbas, beste Frank, alles wat ik nu doe en alles wat ik de afgelopen jaren heb 
gedaan heb ik zonder twijfel te danken aan jou en jouw rotsvaste vertrouwen in mij. 
Om eerlijk te zijn denk ik dat jij veel meer vertrouwen in mij had dan ik menigmaal in 
mezelf… jij hebt op meer vlakken dan je jezelf bewust zult zijn ervoor gezorgd dat ik 
boven mezelf kon uitstijgen. Ik prijs mezelf heel erg gelukkig dat jij me de kans hebt 
gegeven om me als onderzoeker te ontwikkelen en me deze geweldige uitdaging hebt 
gegund. Dit promotietraject was met regelmaat een ‘roller coaster’, maar mede dankzij 
jouw niet aflatende support, positieve blik en wijze woorden ligt hier nu een boekje 
waar ik heel erg trots op ben. Ik hoop dat ik nog heel lang met je mag samenwerken!!
Dr. M.M. Faas, beste Marijke, expert op het gebied van pre-eclampsie en wetenschapper 
pur sang. Jij hebt mij ‘ingewijd’ in vakgebieden waarvan ik nooit gedacht had er ooit 
mee in aanraking te komen. Vanaf het moment dat je bij het onderzoek betrokken bent 
geweest heb je me het vuur aan de schenen gelegd, en wat zal je geduld vaak op de 
proef zijn gesteld! Ik heb ongelofelijk veel van je geleerd en ben vereerd dat ik dit alles 
heb mogen doen onder jouw leiding. ‘I learned from the best!!’
Prof. dr. J.G. Aarnoudse, beste Jan, dank voor je steun, je vertrouwen in mij en de 
mogelijkheid die je me hebt geboden om dit complexe multidisciplinaire promotie-
traject tot een goed einde te brengen.
Prof. dr. C.P. van der Schans, beste Cees, ik paste qua onderzoekslijn eigenlijk niet zo heel 
erg bij het lectoraat ‘Transparante zorgverlening’, maar daar kwamen we gaandeweg 
pas echt achter. Heel vaak heb ik mij een vreemde eend in de bijt gevoeld bij de 
onderzoeksgroep en heb ik getwijfeld over de bijdrage van mij en mijn onderzoek aan 
het lectoraat. Desalniettemin heb jij ervoor gezorgd dat dit promotietraject gerealiseerd 
kon worden en heb je vanaf het begin tot het eind achter me gestaan. Ik ben je veel 
dank verschuldigd!
Dr. M.G. van Pampus, beste Mariëlle, jouw directe manier van communiceren heeft 
mij regelmatig de ‘stuipen op het lijf’ gejaagd, maar heeft er wel voor gezorgd dat 
ik de vaart er in hield, letterlijk en figuurlijk. Ik herinner me bijvoorbeeld nog goed 
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hoe wij samen (ik in jouw kielzog) in ongeveer 10 minuten zo ongeveer het halve 
ziekenhuis hebben volgehangen met posters voor het werven van deelneemsters aan 
de Monocytstudie… de snelheid waarmee dat gebeurde was kenmerkend voor jouw 
inspirerende doortastendheid en enthousiasme. Dank voor je bijdrage aan dit project!
Dr. J.J. van Doormaal, beste Jaap, in de onderzoeksgroep ben jij een belangrijke motor 
geweest. Altijd vol enthousiasme en altijd met nieuwe ideeën, zelfs toen we in nota 
bene jouw vakantie tot één uur ’s nachts samen aan de review bezig zijn geweest. Als 
co-auteur kritisch op de komma’s en punten, maar altijd was jouw feedback positief, 
veilig en opbouwend. Met name daarom ben je de afgelopen jaren in dit woelige 
onderzoeksland een veilig baken geweest!
Leden van de beoordelingscommissie, prof. dr. B.G. Loos, prof. dr. P.P. van den Berg en 
prof. dr. W.M. Molenaar, hartelijk dank voor uw bereidheid om plaats te nemen in de 
leescommissie en voor de tijd die u hebt genomen om dit manuscript te beoordelen.
Mw. D.C. Dekker, lieve Daphne, zonder jou waren de laboratoriumexperimenten 
nooit van de grond gekomen. Ik heb ontzettend geboft dat jij je stageperiode aan dit 
onderzoek wilde besteden. Ik had me geen betere collega kunnen wensen en had me 
geen raad geweten zonder jou. Zeer vakkundig en nauwgezet, en echt altijd bereid te 
helpen als dat nodig was (zelfs regelmatig na werktijd!). En dit alles altijd met een big 
smile. Je bent een prachtmens, je ‘nieuwe’ collega’s mogen wel heel zuinig op je zijn!
Prof. dr. A.J. van Winkelhoff, beste Arie-Jan, natuurlijk op de eerste plaats dank voor 
jouw genereuze bijdrage aan de experimenten. Het feit dat de benodigde materialen 
voor het dierexperiment vanuit Engeland keer op keer niet aankwamen op ons 
laboratorium, heeft mij, maar vast ook jou, veel stress gegeven. Maar ook dank ik je 
voor het meedenken, je kritische vragen over de experimenten, maar vooral voor je 
luisterend oor bij tegenslag. Je moet me toch eens uitleggen hoe het kan dat jij keer op 
keer precies op de juiste momenten díe dingen zegt die ik net nodig heb…
Dr. H.J.M. Harmsen, beste Hermie, dank voor je enthousiaste en hulpvaardige bijdrage 
aan de Monomacstudie. Het was een eer om gebruik te mogen maken van jouw 
expertise op het gebied van de medische microbiologie.
Alle deelneemsters aan de klinische studies wil ik heel hartelijk bedanken voor hun 
vrijwillige deelname. Zonder hen was het onderzoek niet mogelijk geweest.
Prof. dr. E.G. Winkel, lieve Edwin, ‘ex-roomy en mental coach’. Helaas hebben we maar 
heel kort de kamer op de 2e verdieping gedeeld en heb je maar kort de rol van ‘mental 
coach’ kunnen vervullen. Toch is jouw inmiddels gevleugelde uitspraak: ‘Ophouden met 











Want telkens als ik weer dreigde te verzanden in nog meer literatuur verzamelen, nog 
meer lezen en nog meer cursussen doen, heeft jouw opmerking me weer op het rechte 
pad gezet. Thanks!
Drs. P.J.L. de Beukelaar, lieve Peter, onze koffie-overpeinzingen koester ik als dierbare 
juweeltjes. Vaak gaan deze gesprekjes over het werk, over mijn onderzoeksperikelen, 
maar nog veel vaker over zaken die er in het ‘gewone’ leven echt toe doen. Het zijn de 
sprankeltjes van de dag, dat blijven we gewoon altijd doen, toch?
Drs. Y.C.M. de Waal, lieve Yvonne, ‘roomy’, dank je voor je steun, je gezelligheid, 
je bereidwilligheid om te allen tijde mee te denken en het delen van hoogte- en 
dieptepunten. Ik bewonder je zeer, als mens èn als onderzoeker. Nog een paar 
maandjes, dan is de beurt aan jou om te promoveren…
Mijn collega’s, dit traject heeft veel langer geduurd dan aanvankelijk gepland en de 
afgelopen jaren heb ik, om het zo maar te zeggen, behoorlijk onder een steen geleefd. 
Maar jullie niet aflatende belangstelling is een grote steun geweest. Dank jullie wel!
Alle mensen van het laboratorium Medische Biologie, en dan met name Bart en Martin 
(hoe kan het dat jij altijd vrolijk bent?!), maar ook Henk, Linda, Theo en Gerda, die 
mij geholpen hebben om de experimenten goed op de rails te krijgen, heel hartelijk 
bedankt. Martin, heb je er ooit over gedacht om docent te worden? Je zou direct 
gekozen worden tot docent van het jaar, dat weet ik zeker!
Alle mensen van het CDL, twee jaar lang heb ik vrijwel dagelijks op het CDL rondgelopen. 
Alle collega’s daar, Arie, André, Annemieke, Michel, Angela, maar natuurlijk vooral Ralph, 
heel, heel hartelijk dank voor jullie ondersteuning en hulp. Ralph, jij bent al die jaren op 
het CDL heel belangrijk geweest. Wat had ik zonder jou gemoeten…?
Dhr. R.H.H. Brandt, lieve Ronald, dankzij jou ben ik zo’n 34 jaar geleden (zijn we echt 
al zo oud!?) in het grafische vak terecht gekomen. En nog altijd, na al die jaren, ben jij 
mijn grote steun en toeverlaat in grafische nood! Altijd bereid te helpen als dat nodig 
is, ook nu weer, nu mijn kennis van de huidige technieken pijnlijk tekort schoot om 
het proefschrift zo te maken als ik wilde. We hebben het boekje samen gemaakt, hoe 
bijzonder is dat! Zonder jou was het niet zo mooi geworden, dank je wel!
De NVvP, Nederlandse Vereniging voor Parodontologie, ben ik veel dank verschuldigd. 
Zonder de forse subsidie van de NVvP zou dit onderzoekstraject niet mogelijk zijn 
geweest.
Ook Philips Sonicare dank ik heel hartelijk voor de bijdrage aan de klinische studies.
Drs. H.B. van Olm en drs. E. Hekman, lieve Hans en Eddy, toen we jaren geleden met 
z’n drieën ’op zaal’ stonden, spraken we af dat jullie mij terzijde zouden staan tijdens 
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de verdediging van het proefschrift. Nooit gedacht dat het zo lang zou duren voordat
het echt zover zou zijn. Dat jullie na zoveel jaar nog steeds mijn paranimfen willen zijn 
vind ik een grote eer. Ik kan haast niet wachten om dit feestje samen met jullie te vieren!
Mijn fantastische ‘meiden’, dit boekje draag ik aan jullie op. Dat mijn onderzoeksfocus 
heeft gelegen op het gebied van zwangerschapscomplicaties is geen toeval. Lieve 
Kimo, mijn oudste dochter, nog dagelijks word jij geconfronteerd met de gevolgen 
van een moeizame start. Hoe moeilijk moet het zijn, lieverd, om niet alles te kunnen 
bereiken wat je eigenlijk zou willen… Maar je bent zo sterk, en keer op keer laat je je 
niet uit het veld slaan door tegenslagen. Lieve Demi, jij hebt misschien van iedereen 
nog het meest ‘last’ gehad van dit promotietraject. Want het is niet leuk als je moeder 
vrijwel continue niet alleen overdag, maar ook ’s avonds aan het werk is. Inmiddels 
woon je niet eens meer thuis, je studeert al 2 jaar in Leiden, en binnenkort volg je je 
grote droom, je gaat studeren in Amerika! Je hebt jezelf ontwikkeld tot een prachtige, 
getalenteerde en ambitieuze jonge vrouw, die beslist niet de gemakkelijkste weg kiest. 
Mijn meisje, jij komt er wel! Kiem en Deem, jullie zijn doorzetters… allebei… ik ben zo 
verschrikkelijk trots op jullie!!!
 
Lieve Jasmijn en Iris, het was voor jullie vast niet gemakkelijk om een ‘stiefmoeder’ te 
accepteren naast jullie eigen moeder. Een stiefmoeder die andere ideeën had over hoe 
een gezin er uit moest zien dan jullie eigen moeder, en die bovendien ook nog heel 
druk was met schrijven. Jullie tweetjes hebben ons zomaar geaccepteerd in jullie leven. 
Het was wel eens roerig de afgelopen jaren, maar jullie zijn prachtige meiden, jullie 
ouders mogen heel erg trots zijn op jullie! Ik ben het in ieder geval.
Mijn lief, Roelof, ik was al een tijdje druk met het promotietraject bezig toen wij elkaar 
via een wel heel bijzondere weg dankzij de mondzorg hebben gevonden (Bea, mijn 
eeuwige dank!!). Het opstarten van een fusiegezin met drie puberende meiden heeft 
voor meer en hogere golven gezorgd dan we van te voren ooit hadden kunnen voorzien 
en alle drukte rondom mijn promotie maakte dat beslist niet makkelijker. Maar wat 
hebben we het goed en wat zijn we gelukkig samen!! Bij jou mag ik schuilen, met jouw 
armen om me heen hoef ik niet altijd sterk te zijn, wat een ongelofelijk gevoel is dat. Bij 
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